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Abstract 
Apelin was discovered in 1998 as the endogenous peptide ligand of the orphan APJ 
receptor. The apelin system is well conserved across vertebrate species and is 
reported to have cardiovascular effects including positive inotropy, vasodilation, 
vasoconstriction and cardioprotection during ischaemia. Recent studies in human 
healthy volunteers and in chronic heart failure patients have highlighted the apelin 
system as a potential target for drug development. However, the cellular and 
molecular pathways through which apelin acts remain poorly understood. This study 
aimed to confirm the inotropic and vasoactive actions of apelin and to further 
examine the proposed cardioprotective effects of apelin under ischaemic and hypoxic 
conditions. Cardioprotection is defined as a mechanism, for example induced by a 
drug, which reduces injury in response to ischaemia or hypoxia. 
 
In vivo in the anaesthetised rat, apelin was administered as a bolus dose via the 
cannulated jugular vein and mean arterial pressure was measured by cannulation of 
the carotid artery. Pyr-apelin-13 had no effect on heart rate or mean arterial pressure. 
Apelin-13 decreased mean arterial pressure by approximately 20 mmHg, although 
the effect was highly variable among animals. Apelin-16 consistently lowered heart 
rate, but had no effect on mean arterial pressure. In rat isolated mesenteric arteries, 
studied using wire myography, apelin-13 and apelin-36 had no vasodilator or 
vasoconstrictor effect.  
 
In rat isolated right ventricular papillary muscles and right atrial strips, no change in 
tension, time to peak or time to relax was observed in response to pyr-apelin-13 
   xi 
despite responding to standard pharmacological stimuli such as noradrenaline and 
increased calcium concentrations in the bathing medium. In isolated, perfused rat 
heart (Langendorff), infusion of apelin-16 for 15 minutes did not alter developed 
pressure, rate of rise or rate of fall detected by an intraventricular balloon positioned 
in the left ventricle throughout the infusion. As the isolated perfused hearts did not 
demonstrate an inotropic effect in response to apelin, no cardioprotective studies 
were carried out in this model. 
 
Cardioprotective studies of apelin were performed in zebrafish embryos 3 – 5 days 
post fertilisation (dpf). I developed a hypoxia-recovery model in which we could test 
the effect of pharmacological agents, including apelin, on the hypoxia-recovery 
response. In zebrafish embryos 3 dpf, 2h hypoxia (1% oxygen) reduced heart rate 
and wall motion amplitude (to approximately 90% of control) and contraction 
velocity and relaxation velocity (to approximately 80% of control). All parameters 
recovered during a subsequent 2h in normoxia. Incubation in pyr-apelin-13 for 1h 
prior to and throughout hypoxia did not affect the depression in heart rate observed 
on exposure to hypoxia. However, apelin incubation resulted in an improvement in 
wall motion amplitude and relaxation velocity and a significant improvement in 
contraction velocity after hypoxia and throughout recovery. Pyr-apelin-13 had no 
inotropic or chronotropic effect on baseline heart function in embryos 3 dpf or in 
isolated hearts from embryos. However, apelin knockdown using a morpholino 
targeting the exon 2/intron 2 boundary of apelin pre-mRNA resulted in a high 
mortality rate and a severe total body and cardiovascular phenotype, suggesting that 
endogenous apelin is crucial during development in zebrafish embryos. 
   xii 
In order to test pharmacological agents more efficiently, I developed a semi-
quantitative scoring method to screen a larger number of embryos in a reduced time 
period. Heart rate and circulation was defined as normal, reduced or absent after 2h 
and 4h in hypoxia and during recovery in normoxia. The abundance of apelin and 
HIF-1α mRNA was measured using quantitative RT-PCR. In zebrafish 5 dpf, a 
marked decrease in apelin mRNA expression was observed after 4h, but not 2h, 
hypoxia and this was not accompanied by a change in HIF-1α mRNA expression. In 
zebrafish 5 dpf, exogenous pyr-apelin-13 did not affect the proportion of embryos 
with normal heart rate and circulation at any timepoint in this model. However, 
desferrioxamine (iron chelator) and α-ketoglutarate (metabolite involved in aerobic 
respiration) significantly increased the proportion of embryos with normal heart rate 
and circulation during the recovery phase.  
 
In summary, apelin-13 and apelin-16 were effective in lowering mean arterial 
pressure and heart rate, respectively, in the anaesthetised rat. However, apelin-13 did 
not vasodilate or vasoconstrict rat isolated mesenteric arteries. There was no effect of 
apelin on contractility parameters in rat isolated papillary muscles or in the isolated, 
perfused rat heart which made it difficult to pursue a cardioprotective effect in this 
model. In zebrafish, endogenous apelin appeared to be crucial in the development of 
the embryo, while exogenous apelin had no inotropic effect on cardiac function. In 
hypoxia-recovery, we demonstrate a cardioprotective effect of apelin in zebrafish 3 
dpf, but not zebrafish 5 dpf. 
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EDTA    ethylenediaminetetraacetic acid 
ERK    extracellular-regulated kinase 
ENU    N-ethyl-N-nitrosourea 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
Gi    inhibitory G-protein    
GPCR    G-protein coupled receptor 
GFP    green fluorescent protein 
HR    heart rate 
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h    hour 
hpf    hours post fertilisation 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF-1α   hypoxia-inducible factor-1α 
HRE    hypoxia-response element 
IP3    inositol-1,4,5-trisphosphate  
ICV    intracerebroventricular  
IV    intravenous 
KH    Krebs-Henseleit 
L-NAME   N-nitro-L-arginine methyl ester 
LV    left ventricle 
LVEDP   left ventricular end diastolic pressure 
MAP    mean arterial pressure 
MAPK    mitogen-activated protein kinase 
MO    morpholino 
NCX    Na+/Ca+ exchanger 
NHE    Na+/H+ exchanger 
NO    nitric oxide 
NA    noradrenaline 
Pmax    maximum pressure 
PM    papillary muscle 
PE    phenylephrine 
PLC    phopholipase C 
PACAP   pituitary adenylate cyclase-activating peptide  
   xxii 
PCR    polymerase chain reaction 
PVDF    polyvinylidene fluoride 
PHD    prolyl hydroxylase enzymes 
PKC    protein kinase C 
pyr-apelin-13    pyroglutamated apelin-13 
qPCR    quantitative polymerase chain reaction 
RV    relaxation velocity 
RA    right atrium 
RV    right ventricle 
RISK    reperfusion injury salvage kinase 
RT-PCR   reverse transcriptase polymerase chain reaction 
RPL13a   ribosomal protein L13a 
SV    sinus venosus 
SM    smooth muscle 
SDS    sodium dodecyl sulfate 
SNP    sodium nitroprusside 
sGC    soluble guanylate cyclase 
TILLING   targeting induced local lesions in genomes 
Ub    ubiquitin 
UPL    Universal Probe Library 
VHL    von Hippel-Lindau factor 
WMA    wall motion amplitude 
YSL    yolk syncytial layer 
ZF    zebrafish 
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1.1 Apelin and the APJ receptor 
1.1.1 Apelin 
Apelin (named after APJ endogenous ligand) was first isolated from bovine stomach 
extracts in a screening experiment using Chinese hamster ovary (CHO) cells 
expressing the orphan receptor, APJ. A 17 amino acid peptide was isolated that was 
shown to arise from a 77 amino acid precursor, preproapelin (Tatemoto et al., 1998). 
Several apelin isoforms have since been isolated, or synthesised, and have identical 
13 amino acids at the C-terminal (Fig 1.1). Crucially, the 12 C-terminal amino acids 
appear to be those involved in agonist binding  (De Mota et al., 2000; Reaux et al., 
2001). Synthetic forms of apelin-13 (containing 13 amino acids) and apelin-36 
(containing 36 amino acids) were also shown to increase the extracellular 
acidification rate in CHO cells expressing APJ (Tatemoto et al., 1998). 
Figure 1.1: Apelin synthesis, post-translational processing and metabolism. 
Apelin isoforms arise from an apelin prepropeptide; the number following the apelin 
isoform denotes the number of amino acids. Figure adapted from Japp and Newby 
(2008). 
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Apelin-13 and apelin-36 are endogenous apelin isoforms expressed in humans 
(Tatemoto et al., 1998) and rats (Lee et al., 2000). Apelin expression has also been 
detected in the zebrafish early in development (Zeng et al., 2007). The apelin gene 
has been identified in numerous species including horse, dog, pig, sheep, cow and 
chicken according to the Ensembl Genome Browser (www.ensembl.org). However, 
apelin expression has neither been identified in Drosophila nor does the apelin gene 
have a homologue in the Drosophila genome, suggesting apelin is only conserved 
among vertebrates. 
 
Other forms of apelin (apelin-12, apelin-16) have been synthesised, although it is not 
clear if these forms are endogenous. Certainly, in humans, pyr-apelin-13 is the 
predominant form (Maguire et al., 2009). Apelin-13 is the only form of apelin known 
to undergo post-translational pyroglutamation which is a modification known to 
render peptides more resistant to degradation by carboxypeptidases (Russo et al., 
2002). 
 
Until recently, apelin was thought to be degraded by the carboxypeptidase, 
angiotensin-converting enzyme 2 (ACE-2) (Vickers et al., 2002). However, recent 
data suggest that this may not be the case. It has been demonstrated that the action of 
ACE-2 on apelin-13 results in a cyclic peptide with similar efficacy and potency to 
apelin-13 (Davenport et al., 2009). Therefore, the degradation pathway of apelin is, 
as yet, unclear. 
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1.1.1.2 Distribution 
Plasma levels of apelin in rodents and humans are in the nanomolar range (Andersen 
et al., 2009; Chen et al., 2003). Apelin is thought to be produced in the right atrium 
where tissue levels of apelin are higher than in ventricular tissue (Foldes et al., 
2003). Apelin is produced by adipocytes in response to insulin and apelin levels in 
plasma of obese mice are increased compared to normal mice (Boucher et al., 2005). 
A combination of these origins of the peptide is responsible for plasma apelin. 
 
Within the cardiovascular system, apelin has been identified in the endothelium of 
the endocardium, in vascular endothelial cells of the heart and in the endothelium of 
large conduit vessels (Kleinz et al., 2004). Within the cell, Kleinz et al. (2005) report 
that apelin is closely associated with the nuclear surface and is also found in vesicle-
like structures in the cytoplasm. 
 
In zebrafish, apelin expression was first detected by reverse transcription polymerase 
chain reaction (RT-PCR) at around 9 hours post fertilisation (hpf). By in situ 
hybridisation, apelin expression was observed in the notochord and developing heart 
as well as in specific regions in the head (Zeng et al., 2007). The plasma 
concentration, cellular and spatial distribution of apelin in adult zebrafish is unclear 





   5 
1.1.2 APJ Receptor 
1.1.2.1 Orphan receptor 
The APJ receptor, a 7 transmembrane domain G-protein coupled receptor (GPCR), 
was first characterised by O’Dowd et al. (1993) and at the time was an orphan 
receptor. Five years later its ligand, apelin (named after APJ endogenous ligand), was 
identified using reverse pharmacology (Tatemoto et al., 1998). Bovine stomach 
extracts were added to CHO cell cultures expressing the APJ receptor. Extracellular 
acidification rates were measured and apelin was isolated and identified from an 
extract which increased the extracellular acidification rate (Tatemoto et al., 1998). 
This assay was based on the principle that the binding of a ligand to a receptor 
releases protons and thus increases the acidity of the extracellular space. 
 
1.1.2.2 APJ receptor distribution in rat and human tissues 
Apelin binding sites have been identified in the hearts of both rat and human and in 
human blood vessels, including the coronary artery and saphenous vein 
(Katugampola et al., 2001). Immunocytochemistry of human and rat tissue identified 
the APJ receptor in endothelial cells of intramyocardial vessels, small coronary 
arteries, the endocardium and large conduit vessels (Kleinz et al., 2005). These 
authors suggest that this distribution may indicate a paracrine role of the apelin/APJ 
system. Within rat ventricular myocytes, Farkasfalvi et al. (2007) demonstrated that 
the APJ receptor was found in T-tubules and at the intercalated disc region, 
providing evidence for a possible role in molecular signalling between myocytes.  
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1.1.2.3 Apelin receptor distribution by in-situ hybridisation studies in zebrafish 
embryos 
In zebrafish, two genes encode apelin receptors with considerable sequence 
homology. As a result there are two closely related receptor subtypes: angiotensin 
receptor-like 1a (agtrl1a, sometimes known as aplnra) and angiotensin receptor-like 
1b (agtrl1b, sometimes known as aplnrb). Agtrl1a receptor expression was first 
detected by in situ hybridisation at 3.7 hpf in a dorsal location in the embryo. At the 
two somite stage, agtrl1a expression was noted in areas which contribute to the heart 
and vasculature, among other tissues. However, expression in the dorsal aorta was 
not visualised at this early stage, leading the authors to suggest that agtrl1a 
expression may be confined to the venous circulation (Tucker et al., 2007). Agtrl1b 
receptor expression can be detected in the blastoderm and mesodermal precursors by 
in situ hybridisation, as early as agtrl1a, at 4 hpf. Agtrl1b expression was detected in 
the developing heart as shown by expression patterns collocated with cardiac myosin 
light chain 2 (cmlc2). Agtr11b was also detected in the zebrafish dorsal aorta, caudal 
vein and intersomitic blood vessels at 24 hpf (Zeng et al., 2007). Apelin expression 
patterns in the adult zebrafish have not been reported. 
 
1.1.2.4 Downstream signalling mechanisms 
The APJ receptor is thought to be coupled to both Gi and Gq. Pertussis toxin has been 
shown to abolish extracellular-regulated kinase (ERK) activation by apelin in CHO 
cells expressing the APJ receptor (Masri et al., 2002); while Gq signal transduction 
pathway inhibitors have been shown to attenuate the inotropic response to apelin ex 
vivo in the isolated perfused rat heart (Szokodi et al., 2002). 
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A signalling mechanism for the APJ receptor has been proposed, based on inhibitor 
studies. Activation of the APJ receptor and Gq by apelin is thought to stimulate 
phospholipase C (PLC) which in turn triggers the formation of diacylglycerol (DAG) 





 exchanger (NHE) which carries H
+
 ions out of the cell, 
therefore increasing the intracellular pH. In isolated perfused rat hearts, inhibitors of 
each stage of this pathway blocked the inotropic response to apelin to a similar 
degree (Szokodi et al., 2002). Increasing intracellular pH has also been suggested to 
increase the sensitivity of myofilaments to calcium (Karmazyn et al., 1999). IP3 acts 
on the sarcoplasmic reticulum and triggers calcium release into the cytosol. This, in 
combination with the increase in calcium caused by the reverse action of the sodium 
calcium exchanger (NCX), potentiates the overall increase in calcium in the cell. 
This signalling mechanism may account for both the vasoconstrictor and inotropic 
properties of apelin. However, there is still some debate as to whether the increase in 
cardiac contractility in response to apelin is ultimately due to an increase in calcium 
in the cell or an increase in myofilament sensitivity to calcium. Dai et al. (2006) 
measured Ca
2+





]i) is responsible for the inotropic effect. In 
contrast, Farkasfalvi et al. (2007) report that they did not observe increased [Ca
2+
]i in 
rat cardiomyocytes from both normal and failing hearts exposed to apelin-16. They 
hypothesise that the inotropic effect of apelin is due to increased myofilament 
sensitivity to Ca
2+




   8 
The vasodilator actions of apelin are thought to be nitric oxide (NO) dependent in 
healthy individuals (Japp et al., 2008). It is proposed that the calcium increase that 
occurs after apelin activation of the APJ receptor, activates endothelial NO synthase 
(eNOS). The resultant NO acts on smooth muscle (SM) cells via soluble guanylate 
cyclase (sGC) to relax SM and thus vasodilate the vessel (see Japp and Newby, 
2008). 
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1.2 The cardiovascular effects of apelin 
1.2.1 The effect of apelin on the heart 
Szokodi et al. (2002) demonstrated that apelin-16 produces a positive inotropic 
response in isolated perfused rat hearts with the effect more pronounced at increased 
preload. These authors also demonstrated that inhibitors of PLC, PKC, NCX and 
NHE suppressed this response, thereby beginning to elucidate a possible mechanism 
for the inotropic actions of apelin. In vivo, apelin-16 significantly increased 
maximum pressure development (Pmax) and the rate of rise of developed pressure 
towards the peak (dP/dt max) after 15 mins of intravenous infusion in control rats. In 
rats with heart failure induced by coronary artery ligation this effect on contractility 
was observed after a shorter period of infusion (5 mins) and maintained throughout 
the infusion period (Berry et al., 2004). Berry et al. (2004) also reported that apelin-
16 in vivo increased the rate of fall of developed pressure towards baseline (dP/dt 
min) after 15 mins infusion in both control and heart failure animals. In the mouse, 
Ashley et al. (2005) found an increase in cardiac contractility, measured by Doppler 
ultrasound, after chronic daily infusion for 2 weeks of pyroglutamated apelin-13 
(pyr-apelin-13) in vivo using minipumps. 
 
1.2.2 Vasoactive properties of apelin 
Katumgampola et al. (2001) showed that pyr-apelin-13 caused constriction of human 
saphenous vein rings denuded of endothelium. This was the first report showing a 
functional influence of the apelin/APJ system on the cardiovascular system. Salcedo 
et al. (2007) later reported that human mesenteric arteries with intact endothelium 
relaxed in response to apelin. In the rat, apelin-17 has also been shown to cause 
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vasodilation of juxtamedullary afferent and efferent arterioles of the kidney (Hus-
Citharel et al., 2008). Therefore, the action of apelin on blood vessels, as a 
vasodilator or vasoconstrictor, appears to be dependent on the presence or absence of 
the endothelium. The first published non-peptidic apelin agonist (E339-3D6) is able 
to vasodilate preconstricted rat aorta, although the authors failed to report whether or 
not apelin itself had an effect on this preparation in their hands (Iturrioz et al., 2009).  
 
In vivo studies have also demonstrated the vasoactive properties of the apelin 
peptide. In sheep, intravenous bolus apelin-13 produced an initial decrease followed 
by an increase in mean arterial pressure (MAP) (Charles et al., 2006). Bolus injection 
of apelin resulted in a decrease in MAP in anaesthetised rats (Tatemoto et al., 2001), 
but an increase in MAP in conscious rats (Kagiyama et al., 2005). 
 
1.2.3 Apelin and APJ knockout mice 
Apelin knockout mice exhibit a normal phenotype with normal body weight, food 
and water intake and heart rate (Kuba et al., 2007). The hearts of these mice are 
structurally normal. Interestingly, aged apelin knockout mice display progressive 
heart failure and a more severe impairment in contractility in response to a model of 
pressure overload induced by aortic banding than wild-type controls (Kuba et al., 
2007). The development of the retinal vasculature has also been reportedly delayed 
in apelin knockout mice in the postnatal period (14 days), although the 
developmental delay was no longer detectable at the age of 84 days (Kasai et al., 
2008).  
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APJ knockout mice also exhibit a normal phenotype. When exposed to a high salt 
diet, APJ knockout mice produce a higher volume of urine compared to wild-type 
controls (Roberts et al., 2009). Wild-type mice produce less urine in response to 
water deprivation, whereas APJ knockout mice continue to produce the same volume 
of urine as they did prior to water deprivation (Roberts et al., 2009). An increased 
vasoconstrictor response to angiotensin-II (ATII) in apelin knockout mice has also 
been reported (Ishida et al., 2004). These data indicate that the APJ receptor plays a 
key role in fluid homeostasis in mice. 
 
In apolipoprotein E (ApoE) and APJ double-knockout mice, atherosclerotic lesions 
following high cholesterol feeding were decreased compared to ApoE knockout 
mice. Production of superoxide radicals in the vasculature were also decreased in 
these double-knockout mice suggesting a role for the apelin receptor in oxidative-
stress induced atherosclerosis (Hashimoto et al., 2007). However, in ApoE knockout 
mice, atherosclerosis induced by treatment with ATII, was attenuated by apelin 
delivered by osmotic minipump. Similarly, in ApoE and apelin double-knockout 
mice, atherosclerotic lesions induced by a high cholesterol diet were increased 
compared to ApoE knockout mice (Chun et al., 2008). 
 
1.2.4 Apelin and its potential role in cardiovascular disease 
Current treatment of chronic heart failure includes use of β-blockers and ACE 
inhibitors. These slow HR and reduce blood pressure, thus alleviating the loading 
conditions on the failing heart (Havranek et al., 1998; Swedberg et al., 2005). In 
some cases of acute heart failure, inotropes, for example dobutamine (β-agonist), are 
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useful. This is especially true in cases where low blood pressure is a feature or where 
renal blood flow and consequently urine output falls.  However, numerous studies 
have suggested that longer term therapy with inotropic drugs is associated with 
increased mortality (sudden death) (Schafer et al., 2000; see Goldhaber and Hamilton 
et al., 2010). 
 
Continuous apelin infusion for 14 days using minipumps in mice did not result in 
cardiac hypertrophy (Ashley et al., 2005). Longer term effects have not yet been 
studied, but at this stage an agonist of the apelin system is a promising therapeutic 
target as an agent that reduces MAP and is positively inotropic. 
 
Dai et al. (2006) report that apelin-12 has a more profound inotropic effect in cardiac 
muscle from rats with heart failure induced by chronic hypoxia than in cardiac 
muscle from control rats. Conversely, Farkasfalvi et al. (2007) found no difference in 
the contractile response of failing and control isolated cardiomyocytes to apelin-16 in 
a coronary artery ligation heart failure model. These differences may be due to the 
underlying aetiology of the induced-heart failure and the type of preparation used to 
study the effects of apelin. 
 
Sarzani et al. (2007) show that, in humans, plasma apelin levels are augmented in 
mild forms of heart failure, but are lower in more severe heart failure. This suggests 
that, as the disease progresses, plasma levels of the peptide are eventually down-
regulated. Implantation of a left ventricular assist device was shown to reverse this 
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pattern (Chen et al., 2003). Apelin may therefore be offering some protection 
initially, but this potential benefit may be lost in the longer term. 
 
1.2.5 Metabolic effects of apelin 
In obesity, a major risk factor for cardiovascular disease, apelin levels are increased 
(Heinonen et al., 2005). Indeed, apelin has been shown to be produced in adipocytes 
(Boucher et al., 2005). A single intracerebroventricular (ICV) injection of apelin-13 
caused a decrease in food and water intake in obese rats eating normal chow, but had 
no effect on obese rats eating a high fat diet. Obese rats had higher hypothalamic 
APJ mRNA expression compared to controls. However, ICV apelin-13 administered 
to obese rats on a high fat diet caused downregulation of the APJ receptor (Clarke et 
al., 2009).  
 
Apelin may be associated with insulin resistance. In patients with established and 
treated type 2 diabetes mellitus, plasma apelin is increased (Li et al., 2006). 
Conversely, in newly diagnosed and untreated type 2 diabetics, apelin levels are 
lower than normal controls (Erdem et al., 2008). In a diabetic mouse model (db/db 
mouse), Zhong et al. (2007b) found an increased vasoconstrictor response to ATII 
and a decreased vasodilator response to acetylcholine (ACh) in aortic rings compared 
to those from control db/m+ mice. Preincubation of the db/db aortic rings with 
apelin, reduced the vasoconstrictor response to ATII and increased the vasodilator 
response to acetylcholine (ACh) to levels comparable with db/m+ control mice. 
These authors also identified a significant decrease in APJ protein expression in the 
aortas of db/db mice. In obese and insulin-resistant mice, intravenous apelin injection 
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lowered blood glucose and increased glucose utilisation in skeletal muscle (Dray et 
al., 2008). Taken together, these studies suggest a role for apelin in maintaining 
sensitivity to insulin. 
 
Hypertension, a condition which in 2005 was reported as affecting 26.4% of the 
global adult population (Kearney et al., 2005), is another potential therapeutic target 
for an apelin agonist. Although NO is thought to be responsible for the vasodilatory 
properties of apelin in healthy individuals (Japp et al., 2008); the effect appears to be 
prostanoid dependent in disease (Maguire et al., 2009). Whatever the mechanism, a 
wide range of endothelium intact human vessels (mammary artery, mesenteric artery, 
hepatic artery) vasodilate in response to apelin in vitro (Maguire et al., 2009; Salcedo 
et al., 2007). Promisingly, human forearm blood flow is increased in response to 
apelin in vivo (Japp et al., 2008) suggesting apelin as a potential antihypertensive. 
 
Therefore, activation of the apelin system may be of benefit in heart failure, obesity, 
diabetes and hypertension. However, peptide drug delivery is not possible orally and 
this presents a challenge. Last year, Itturrioz et al. (2009) described their discovery 
of the first non-peptidic apelin agonist, E339-3D6. With optimisation of this agonist 
and the development of future non-peptidic agonists, the apelin system may yet be 
able to be exploited for therapeutic gain. 
 
In addition to the potential therapeutic targets described above, apelin has also been 
termed “cardioprotective” in ischaemic heart models via pathways linked to the 
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hypoxia inducible factor-1α (HIF-1α) system which is involved in physiological and 
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1.3 Hypoxia and Ischaemia 
1.3.1 Hypoxia inducible factor-1α 
Hypoxia inducible factors are transcription factors involved in oxygen sensing and 
signalling in response to changes in cellular oxygen. There are three hypoxia 
inducible factors (HIF 1-3) which each comprise α and β subunits (Wenger, 2000). 
HIF-1α is widely expressed and essential. Knockout of the HIF-1α gene results in 
embryonic lethality in mice. Regression of the vascular system was observed at 
embryonic day 9.0 as well as sparse endothelium and although cell death was 
widespread throughout HIF-1a -/- mice, the heart did not show any evidence of cell 
death (Kotch et al., 1999).  
 
HIF-1α is marked for degradation by hydroxylation. The enzymes responsible for 
this are the prolyl hydroxylase (PHD) enzymes. These enzymes form a complex with 
iron, α-ketoglutarate (αKG) and oxygen in the cytoplasm in order to hydroxylate 
HIF-1α. When oxygen is present this complex can be formed and HIF-1α is 
degraded. However, in hypoxia, the complex cannot be formed. Instead, HIF-1α 
translocates to the nucleus where it forms a heterodimer with HIF-1β. This 
heterodimer binds to the hypoxia-response element (RCGTG) of hypoxia responsive 
genes and can initiate transcription (Qutub et al., 2006).  
 
1.3.1.1 The role of HIF-1α in apelin gene expression 
Apelin is up-regulated under hypoxic conditions by a HIF-dependent mechanism. 
Ronkainen et al. (2007) first described the link between apelin and HIF-1α by 
demonstrating that hypoxia increased apelin expression in rat myocardium and 
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cultured rat cardiomyocytes and that this effect could be abolished by the HIF 
inhibitory Per/Arnt/Sim protein. Furthermore, Eyries et al. (2008) identified the 
hypoxia-response element on the apelin gene and showed that cobalt chloride, by 
activation of the HIF pathway, promoted regeneration of the adult zebrafish caudal 
fin. By semiquantitative real-time PCR, this group also showed that apelin RNA 
expression was increased in regenerating fins treated with cobalt chloride. Chronic 
infusion of apelin-13 was also shown to attenuate the effects of pulmonary 
hypertension induced in rats exposed to hypoxia (Mao et al., 2009). 
 
1.3.1.2 Drugs modulating the HIF-1α pathway 
Drugs can modulate the HIF-1α pathway by upregulating or downregulating the HIF-
1α degradation pathway. Desferrioxamine (DFO) is an iron chelator and by this 
action stops the PHD complex being formed and consequently activates the HIF-1α 
pathway (Tang et al., 2008). Conversely, αKG is a substrate for the PHD enzymes, 
therefore speeding up the degradation of HIF-1α and thus having an inhibitory affect 











































Figure 1.2:  HIF-1α pathways and mechanism of action of HIF-1α modulators.  
In normoxia, HIF-1α is hydroxylated by a prolyl hydroxylase enzyme (which 
requires iron, α-ketoglutarate and oxygen to bind HIF-1α), targetting HIF-1α for 
degradation via the ubiquitin pathway. DFO binds iron thereby disrupting the PHD 
complex, inhibiting degradation of HIF and potentiating the HIF pathway. In 
hypoxia, HIF-1α translocates to the nucleus as in the absence of oxygen the PHD 
complex cannot form. HIF-1α forms a heterodimer with HIF-1β and binds to the 
hypoxia response element on hypoxia sensitive genes and can upregulate or 
downregulate gene transcription. 
DFO – desferrioxamine, α-KG - α-ketoglutarate, PHD – prolyl hydroxylase, VHL – 
von Hippel-Lindau factor, Asc – ascorbate, Ub – ubiquitin, HRE – hypoxia-response 
element. Adapted from Qutub et al. (2006). 
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1.3.2 Ischaemia 
Ischaemia is characterised by reduced blood flow which fails to provide sufficient 
oxygenation to tissues. Ischaemia always results in hypoxia in the tissues in question 
and, therefore, the two conditions are inextricably linked. Ischaemic heart disease, in 
which there is a reduction in blood flow to the myocardium, is a global problem and 
was responsible for 12% of deaths worldwide in 2004 (World Health Organisation, 
2004).  
 
1.3.2.1 The reported cardioprotective effects of apelin 
As apelin expression has been shown to be influenced by hypoxia, it is unsurprising 
that the effect of apelin in ischaemia has been studied. In a model of coronary artery 
ligation in isolated perfused mouse hearts, apelin-13 and apelin-36 were shown to be 
cardioprotective as reperfusion in the presence of exogenous apelin resulted in a 
smaller infarct size than reperfusion with saline alone (Simpkin et al., 2007). 
 
Similarly, Kleinz et al. (2008) demonstrated that pyr-apelin-13 reduces infarct size in 
a coronary artery ligation model in isolated perfused rat hearts when administered 
during reperfusion, but not when administered during the ischaemic period. In 
contrast to the work of Simpkin et al. (2007), Kleinz et al. (2008) found that the 
cardioprotective effect of apelin in the rat heart was not mediated via PI3K/Akt in the 
reperfusion injury salvage kinase (RISK) pathway. 
 
In a rat model of isoproterenol-induced myocardial injury, apelin and APJ mRNA 
expression was decreased, while APJ receptor protein expression was increased. 
   20 
Apelin treatment of these animals resulted in an improvement in left ventricular (LV) 
contractility parameters such as an increase in left ventricular developed pressure 
(LVDP), LV dP/dt max and LV dP/dt min. Furthermore, treatment with high or low 
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1.4 Zebrafish: a model organism for cardiovascular research 
Zebrafish (Danio rerio (Dr)) (Fig 1.3) are an ideal model for research. In comparison 
to rodents, they are far cheaper to maintain and breed. Large numbers of offspring 
can be collected weekly from one tank of adult fish and this can be expected to be 
maintained for 12 - 18 months (see Rocke et al., 2009). The large numbers of eggs 
collected mean that experimental studies can use high numbers of embryos; much 
higher than would be realistic in a rodent study. There is however arguably more 
variation among populations of zebrafish embryos, even among offspring collected 



















Figure 1.3: Adult zebrafish (i) and optically transparent embryonic zebrafish (3 
days post fertilisation (dpf)) (ii).  
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In particular, zebrafish embryos are a key model in the cardiovascular field as their 
optical transparency allows the heart and vasculature to be visualised non-invasively 
by light microscopy. Embedding the zebrafish embryos in agar, which has been 
shown to have no detrimental effects on the embryo (Craig et al., 2006; Denvir et al., 
2008), allows clear and reproducible images to be gathered as the fish are held still 
without anaesthesia. Although anaesthetic must be administered for the embedding 
process, this has minor effects on heart function and is fully reversible within 30 
minutes (Denvir et al., 2008). Once zebrafish are embedded detailed measurements 
of heart function may be carried out using techniques such as ultrasound (Sun et al., 
2008) and, as in this study, video edge detection of heart wall motion (Denvir et al., 
2008). 
 
The effect of drugs can also be studied. Drugs can be injected into zebrafish embryos 
(Milan et al., 2003), but are more commonly administered to embryos through the 
bathing water and this has been performed successfully in many studies (Denvir et 
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1.4.1 Development of zebrafish embryos 
Development of the zebrafish embryo is a rapid process of which the key features 
can be observed by light microscopy and is summarised in Fig 1.4 (Kimmel et al., 
1995). Development begins with a cleavage period (0.75 – 2.25h) in which cells 
(blastomeres) divide at approximately 15 minute intervals. The blastula period (2.25 
– 5.25h) encompasses the period in development where the blastomeres appear as a 
ball of cells, now termed the blastoderm. During the blastula period, the embryo 
enters midblastula transition in which zygotic gene transcription is activated and 
translation of maternally inherited mRNA ends (Kane and Kimmel, 1993). The yolk 
syncytial layer (YSL) is formed when the cytoplasm and nuclei of the blastomeres on 
the margin next to the yolk cell are released into the cytoplasm of the yolk cell 
immediately next to the blastoderm. Epiboly begins in the late blastula period and 
continues in the gastrula period (5.25 – 10h) (Kimmel et al., 1995). 
 
Epiboly is a process of thinning and spreading of cell layers and continues during the 
gastrula period (5.25 – 10h). The blastoderm moves towards the outermost layer of 
cells termed the enveloping layer (EVL). Both EVL and blastoderm cell layers now 
move around the border of the embryo, gradually enclosing more and more of the 
yolk cell (see Fig 5.1). At the end of the gastrula period the yolk cell is surrounded 
completely (Kimmel et al., 1995). The segmentation period (10 – 24 h) follows, in 
which the number of somites increase as does the length of the embryo. The tail bud 
forms and the first organs develop, including the brain, otic vesicles and the 
pronephric kidney. The majority of cells within the somites become muscle cells and 
the first weak muscular contractions are visible at this stage of development. At the 
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end of the segmentation period, the blood island is clearly visible and contains 
dividing and differentiating blood cells (Herbomel et al., 1999). 
 
The pharyngula arches develop during the pharyngula stage (24 – 48 h). These 
arches will become the jaw, operculum and the gills. The heart is first visible at this 
stage below the brain. The heart begins to beat, at first with no direction, and later as 
a peristaltic wave. The vasculature is now also visible and blood cells circulate 
(Kimmel et al., 1995).  Other organs including the intestines are thought to be 
developing around this time, but cannot be visualised by light microscopy. During 
the hatching stage (48 – 72h), pectoral fins, jaw and gills develop and embryos hatch 




























































Figure 1.4: Camera lucida sketches of the zebrafish embryo at selected 
developmental stages. 
Arrowheads indicate the smooth surface between blastoderm and yolk cell at the sphere stage (4h) 
(section 5.1.4.3) and the EVL, blastoderm, YSL and yolk cell involved in epiboly (section 5.1.2). 
Arrowheads also indicate the developing heart at 31h, 48h and 72h. The heart is first visible at 31h in 
these images, appears as a tube at 48h and heart looping has taken place by 72h. Scale bar 0.5 mm. 
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1.5 Hypothesis and Aims 
1.5.1 Hypothesis 
This study hypothesises that the peptide apelin and its receptor are involved in a 
range of cardiovascular mechanisms including cardiac inotropy, vasodilatation and 
cardioprotection. These mechanisms are conserved across species. 
 
1.5.2 Models for the investigation of the cardiovascular effects of apelin 
In order to investigate the cardiovascular effects of apelin, rat and zebrafish models 
were used. The rat models (isolated perfused rat heart, isolated papillary muscles and 
myography) were chosen as these are well-characterised in vitro techniques for the 
study of potentially vasoactive and inotropic agents which were also well established 
in our laboratory. Indeed, in the discovery of the functional effects of the peptide 
endothelin, all three of these models have been used (Henriksson et al., 2003; Qi et 
al., 2001; Yamamoto et al., 2004). The isolated perfused rat heart experiments were 
performed in this model as in addition to studying the inotropic effect of apelin, this 
model had the potential to perform a cardioprotection study. 
 
The zebrafish was used as it allowed for rapid measurement of cardiovascular 
parameters in vivo and drugs could be administered easily via the bathing water. This 
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1.5.3 Aims 
In order to investigate this hypothesis, the aims of the work were: 
i. to study the inotropic effects of apelin in vitro in isolated papillary muscles 
and atrial strips and in the isolated, perfused rat heart (Langendorff) 
ii. to determine whether apelin has vasoactive properties in vivo and in rat 
mesenteric resistance arteries in vitro 
iii. to develop a hypoxia-recovery model in the zebrafish and to use this model to 
investigate the influence of the apelin system on the cardiovascular response 
to hypoxia 
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2.1 Apelin in vivo in the rat 
Animals were used in accordance with the Animals (Scientific Procedures) Act 1986 
and with local ethical consent. All rats used in this study were housed in the Little 
France Biomedical Research Facility at the University of Edinburgh, except where 
clearly stated, on a 12h light: 12h dark cycle with free access to food and water. 
 
A series of in vivo experiments were performed. Male Wistar rats (200 – 500 g, n = 
16) were anaesthetised by inhalation of isoflurane. The rats were placed in an 
anaesthetising chamber and anaesthesia was induced by 5% isoflurane  
delivered in 100% oxygen.  After induction, anaesthesia was maintained with 2 - 
2.5% isoflurane in 100% oxygen via a nose cone. The rat was placed on a heat pad 
(27 °C) and the depth of anaesthesia was confirmed by the absence of a withdrawal 
reflex in response to a strong paw pinch. The jugular vein and carotid artery were 
cannulated by insertion of cannula tubing (outer diameter 0.96 mm, inner diameter 
0.58 mm) (Jencons, Leicestershire, UK). Apelin was administered via the jugular 
vein. Data was recorded by a Powerlab™ recorder and analysed by Chart 5 software 
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2.2 Papillary muscle and atrial strip preparations 
Male Sprague Dawley rats (300 - 450 g) were sacrificed by cervical dislocation. The 
heart was rapidly excised and placed in chilled (4 °C) Krebs-Henseleit solution (KH) 
((in mM) NaCl 119, KCl 4.7, CaCl2 2, MgSO4 1.17, NaHCO3 25, KH2PO4 1.18, 
ethylenediaminetetraacetic acid (EDTA) 0.026 and D-glucose 5.5) and allowed to 
beat to expel blood before being transferred to chilled KH (containing 2,3-
butanedione 2-monoxime (30 mM)). Pinning the apex to hold the heart in place, the 
right ventricle was carefully opened and right ventricular papillary muscles were 
dissected free by first freeing the chordae and secondly freeing the base of the 
papillary muscle. Right atrial strips were dissected by cutting a strip free from the 
atria, allowing the muscle fibres to run down the length of the tissue strip. A loop 
was tightened around the chordae of the papillary muscle or one end of the atrial strip 
and the base of the muscle was held in place by a clip attached to a tissue holder. The 
tissue holder was mounted vertically in line with a micrometer via a wire rod 
connected to a force transducer (World Precision Instruments, Stevenage, UK). The 
tissue holder with papillary muscle or atrial strip was quickly placed in a tissue bath 
containing KH maintained at 35 °C and bubbled continuously with 95% O2/5% CO2. 
 
The base of the tissue holder had embedded point electrodes permitting electrical 
stimulation at a voltage 30% above threshold. Papillary muscles were stimulated at a 
rate of 2 Hz (duration 2 ms); atrial strips were stimulated at a rate of 1 Hz (duration 5 
ms) and allowed to equilibrate over a period of 30 minutes prior to any experimental 
protocol beginning. Any muscle preparation that demonstrated more than a 30% drop 
in peak developed force within this equilibration period was discarded. Data was 
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recorded continuously by a Powerlab™ recorder and analysed by Chart 5 software 
(ADInstruments, Oxfordshire, UK). 
 
2.3 Isolated, perfused rat heart (Langendorff) 
Rats were housed in the animal facility of the Glasgow Cardiovascular Research 
Centre at the University of Glasgow on a 12h light: 12h dark cycle with free access 
to food and water. Male Wistar rats (250 g) were killed by concussion followed by 
cervical dislocation. The heart and surrounding tissue was rapidly excised and placed 
in cold (4 °C) HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer 
((in mM) NaCl 140, KCl 4, MgCl2 1, HEPES 5, glucose 11.1; pH 7.4) and washed 
gently to remove blood before transferring to another beaker of cold HEPES buffer. 
The heart and aorta were dissected free of adhering tissue. The aorta was held below 
the cannula for a few seconds to allow it to fill with solution before clipping and then 
securely tying the aorta onto the cannula. The heart was perfused with Tyrodes 
solution ((in mM) NaCl 116, NaHCO3 20, Na2HPO4 0.4, MgSO4 1, KCl 4, glucose 
11, CaCl2 2.5) at 10 ml/min and maintained at 37 ± 1 °C for the duration of the 
experiment. 
 
For measurement of left ventricular pressure, a latex balloon (size 5, Harvard 
Apparatus Ltd., Kent, UK) was attached to a cannula (Harvard Apparatus Ltd., Kent, 
UK) and connected to a syringe via a fluid filled tube (Fig 2.1). A pressure-volume 
catheter (Millar Instruments, Texas, USA) was inserted through the cannula and held 
in place using a connected haemostat valve. An incision was made in the left atrium 
and a hole was cut to allow the mitral valve to be seen. The balloon was deflated and 
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fed through the left atrium and mitral valve using forceps. Once positioned in the 
ventricle the balloon was inflated with distilled water using the attached syringe to 
achieve a diastolic pressure of 5 mmHg as recorded by Chart 5 software 
(ADInstruments, Oxfordshire, UK). 
 
Pacing wires were attached to the right atrium and the heart was paced at 5 Hz 
(duration 2 ms) using a constant voltage isolated stimulator (Digitimer Ltd., 
Hertfordshire, UK) attached to a generator. The effect of apelin-16 on the isolated 
heart was then studied by adding apelin-16 to the perfusate. 
 
Figure 2.1: Isolated, perfused, rat heart (Langendorff). 
The aorta is cannulated for retrograde perfusion of the heart. A balloon is inserted 
into the LV via the left atrium and pacing wires are attached to the RA.  
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2.4 Myography 
Male Sprague Dawley rats (300 - 400 g) were sacrificed by cervical dislocation. The 
mesentery was removed from the animal and pinned out on a petri dish in chilled (4 
°C) PSS. Adherent fat and the mesenteric vein were cut away. Second or third order 
mesenteric arteries were then cut free of the mesentery with a single cut at each end 
to give vessels approximately 2 mm in length.  
 
A 40 µm tungsten wire was attached to the myograph chamber containing chilled 
KH solution. This wire was passed through the lumen of the vessel and secured to 
the myograph so that this wire secured the vessel to the transducer. A second wire 
was passed through the lumen and secured at both ends to a micromanipulator. The 
vessel length was then measured using a graticule eyepiece attached to the 
microscope. The myograph chamber was then placed back onto the myograph and 
the chilled KH was replaced with warm (37 °C) KH. 
 
Resting tension was increased slowly to 6 mN in second order mesenteric arteries 
and 4 mN in third order mesenteric arteries. Vessels were allowed to equilibrate for 
30 minutes at resting tension and were then re-tensioned after 15 minutes to correct 
for a drop-off in tension before beginning the experimental protocol described in 
chapter 4. Data was recorded by a Powerlab™ recorder and analysed by Chart 5 
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2.4.1 Data analysis 
PE concentration response curves were expressed as contraction in mN per mm of 
vessel length, calculated by the following: 
 
Relaxation of vessels to ACh was expressed as the percentage relaxation of PE 
preconstriction. pD2 (negative log of the EC50) and slope of PE and ACh 
concentration response curves were determined by GraphPad Prism 5.0 (GraphPad 
Software Inc., California, USA) by nonlinear regression. Where a sigmoidal curve 
was not fitted by Prism 5.0 automatically, the slope was fixed to 1 or the top and 
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2.5 Zebrafish Husbandry 
All zebrafish used for the studies presented in this thesis were kept in the Biomedical 
Research Resources Zebrafish Facility at the Queen’s Medical Research Institute, 
University of Edinburgh in 10 L tanks (Aquatic Habitats, Florida, USA) on a 14 h 
light: 10 hour dark cycle. Water temperature (26 – 28 °C) and pH (6.8 – 7.5) were 
checked daily. Ammonia (< 0.25 mg/L), nitrate (< 200 mg/L) and nitrite (< 0.15 
mg/L) levels as well as conductivity (180 – 350 µS) were measured weekly and 
maintained within levels appropriate to the maintenance of zebrafish stocks 
according to Brand et al. (2002). Zebrafish were fed twice daily.  
 
2.5.1 Collection of fertilised eggs (Marbling) 
Each tank was marbled as required to provide embryos for experiments. The evening 
before eggs were required, a tray of marbles on a wire mesh with a solid box 
underneath was placed into the tank. The following morning approximately an hour 
after the lights came on, the tray was removed from the tank and the water in the 
bottom of the box was passed through a tea strainer to collect eggs. Eggs were placed 
in a petri dish of dechlorinated system water containing methylene blue and placed in 
an incubator maintained at 28.5 °C. The water in the petri dishes was cleaned daily 
until the fish were prepared for an experiment. 
 
2.5.2 Pair mating 
In cases where large quantities of zebrafish eggs were required for experiments or 
when tanks of fish were not producing enough eggs regularly, pair mating was 
carried out. This involved putting one female and two males in a smaller tank and 
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separating the female from the male fish by a clear plastic barrier the evening before 
eggs were required. Marbles and plastic greenery were also placed in the tank. The 
barrier was removed from the tank as the lights came on the following morning and 
the fish were left for up to 2h before the water was strained and eggs collected and 
incubated as described above. 
 
2.6 Zebrafish Experiments 
2.6.1 Video edge detection 
Video edge detection was used to measure zebrafish ventricular wall motion. 
Zebrafish embryos were anaesthetised in MS-222 (tricaine) (20 µM) which blocks 
sodium channels to inhibit the generation and conduction of action potentials 
(Hedrick et al., 2003). The embryos were placed into molten agar, taking care to 
make sure it was not too hot, and orientated on their sides using forceps. 
Dechlorinated system water was added on top of the solidified agar. Embedded 
zebrafish were allowed to recover overnight in the incubator (28.5 °C) and could 
then be examined without anaesthesia.  The system water in each dish was replaced 
before the start of each experiment. 
 
A black and white high frame rate video camera (120 Hz) attached to a light 
microscope (Axioskop II MOT compound microscope) with a x 40 water dipper 
objective lens was used to visualise the hearts of the zebrafish. Video edge detection 
software (IonOptix Ltd., Dublin, Ireland) allows an image of the zebrafish ventricle 
to be observed continuously on a computer monitor. The IonOptix system is adapted 
from that used for tracking the motion of isolated cardiomyocytes. A cursor is placed 
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on the zebrafish ventricle wall to track its movement. The tracking of the wall can be 
controlled by adjusting settings on the software such as width and sensitivity of the 
signal and also by altering the light and focus on the microscope. The movement of 
the cursor as it tracks the ventricle wall is recorded as a continuous trace consisting 
of multiple movement transients (Fig 2.2). From these transients the following 
parameters of zebrafish ventricular wall motion can be determined: contraction 
velocity, relaxation velocity, magnitude of wall motion and heart rate. Each transient 
represents one cardiac cycle. Between 10 and 20 transients were analysed for each 
fish at each condition and time point, in no more than two groups of consecutive 
transients. This technique was used to study regional differences in the wall motion 
of the zebrafish embryo ventricle and to assess both the effect of drugs and hypoxia 
on ventricular wall motion. Further details of these experiments can be found in the 
relevant chapters. 
Figure 2.2: Video edge detection. 
Video edge detection produces transients, each representing one cardiac cycle. 
Contraction velocity, relaxation velocity and wall motion amplitude are calculated 
from IonOptix software as shown. Contraction is downwards as length decreases. 
Enlargement is of boxed area. 
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2.6.1.1 Regional differences in ventricle wall motion in the zebrafish embryo 
During preliminary experiments, we observed that wall motion varied depending on 
the region of the zebrafish embryo ventricle measured. Therefore, experiments were 
conducted to investigate the differences in wall motion at five regions of interest in 
order to determine the region that would be best suited to further experiments. 
 
The zebrafish embryo ventricle was split into five regions of interest: inner wall, 
outer wall, inner near bulbus arteriosus, outer near bulbus arteriosus and the apical 
region (Fig 2.3). For each embryo in these experiments, as many as possible of these 
five regions of interest were tracked using the video edge detection system allowing 
the calculation of contraction velocity, relaxation velocity, amplitude of wall motion 










Figure 2.3: Zebrafish embryo heart. 
Zebrafish embryo heart diagram with ventricular wall regions of interest: outer mid, 
inner mid, outer near bulbus arteriosus (BA), inner near BA and apical region. 
Shaded area represents atrioventricular valve. Arrows show direction of blood flow. 
SV – sinus venosus, A – atrium, V – ventricle. 
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Zebrafish (3 dpf) had a HR of 156.3 ± 6.4 bpm (n = 4, 4 - 6 embryos per 
experiment). Contraction velocity and relaxation velocity were significantly faster at 
the apical region than at all other regions measured (P < 0.0001 one-way ANOVA; 
Fig 2.5). Wall motion amplitude was greater at the apical region than all other 
regions (P < 0.0001 one-way ANOVA; Fig 2.6). No differences were found between 





















Figure 2.4: Representative traces and values showing regional differences in 
ventricular wall motion in a zebrafish embryo 3 dpf. 
CV – contraction velocity (µm/s), RV – relaxation velocity (µm/s), WMA – wall 
motion amplitude (µm), V – ventricle, BA – bulbus arteriosus. Contraction is 
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Throughout these experiments, we observed that the apical region was the region that 
could be captured most reproducibly. However, as this region had greater contraction 
velocity, relaxation velocity and wall motion amplitude, it was important to re-
measure the same region in a given embryo in the case of experiments carried out 
over time. Therefore, for all experiments presented in this thesis, measurements have 
been made at the apical region where possible. If this was not possible, 
measurements were made at an alternative region and where the experiment was 






















Figure 2.5: Regional differences in contraction and relaxation velocity in 
zebrafish embryos 3 dpf.  
Contraction velocity: apical region vs. outer near BA * P < 0.05, apical region vs. all 
other regions *** P < 0.001 by one-way ANOVA; Relaxation velocity: apical region 






























Figure 2.6: Regional differences in wall motion amplitude in zebrafish embryos 
3 dpf. 
Apical region vs all other regions *** P < 0.001 by one-way ANOVA. n = 4, 4 – 6 
embryos per experiment.  
 
2.6.1.2 Zebrafish isolated embryonic hearts  
Transgenic zebrafish (cardiac myosin light chain 2: green fluorescent protein 
(cmlc2:GFP)) (Burns et al., 2005) (3 dpf and 4 dpf) were anaesthetised with MS-222. 
HEPES buffer (pH 7.4) was prepared, which contained: (in mM) (HEPES 10, NaCl 
136, KCl 5.4, MgSO4 1, Na2HPO4 0.3, glucose 10, CaCl2 2.5). Bovine serum 
albumin (BSA) (600 mg per 50 ml HEPES buffer) was added to the prepared buffer. 
Anaesthetised embryos were placed one at a time into the HEPES buffer plus BSA 
solution and their hearts were visualised using a dissection microscope with GFP 
filter. Hearts were isolated mechanically using one pair of forceps to hold the tail of 
*** 
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the embryo and the other to detach the heart by quickly and carefully freeing it from 
the surrounding tissue (Fig 2.7). 
 
A 20 µl pipette was used to place the heart in a well in a prepared mould. HEPES 
buffer (without BSA) (3 ml) was added and an Axioskop II MOT compound 
microscope with a x 40 water dipper objective lens was used to locate the heart. 
Video edge detection, as described above, was used to measure isolated embryonic 












Figure 2.7: Isolated heart from zebrafish 3 dpf. 
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2.6.2 Measurement of ejection fraction 
Ejection fraction was measured by anaesthetising embryos with minimal anaesthetic 
which inhibited swimming, but not heart function. A black and white high frame rate 
video camera attached to a light microscope (Axioskop II MOT compound 
microscope) with a x 40 water dipper objective lens was used to visualise the hearts 
of the zebrafish. The camera was attached to a Pinnacle Studio™ MovieBox (Avid 
Technology, S.L., Madrid, Spain) which allowed recording of a video of the heart 
using the Pinnacle Studio™ software. This video was processed using VirtualDub 
software (www.virtualdub.org) to convert the video file into a series of still images. 
Using ImageJ software (http://rsb.info.nih.gov/ij/), the area of the ventricle (in 
pixels) was measured in systole and diastole in three consecutive cardiac cycles. The 
ejection fraction (EF) was calculated for each cardiac cycle using the formula:  
  
 
The mean ejection fraction from three cardiac cycles was used as the ejection 
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2.6.3 Semi-quantitative scoring assessment: Hypoxia-Recovery Model 
I developed a zebrafish embryo cardiac hypoxia-recovery model as part of the 
experimental work leading to this thesis. Zebrafish (3 dpf and 5 dpf) in dechlorinated 
system water were placed in the hypoxic chamber (1% oxygen, 94% nitrogen, 5% 
carbon dioxide; 26 °C) for 2h or 4h. After the assigned time in the hypoxic chamber, 
heart and circulatory function were assessed under a light microscope and each fish 
was described as having normal, reduced or absent heart rate (HR) and circulation 
compared to normoxic controls. A reduced HR was defined as less than 100 bpm. 
Circulatory assessments were also made 2h and 4h post-treatment recovery in 
normoxic conditions. Zebrafish embryos were euthanised in MS-222 and placed in 
RNAlater
®
 (used according to manufacturer’s instructions) (Applied Biosystems, 
Warrington, UK) for subsequent qualitative and quantitative assessment of 
abundance of mRNA of interest (see chapter 6).  
 
Using this semi-quantitative assessment of global cardiovascular function, I was able 
to quite rapidly screen large numbers of embryos using a number of drugs that could 
potentially affect the hypoxic response. This emerged as a more efficient 
methodology for screening candidate drugs compared to the video edge detection 
system where we could use only small numbers of embryos and screen fewer drugs 
in a more time consuming approach. For example, using video edge detection, 4 
embryos per group could be measured at a given timepoint, compared to screening of 
10 embryos per group per timepoint using the global circulatory assessment. 
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A typical experimental protocol involved zebrafish embryos (5 dpf) incubated in a 
candidate drug or its vehicle for 1h before the embryos were exposed to hypoxia (1% 
oxygen) or normoxia for 2h. Qualitative assessments of cardiovascular function were 
made before, immediately after, and at 2h and 4h post-treatment recovery in 
normoxic conditions (see chapter 6). 
 
2.6.4 Morpholino 
2.6.4.1 General applications of MO technology 
Morpholino technology is widely used in zebrafish research. Morpholinos are nucleic 
acid analogues which bind to mRNA and allow knockdown of expression of a gene 
of interest (Summerton, 1999). Morpholinos can be injected into embryos from the 
one cell stage until the 16 cell stage and knockdown expression of the gene of 
interest. Morpholinos act by blocking translation or appropriate splicing by binding 
near the start codon AUG or binding (Fig 2.8) at an exon/intron boundary, 
respectively (Fig 2.9). Successful knockdown of gene expression can be 
demonstrated by western blot or immunohistochemistry in the case of a translation 
blocking morpholino where an antibody is available. RT-PCR or qPCR is used to 
show successful knockdown of expression in experiments using splice blocking 














Figure 2.8: Translation blocking morpholinos. 
Morpholinos blocking translation bind to or near to the start codon ATG to sterically 








Figure 2.9: Morpholinos interfering with correct splicing of a pre-mRNA bind 
at an exon/intron boundary. 
In this example, the morpholino binds at the boundary of exon 2/intron 2 sterically 
inhibiting binding of the spliceosome. This causes alternative splicing which results 
in deletion of exon 2 in the final mRNA transcript (I1 – intron 1, I2 – intron 2; Figure 
from www.gene-tools.com). 
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2.6.4.2 Zebrafish microinjection of morpholinos 
Needles for morpholino injections were prepared from glass capillaries (outer 
diameter 1 mm, inner diameter 0.78 mm; Harvard Apparatus Ltd., Kent, UK) using a 
P-97 micropipette puller (Sutter Instrument Company, CA, USA). Morpholinos were 
diluted, as required, in potassium chloride (1 mM). Morpholinos were loaded into the 
prepared needles and attached to a micromanipulator (Narishige International Ltd., 
London, UK). The micromanipulator was connected to the IM-300 microinjector 
(Narishige International Ltd., London, UK). The system was balanced by air in a 
pressurised gas cylinder which was set to a pressure of approximately 15 psi 
throughout the morpholino injections. The quantity of each morpholino injected was 
calculated by injecting a bolus of morpholino into a drop of mineral oil on a graticule 
(see section 5.2.4.2). Then, eggs (1 – 4 cell) were lined up on a plastic mould with 
minimal water and the morpholino was injected into the cytoplasmic streaming area 
of the egg (Fig 2.10). After injection, eggs were transferred to system water 
containing methylene blue and stored in an incubator (28.5 °C). 
 
 
Figure 2.10: Morpholinos are injected into the cytoplasmic streaming area in 1 – 
4 cell eggs. 
Figure adapted from Kimmel et al., 1995. 
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2.7 Molecular techniques 
2.7.1 Western Blotting 
2.7.1.1 Protein extraction and quantification 
Tissue for protein extraction was dissected on ice and kept in PBS until all samples 
were prepared. Tissue was weighed and protein was extracted by 5 minutes 
incubation in RIPA buffer on ice (300 µl per 100 mg tissue) containing 
phenylmethylsulfonyl fluoride (1 mM) and protease inhibitors (Sigma-Aldrich 
protease inhibitor cocktail P2714: AEBSF 2 mM, E-64 14µM, Bestatin 130 µM, 
Leupeptin 0.9 µM, Aprotinin 0.3 µM, EDTA 1 mM). Tissue was then homogenised 
with two metal beads in a mixer mill MM301 (60 – 120 s; 30 Hz) (Retsch, Leeds, 
UK). The beads were removed and each sample was centrifuged and the protein 
supernatant collected and stored (-20 °C). 
 
Protein was quantified using a bicinchoninic acid (BCA) assay kit (Thermo Scientific 
UK Ltd., Loughborough, UK). Protein samples were diluted 1/10 and loaded in 
duplicate in a 96-well plate with protein standards (Thermo Scientific UK Ltd., 
Loughborough, UK). A colourimetric dye was added to the samples before 
incubation in the dark for 30 minutes. Absorbance at a wavelength of 562 nm was 
detected and measured by a MRX microplate plate reader (Dynex Laboratories Ltd., 
West Sussex, UK). Protein concentrations were calculated by comparison with the 
standard curve. Protein samples were diluted with a 1% sucrose solution and loading 
dye (dithiothreitol (DTT) 0.5 M, sodium dodecyl sulfate (SDS) 10%, sucrose 14%, 
bromophenol blue 0.01%) to a final protein content of 7.5 µg per sample. 
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2.7.1.2 Blotting and Transfer 
Prepared protein samples were incubated at 95 °C with DTT (0.5 M) for 5 min and 
loaded (20 µl) on a protein gel (Thermo Scientific UK Ltd., Loughborough, UK). 
Samples were run using SDS/Tris/Hepes running buffer (x 1) (Thermo Scientific UK 
Ltd., Loughborough, UK) in a gel tank at 100 V for 45 min. Protein from the gel was 
then transferred to a polyvinylidene fluoride (PVDF) membrane by a wet transfer 
method (200 mA, 60 min) using transfer buffer (Tris base pH 8.3 25 mM, glycine 
192 mM, methanol 20%). 
 
2.7.1.3 Probing with anti-rat APJ antibody 
Blocking was performed using 5% dried milk in TBST (NaCl 137 mM, Tris base pH 
7.5 20 mM, Tween 20 0.1%) for 1h before overnight incubation in anti-rat APJ 
diluted in TBST with 5% dried milk (1:1250) (GeneTex, Inc., distributed by Patricell 
Ltd., Nottingham, UK; Cat no: GTX78179). After 3 x 5 min washes in TBST, the 
membrane was incubated in TBST containing secondary anti-rabbit IgG conjugated 
to horseradish peroxidise (1:10,000) (Santa Cruz Biotechnology, Heidelberg, 
Germany; Cat no: SC-2030) for 2h. Finally, 3 x 5 min TBST washes were 
performed. The membrane was placed on a shaker or roller for all blocking, washing 
and antibody incubation steps. With the exception of overnight incubation in primary 
antibody which was performed at 4 °C, all steps were carried out at room 
temperature. Enhanced chemiluminescence (ECL) (GE Healthcare, 
Buckinghamshire, UK) was applied to the membrane according to manufacturer’s 
instructions. Photographic film was exposed to the ECL-loaded membrane for 40 
minutes in a dark room to visualise the protein bands.  
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2.7.1.4 Membrane stripping and re-probing  
To perform a loading control on the same PVDF membrane, the membrane was 
stripped by incubation (70 °C, 1h) in stripping buffer (SDS 2%, Tris base 62.5 mM 
pH 6.8, β-mercaptoethanol 0.8%), followed by washing in TBST (4 x 5 min). The 
membrane was blocked in 5% dried milk in TBST for 1h. Incubation in anti-rabbit 
GAPDH (1:10,000) (Sigma Aldrich, Dorset, UK; Cat no: G9545-2UL) was then 
carried out overnight. Following 3 x 5 min TBST washes, the membrane was 
incubated in TBST containing secondary anti-rabbit IgG conjugated to horseradish 
peroxidise (1:10,000) (Santa Cruz Biotechnology, Inc., Heidelberg, Germany; Cat 
no: SC-2030) for 2 h. Finally, 3 x 5 min TBST washes were performed before 
visualisation with ECL (exposure 20 minutes) as before. 
 
2.7.2 Polymerase chain reaction (PCR) 
2.7.2.1 RNA extraction and quantification 
RNA from adult zebrafish heart was extracted using trizol (Invitrogen, Paisley, UK) 
by the following method. Adult zebrafish (n = 9) were killed by overdose with 
tricaine. Hearts were dissected free and placed in RNAlater
®
 (Applied Biosystems, 
Warrington, UK). RNA extraction was performed by homogenising hearts in groups 
of 3 in trizol (500 µl) using a bead mixer mill (60 s; 30 Hz) proceeding according to 
the manufacturer’s instructions. To eliminate potential DNA contamination, each 
RNA sample was treated with DNase I (Roche Diagnostics Ltd., West Sussex, UK). 
 
RNA extraction from zebrafish embryos was performed using the RNeasy mini kit 
(Qiagen Ltd., West Sussex, UK) which allowed sufficient RNA to be extracted using 
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10 embryos per group. Embryos were stored in RNAlater
®
 after experimental 
treatments and were homogenised in buffer RLT (provided in the kit) using a bead 
mixer mill (45 s; 30 Hz) immediately before RNA extraction. DNase treatment was 
performed at the time of RNA extraction using the DNase I kit (Qiagen Ltd., West 
Sussex, UK) according to manufacturer’s instructions.  
 
RNA was quantified using a NanoDrop
®
 spectrophotometer ND-1000 (Thermo 
Scientific, Delaware, USA) which measured absorbance at a wavelength of 260 nm 
(extinction coefficient 40 ng/µl). RNA integrity was verified by: (i) a 260 nm/280 nm 
absorbance ratio close to 2 and (ii) by running RNA samples with cresol red loading 
dye at 100 V for 1 h on a 1% agarose gel (Promega, Southampton, UK). RNA 
samples were visualised with ethidium bromide (2 µM) as two bands corresponding 
to the 28S and 18S ribosomal subunits which are present in a 2:1 ratio in eukaryotic 










Figure 2.11: RNA gel showing ribosomal subunits 28S and 18S in a 2:1 ratio confirming 
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2.7.2.3 Reverse transcription PCR 
RNA was transcribed to cDNA (0.5 – 1 µg) using a high capacity cDNA reverse 
transcription kit (Applied Biosystems, Warrington, UK) according to manufacturer’s 
instructions. A water only negative control was included as were controls which 
omitted the reverse transcriptase enzyme. These negative controls demonstrate that 
there are no genomic DNA contaminants or other contaminants in the sample. 
 
Detection of mRNA of interest was achieved by PCR (see relevant chapters for 
details). Primer pairs were designed using Primer 3 software followed by entering the 
amplicon in BLAST to ensure its specificity. PCR was performed using primer pairs 
(Eurofins MWG Operon) and PCR Master Mix (Promega UK Ltd., Southampton, 
UK). Each 25 µl PCR reaction volume contained cDNA (1 µg), forward and reverse 
primers (0.4 µM each), Taq DNA polymerase (0.625 units), dNTPs (200 µM each) 
and MgCl2 (1.5 mM). The PCR program was as follows: 94 °C for 5 min, 30 cycles 
of 94 °C for 15 s, 55 °C for 30 s and 72 °C for 1 min, followed by 72 °C for 10 min.  
PCR products were separated by electrophoresis at 100 V on a 1% agarose gel 
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2.7.2.4 Reverse Transcription Quantitative PCR 
For reverse transcription quantitative PCR (qPCR) experiments, RNA was extracted 
from zebrafish embryos as described above. The universal probe library (UPL) 
(Roche Diagnostics Ltd., UK) was used. The Assay Design Center on the Roche 
website (http://www.roche-applied-science.com/sis/rtpcr/upl/ezhome.html) allowed 
qPCR assays to be designed for mRNA of interest in zebrafish. 
 
PCR was performed using primer pairs (Eurofins MWG Operon) and LightCycler
®
 
480 Probes Master Mix (Roche Diagnostics Ltd., UK). Each sample was assayed in 
triplicate. Each 10 µl qPCR reaction volume contained cDNA (0.0125 µg), 1 x 
LightCycler
®
 480 Probes Master Mix (containing FastStart Taq DNA Polymerase, 
reaction buffer, dNTP mix (with dUTP instead of dTTP) and MgCl2 6.4 mM), UPL 
probe (100 nM), forward and reverse primers (200 nM each). QPCR was performed 
using a LightCycler480
®
 (Roche Diagnostics Ltd., UK) which detected the 
fluorophore FAM. The qPCR program was as follows: 95 °C for 5 min, 50 cycles of 
95 °C for 10 s, 60 °C for 30 s and 72 °C for 1 s, followed by 40 °C for 30 s. 
 
Standard curves (slope -3.3, efficiency 1.7 – 2.1, R
2
 > 0.9; Fig 2.12) made by serial 
dilutions of pooled cDNA (0.5 µg) (1/4 – 1/1024) for each primer-probe set were 
performed to validate the qPCR assays. For each experiment, appropriate reference 
genes that did not change across experimental groups were selected. Transcripts were 
quantified by comparison with the standard curve and the mRNA of interest was then 
corrected by the mean of the appropriate reference genes. 
 
 



















2.8 Statistical Analysis 
Data are presented as mean ± standard error of the mean (SEM). Comparison of two 
groups was made by unpaired t-tests (GraphPad Prism
®
 5.0). Comparison of three or 
more groups was made by one-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test (GraphPad Prism
®
 5.0) or repeated measures one-way 
ANOVA followed by post-hoc test for linear trend (GraphPad Prism
®
 5.0) in the case 
of time course experiments. Two-way ANOVA followed by Bonferroni post-hoc test 
was used to compare groups affected by two factors eg. drug and time. Comparison 
of Kaplan-Meier survival curves was made by the Log rank (Mantel-Cox) test 
(GraphPad Prism
®
 5.0). Significance was accepted at P < 0.05. For categorical data, 
comparison of proportions was carried out (MedCalc
®
 Version 11.3.1.0) and to 
account for multiple comparisons in these cases, significance was accepted at P < 
0.01. 
 
EF1a Standard Curve 
Log concentration 
Example Standard Curve 
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2.8.1 Experimental unit in zebrafish experiments 
For all zebrafish experiments, the definition of the experimental unit (or n) was 
important. The majority of experiments were performed in dishes of zebrafish 
embryos, where there may be unknown factors that influence all embryos in a given 
dish, but not in another dish. Therefore, the experimental unit is reported as the 
number of times the experiment was performed ie. the number of dishes of embryos 
rather than the actual number of embryos. However, the actual number of embryos 
used per experimental unit will be given after the n number. Where fish were kept in 
their own well, for example in the case of the ejection fraction experiment performed 




Pyr-apelin-13, apelin-13, apelin-16 and apelin-36 were purchased from Phoenix 
Europe GmbH (Karlsruhe, Germany). Purchased apelin was reconstituted with 
distilled water to make a stock solution (10 µM), aliquoted and stored at -20 °C. A 
fresh aliquot was diluted for each experiment. All other drugs and reagents are from 



















Chapter 3 The inotropic effects of apelin
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3.1 Introduction 
 
In 2002, apelin-16 was shown to be an inotrope (increase force of contraction) in the 
isolated perfused rat heart (Szokodi et al., 2002). Apelin’s inotropic effect was 
observed after 2 minutes of infusion and reached a maximum at 25 minutes. Apelin-
16 increased dP/dt max significantly compared to vehicle infusion when preload was 
increased to 10 mmHg and 15 mmHg, but not at a left ventricular end diastolic 
pressure (LVEDP) of 5 mmHg (Szokodi et al., 2002). 
 
Apelin-16 is also inotropic in vivo. Apelin-16 significantly increased maximum 
pressure (Pmax) and rate of rise towards the peak (dP/dt max) after 5 minutes 
infusion in rats with heart failure induced by coronary artery ligation, but the effect 
was not observed in control animals until 15 minutes infusion via the femoral vein. 
Apelin-16 increased rate of fall towards baseline (dP/dt min) after 15 mins in both 
groups (Berry et al., 2004). However, in the mouse, intravenous apelin-12 decreased 
Pmax and did not affect dP/dt max. Chronic administration of pyr-apelin-13, on the 
other hand, increased LV contractility as measured by Doppler ultrasound (Ashley et 
al., 2005). 
 
In right ventricular trabeculae in the rat, apelin-12 increased force and intracellular 
calcium concentration significantly in trabeculae from animals with heart failure, but 
not in control animals (Dai et al., 2006). In rat ventricular myocytes, apelin-16 
increased sarcomere shortening in both normal and failing myocytes, but had no 
effect on the intracellular calcium concentration (Farkasfalvi et al., 2007), leading 
the authors to suggest that an increase in sensitivity of the myofilaments to calcium is 
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responsible for the effect. The maximum effect was observed after 1 min and lasted 
1-2 mins (Farkasfalvi et al., 2007). In human paced atrial strips from patients 
undergoing coronary bypass surgery, apelin-13, pyr-apelin-13 and apelin-36 all 
produced an increase in force (Maguire et al., 2009). 
 
In the first study assessing the inotropic effect of apelin in humans in vivo, apelin-36 
decreased both maximum left ventricular pressure and end-diastolic pressure, while 
significantly increasing dP/dt max (Japp et al., 2010). As these are load-dependent 
measures of cardiac contractility, it is difficult to determine if apelin is increasing 
contractility independent of load on the heart (Japp et al., 2010). Vasodilation of 
coronary arteries also occurred with apelin administration which may contribute to 
the inotropic effect, as seen with some calcium antagonists (see Schwartz et al., 
1985). 
 
The mechanism of apelin’s inotropic action is not yet fully understood. However, it 
is thought that the APJ receptor couples to Gq, activating phospholipase C and 
protein kinase C (PKC) as demonstrated by inhibitors of these pathways attenuating 
the inotropic response in isolated rat hearts (Szokodi et al., 2002). Furthermore, PKC 




 exchange leading to the NCX working in reverse and 
thereby increasing intracellular calcium. In isolated perfused rat hearts, inhibition of 
the NCX blunted apelin’s inotropic response (Szokodi et al., 2002). 
 
Some groups argue that inotropy after apelin administration is due to an increase in 
intracellular calcium concentration (Dai et al., 2006). However, others believe that 
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intracellular calcium concentration is unaffected and that an increase in sensitivity of 
the myofilaments to calcium is responsible for the effect (Farkasfalvi et al., 2007).   
 
From the published literature, it appears that apelin has its greatest inotropic effect in 
disease states such as heart failure. Indeed endogenous apelin appears to be crucial 
for cardiac contractility to be maintained in ageing and in the face of increased 
afterload as shown in studies with apelin knockout mice (Kuba et al., 2007). In 
humans, apelin levels are increased in mild heart failure, but decrease to control 
levels in severe heart failure (Chen et al., 2003; Foldes et al., 2003).  
 
In addition to the effect of disease state on the inotropic response to apelin, species, 
experimental preparation, administration period and the form of apelin investigated 
may all contribute to the variable responses demonstrated in the published studies. 
 
This study aimed to further investigate the inotropic effects of apelin and the specific 
aims of this chapter were: 
i. to demonstrate the presence of the APJ receptor on rat papillary muscles and 
right atrial strips 
ii. to examine the inotropic effects of pyr-apelin-13, both alone and in 
combination with other pharmacological agents, in right ventricular papillary 
muscles and right atrial strips of the rat 
iii. to investigate the inotropic effects of apelin-16 in the isolated perfused rat 
heart 
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3.2 Methods 
3.2.1 Western Blotting 
Western blotting was performed as described in section 2.7.1. Protein was extracted 
from rat right ventricular papillary muscle (n = 2) and right atrial strip (n = 2), run on 
a protein gel and transferred to a polyvinylidene fluoride (PVDF) membrane as 
described. The membrane was probed with anti-rabbit APJ antibody to detect APJ 
protein (42 kDa) and, following stripping of the membrane, re-probed with anti-
rabbit GAPDH to detect GAPDH protein (35 kDa) as a positive control. 
 
3.2.2 Isolated right ventricular papillary muscles and right atrial strips 
Isolated rat right ventricular papillary muscles and rat right atrial strips were 
dissected from the heart and mounted in tissue baths for isometric tension recording 
as outlined (section 2.2).  
 
Cumulative concentration response curves to noradrenaline (NA) (1 – 10,000 nM), 
calcium (2 - 10 mM) and pyr-apelin-13 (1 – 100 nM) were carried out. In papillary 
muscles, the effect of pyr-apelin-13 was also assessed in the presence of NA 1 and 
100 nM, Ca
2+
 5 mM and angiotensin II (ATII) 1 and 100 nM. The papillary muscles 
were pretreated with drugs for 3 minutes prior to pyr-apelin-13 application. At the 
end of each experiment either NA 100 nM or Ca
2+
 10 mM was added to each 
preparation to confirm that the tissue was viable and had the potential to generate a 
positive inotropic response (increase in force of contraction) if this had not been 
carried out as part of the experimental protocol. 
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Time-matched controls were performed for all apelin experiments by the addition of 
an identical volume of vehicle (dH2O) instead of apelin at the appropriate time 
points. For experiments which studied the effect of apelin after pre-treatment with 
another agent, the other drug was used as outlined in the experimental protocol, 
followed by vehicle instead of apelin additions. Decrease in force (termed drop-off) 
with time was also determined in the present study.  
 
3.2.3 Langendorff 
The procedure for successful mounting of the rat heart and retrograde perfusion of 
coronary arteries was carried out as described (section 2.3). A latex balloon was 
inserted into the left ventricle (section 2.3) for measurement of intraventricular 
pressure. Hearts were initially paced at 5 Hz by attachment of pacing wires to the 
right atrium; however breakthrough arrythmias were observed in some preparations 
and in these cases pacing was increased. No heart was paced above 6 Hz. 
 
After 2 mins steady state, apelin-16 (10 nM) was delivered to the heart via the 
perfusate for 15 minutes. At the end of each experiment CaCl2 3.5 mM was perfused 
to confirm that all hearts were viable (and therefore the experiment was valid) and 
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3.3 Results 
3.3.1 APJ receptor expression in right ventricular papillary muscles and right atrial 
strips 
The APJ receptor was detected by western blotting in right ventricular papillary 





Figure 3.1: Western blotting shows APJ protein (42 kDa) and GAPDH (35 kDa) 
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3.3.2 In vitro functional studies 
3.3.2.1 The effect of NA and calcium on rat RV papillary muscles and RA strips 
NA elicited a concentration dependent increase in the force generated by right 
ventricular (RV) papillary muscles (pD2 6.09 ± 0.13, Emax 229.60 ± 82.55 mg, slope 
0.88 ± 0.09, n = 6; Fig 3.2(i)) and right atrial (RA) strips (pD2 6.01 ± 0.15, Emax 
131.40 ± 40.79 mg, slope 1.17 ± 0.17, n = 5; Fig 32(i)). The response of the papillary 
muscles and atrial strips to NA did not differ significantly (P = 0.69 pD2, P = 0.34 
Emax, P = 0.15 slope, unpaired t-test). Ca
2+
 was also able to elicit a concentration 
dependent increase in force in both preparations (papillary muscles, pD2 2.36 ± 0.04, 
Emax 334.30 ± 90.03 mg, slope 3.92 ± 0.45, n = 3; RA strips, pD2 2.32 ± 0.03, Emax 
304.70 ± 66.14 mg, slope 3.29 ± 0.39, n = 6; Fig 3.2(ii)). The response of the 
papillary muscles and atrial strips to Ca
2+
 did not differ significantly (P = 0.46 pD2, 
P = 0.80 Emax, P = 0.36 slope, unpaired t-test). 
 
3.3.2.2 The effect of pyr-apelin-13 on rat RV papillary muscles and RA strips 
Pyr-apelin-13 failed to elicit a response in both RV ventricular papillary muscles and 
RA strips in the presence of 2 mM calcium when 1, 10 and 100 nM were added 
cumulatively at 3 min intervals (papillary muscles n = 4, P = 0.43 two-way ANOVA 
apelin vs vehicle; Fig 3.3(i)). In a larger number of animals, 100 nM had no effect on 
force of contraction in papillary muscles (P = 0.16 one-way ANOVA; n = 9; Fig 
3.3(ii)). In right atrial strips, pyr-apelin-13 (100 nM) had no effect on force of 
contraction (n = 3; Fig 3.3(iii)). Pyr-apelin-13 had no effect on time to peak both in 
time course experiments (P = 0.18 one-way ANOVA; n = 3; Fig 3.4(i)) and in all 
experiments with all doses combined (P = 0.20 one-way ANOVA; n = 3 – 8; Fig 
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3.4(ii)). Pyr-apelin-13 had no effect on time to relaxation both in time course 
experiments (P = 0.38 one-way ANOVA; n = 3; Fig 3.4(iii)) and in all experiments 





















Figure 3.2: Concentration response curves in right ventricular papillary 
muscles and right atrial strip preparations in response to NA (i) and calcium 
(ii). 
(i) n = 6 and n = 5, respectively (ii) n = 3 and n = 6, respectively.
(i) 
(ii) 







































Figure 3.3: Effect of pyr-apelin-13 on RV papillary muscles (i and ii) and RA 
strips (iii) in presence of calcium 2 mM. 
(i) P = 0.42 two-way ANOVA apelin (n = 4) vs vehicle (n = 3), (ii) P = 0.16, n = 4 – 









Figure 3.4: The effect of pyr-apelin-13 on time to peak and time to relaxation in 
RV papillary muscles in the presence of normal baseline calcium (2 mM). 
Pyr-apelin-13 had no effect on time to peak both in time course experiments (P = 
0.18 one-way ANOVA; n = 3) (i) and in all experiments with all doses combined (P 
= 0.20 one-way ANOVA; n = 3 – 8 shown in brackets) (ii). Pyr-apelin-13 had no 
effect on time to relaxation both in time course experiments (P = 0.38 one-way 
ANOVA; n = 3) (iii) and in all experiments with all doses combined (P = 0.87 one-
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In the presence of both low (1 nM) and high (100 nM) NA, pyr-apelin-13 had no 
effect in RV papillary muscles (n = 5 and n = 4, respectively, P = 0.68 and P = 0.26 





















Figure 3.5: Effect of pyr-apelin-13 on RV papillary muscles in the presence of 
NA 1 nM (i) and NA 100 nM (ii). 
(i) P = 0.68 two-way ANOVA apelin (n = 4) vs vehicle (n = 3) (ii) P = 0.26 two-way 
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Similarly, in the presence of high Ca
2+
 (5 mM) and high ATII (100 nM), pyr-apelin-
13 had no effect on the force produced by right ventricular papillary muscles (n = 5 
and n = 3, respectively, P = 0.41 and P = 0.97 two-way ANOVA apelin vs vehicle, 



















Figure 3.6: Effect of pyr-apelin-13 on RV papillary muscles in the presence of 
Ca
2+
 5 mM (i) and ATII 100 nM (ii). 
(i) P = 0.41 two-way ANOVA apelin (n = 5) vs vehicle (n = 3) (ii) P = 0.97 two-way 
ANOVA apelin (n = 3) vs vehicle (n = 3). 
(i) 
(ii) 
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Drop-off in force of both papillary muscle and atrial strip preparations are 
unavoidable in this experimental set-up. It was found that the amplitude of the force 
generated in untreated PM preparations decreased by 2.6 ± 0.6 mg per minute across 
2h (n = 4). In untreated RA strips, the amplitude of force generated decreased by 0.9 
± 0.3 mg (n = 3). Since all experimental protocols lasted approximately 1h 30 from 
equilibration of the preparation, we controlled for drop-off by performing time-
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3.3.3 The effect of apelin-16 in the isolated perfused rat heart 
In the paced, isolated perfused rat heart, apelin-16 (10 nM) had no effect on any of 
the measured parameters of cardiac contractility in the 15 minute infusion period 





16 (10 nM) 
infusion 
HR (bpm) DP (mmHg) dP/dt max dP/dt min 
-1 322.6 ± 13.4 84.5 ± 12.0 3223.7 ± 664.6 2349.7 ± 371.1 
0 322.5 ± 13.4 84.4 ± 12.0 3234.8 ± 661.5 2339.2 ± 354.2 
5 322.5 ± 13.4 81.2 ± 14.3 3226.7 ± 763.4 2278.6 ± 390.5 
10 322.5 ± 13.4 84.1 ± 15.1 3373.8 ± 808.4 2328.6 ± 391.8 
15 323.9 ± 12.8 83.6 ± 14.9 3407.5 ± 774.7 2329.5 ± 401.7 
P 0.39 0.81 0.23 0.53 
 
Table 3.1: Effect of apelin-16 on contractility parameters measured in the 
isolated perfused rat heart. 
















Figure 3.7: Apelin-16 had no effect on intraventricular pressure in the isolated 
perfused rat heart. 
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3.4 Discussion 
 
In these studies, no inotropic effects of apelin peptides were observed in the cardiac 
tissues of the normal rat. APJ protein is present in RV papillary muscle and RA strip 
tissue as determined by western blot. This is in agreement with other studies which 
found the APJ receptor to be widely expressed in rat heart tissue (Katugampola et al., 
2001; Kleinz et al., 2005). However, this does not allow us to determine the cellular 
location of the receptor or whether or not the receptor is active and coupled to its G 
protein. 
 
Using a widely utilised papillary muscle and atrial strip preparation (Skuladottir et 
al., 1997; Sviglerova et al., 2005; Wong et al., 2010), we found no inotropic effect of 
apelin on isolated rat papillary muscles and atrial strips. This is in keeping with the 
results of Dai et al. (2006) who also failed to demonstrate any significant increase in 
force in response to apelin in normal trabeculae. However, they did observe an 
increase in force in response to apelin in trabeculae from rats with heart failure 
induced by chronic hypoxia. This is the only published study assessing the effect of 
apelin on rat cardiac tissue strips. 
 
Dai et al. (2006) used a lower concentration (70 nM) than the highest concentration 
used in the present study, although they were in the same range. The authors 
measured force responses 15 minutes after adding apelin, whereas we measured 
force 3 minutes after each addition in papillary muscles. However, in atrial strip 
experiments, apelin incubation for 30 minutes had no effect so it is unlikely that the 
incubation time was a factor in this case, at least in atrial strips. 
   72 
As there did not appear to be an inotropic effect in isolated papillary muscles and 
atrial strips, we used an isolated rat heart preparation as described by Langendorff 
(1895). The technique is used routinely by many groups over a century later (see 
Skrzypiec-Spring et al., 2007). The isolated, perfused rat heart preparation allows for 
the study of cardiac contractility, isolated from any whole animal effects, for 
example nervous system activity. The preparation in the present study also isolated 
effects on cardiac contractility from the vasoactive effects of apelin as coronary flow 
was held constant. We used apelin-16 for these experiments as this form of apelin 
had previously been reported as an inotrope in a Langendorff preparation (Szokodi et 
al., 2002). 
 
Our intention was to confirm the inotropy of apelin-16 and follow up with a study 
investigating the potential cardioprotective effects of apelin-16 in an ischaemia-
reperfusion model as the cardioprotective effects of apelin-13 and apelin-36 had 
previously been demonstrated using this model (Simpkin et al., 2007). 
 
However, in our study, we were unable to confirm the inotropic effect of apelin-16. 
There are several possible reasons for the discrepancy between the current study and 
that of Szokodi et al. (2002). Firstly, the present study used an intraventricular 
balloon which is a highly sensitive method of measuring cardiac contractions in the 
isolated heart. Szokodi et al. (2002) used a transducer attached to the apex of the 
heart to demonstrate inotropy. Although they also used an intraventricular balloon 
for one part of their study, the effect of apelin infusion on developed pressure was 
not reported. Secondly, the published study reported an increase in dP/dt max when 
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apelin was infused at diastolic pressures of 10 mmHg and 15 mmHg, but not at a 
diastolic pressure of 5 mmHg which was the pressure used in the present study. 
Taken together, these studies suggest that inotropic effects of apelin may only be 
apparent at higher levels of preload. Experiments with increased preload in vitro by 
increasing diastolic pressure using an intraventricular balloon or in vivo by increasing 
venous blood volume would increase our understanding of the effect of apelin under 
conditions of increased preload. 
 
The literature demonstrates that apelin has a greater inotropic effect in tissue from 
heart failure animals (Berry et al., 2004; Dai et al., 2006). Further experiments 
involving measurement of cardiac contractility following in vivo administration of 
apelin to control rats and rats with heart failure using a pressure-volume catheter and 
echocardiography would complement the data presented in this thesis. 
 
In summary, although the presence of the APJ receptor protein on the tissues studied 
is demonstrated here, we were unable to confirm the inotropic response to apelin that 






























Chapter 4 The vasoactive effects of apelin
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4.1 Introduction 
Apelin is synthesised as a prepropeptide of 77 amino acids and is cleaved by 
unknown endopeptidases to the active apelin isoforms which have reported effects on 
the vasculature. Apelin molecules with biological activity have been postulated to be 
degraded by angiotensin converting enzyme-2 (ACE-2) (El Messari et al., 2004), 
although recent data suggests that treatment of apelin peptides with ACE-2 does not 
in fact abolish biological activity (Davenport et al., 2009; Davenport et al., 2010).  
 
The first report of a functional effect of apelin on the vasculature was published in 
2001 when it was demonstrated that pyr-apelin-13 constricted human saphenous vein 
in the absence of a functional endothelium (Katugampola et al., 2001). Salcedo et al. 
(2007) reported that human mesenteric arteries with intact endothelium dilated in 
response to apelin. However, human mesenteric arteries denuded of endothelium did 
not constrict to apelin in this study. In vivo, in healthy volunteers, pyr-apelin-13 and 
apelin-36 caused nitric oxide dependent vasodilatation in forearm resistance vessels. 
However, neither peptide had an effect on dorsal hand vein blood flow (Japp et al., 
2008). 
 
In rats, the only published study that demonstrates a functional effect of apelin on 
vasculature in vitro is that of Hus-Citharel et al. (2008) who report that in 
juxtamedullary afferent arterioles of the kidney, apelin-17 induces vasodilation in 
ATII preconstricted vessels (see Table 4.1). Jia et al. (2007) reported that apelin 
caused nitric oxide production and increased L-arginine uptake in cultured rat aortas, 
but there has been no report of a functional effect of apelin in this tissue. In rat portal 
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vein, preincubation of vessels with apelin attenuated the vasoconstrictor response to 
ATII, but apelin had no effect on its own in vessels with intact or removed 
endothelium (Gurzu et al., 2006).  
 
 
Table 4.1: Apelin in vitro functional studies in rat and human vessels reported in 
the literature. 
 
Despite the limited number of studies on rat in vitro vascular preparations, a number 
of rodent studies have shown a decrease in mean arterial pressure (MAP) in response 
to apelin in vivo. In anaesthetised rats, intravenous apelin-12 decreased mean arterial 
pressure (MAP) and HR (Tatemoto et al., 2001). In conscious rats, intravenous 
apelin-12 decreased MAP and increased HR (Cheng et al., 2003). Conversely, 
intravenous pyr-apelin-13 increased both MAP and HR in conscious rats (Kagiyama 
et al., 2005). In the same study, intracerebroventricular pyr-apelin-13 increased both 
MAP and HR and the effect was more potent at this site than in the periphery. Thus, 
although the majority of publications assessing MAP in an in vivo model report a 
Vessel Apelin effect in in vitro tissue Reference 
Rat Human 
mesenteric artery not reported vasodilator, not 
vasoconstrictor 
Salcedo et al., 
2007 
saphenous vein not reported vasoconstrictor Katugampola et 
al., 2001, 




not reported vasodilator and 
vasoconstrictor 
Maguire et al., 
2009 
aorta not reported not reported  
kidney arteriole vasodilator and 
vasoconstrictor 
not reported Hus-Citharel et 
al., 2008 
portal vein no effect not reported Gurzu et al., 2006 
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decrease in MAP, there is some evidence that suggest the opposite may occur in 
some settings. 
 
As functional vascular responses to apelin in vitro in rats had not been thoroughly 
investigated, this study aimed to further investigate the vasoactive effects of apelin. 
As human mesenteric artery reportedly vasodilated in response to apelin (Salcedo et 
al., 2007), rat mesenteric artery was utilised in the present study as a readily 
available and previously widely used in vitro model for the testing of vasoactive 
compounds (Gitterman et al., 2000; Meens et al., 2009; Retailleau et al., 2010). 
 
This chapter aimed to use both in vivo and in vitro techniques to study the vasoactive 
effects of apelin. The hypothesis investigated in this chapter was that apelin-13 and 
apelin-36 will vasodilate rat mesenteric resistance vessels with intact endothelium 
and vasoconstrict rat mesenteric resistance vessels denuded of endothelium in vitro. 
The in vivo vasoactive effects of apelin in the rat were also inconsistent throughout 
the published literature. Therefore, in order to assess if selected apelin isoforms used 
in this study had activity in an in vivo model, we performed a series of experiments 
in the instrumented, anaesthetised rat. These experiments addressed the hypothesis 
that apelin-13, pyr-apelin-13 and apelin-16 will decrease MAP, with no change in 
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4.2 Methods 
4.2.1 Myography 
Following mounting and tensioning of mesenteric vessels as described in section 2.4, 
each vessel was given three 5 minute exposures to high potassium with a 5 minute 
washout period between each exposure. This was followed by a phenylephrine (PE) 
concentration response curve (1 nM – 100 µM) to determine the PE EC80 of each 
vessel. Following washout, this EC80 concentration of PE was used to preconstrict 
the vessels before performing an ACh concentration response curve (1 nM – 100 
µM) to assess endothelium dependent relaxation. A single concentration of SNP (10 
µM) was added at the end of the ACh curve to determine endothelium independent 
relaxation. Following a final 20 minute washout period, the relaxant and contractile 
effect of apelin-13 and apelin-36 (1 – 100 nM) was examined in vessels that were 
and were not preconstricted with PE, respectively. Apelin-13 was added to third 
order mesenteric arteries in the presence of captopril (100 µM) which was added to 
the bath 30 minutes before the addition of apelin. Captopril, an ACE inhibitor, was 
used to inhibit apelin degradation in the bathing medium as ACE-2 had been 
postulated to be responsible for apelin degradation at the time when the study was 
performed (see Japp and Newby et al., 2008). This, however, does not appear to be 
the case according to the most recent literature (Davenport et al., 2010) and the 
degradation pathway of apelin is unclear. 
 
The endothelium was said to be intact when, in response to ACh, clear relaxations 
were observed on the trace and maximal relaxation was greater than 80%. 
Preconstriction of the vessels before the addition of ACh was 2.28 ± 0.36 mN/mm   
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(n = 11) and 2.51 ± 0.37 mN/mm (n = 6) in second and third order mesenteric 
arteries, respectively. Vessels that were stripped of endothelium accidentally were 
discarded; likewise vessels that were thought to be denuded, but relaxed to ACh were 
excluded. 
 
Data is expressed as mean response above resting tension ± SEM. Responses of 
vasoconstricting agents are expressed as mN/mm length of vessel. Responses of 
vasodilating agents are expressed as percentage relaxation of the preconstriction 
prior to the addition of the vasodilator. 
 
4.2.2 In vivo blood pressure measurements 
Male Wistar rats (300 - 400 g) were anaesthetised and the carotid artery and jugular 
vein were cannulated by insertion of cannula tubing. Apelin-13, apelin-16 or pyr-
apelin-13 (10 nM/kg) was delivered to the jugular vein via the inserted cannula and 
blood pressure was measured at the carotid artery via a fluid filled transducer 
attached to the inserted cannula. 
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4.3 Results 
4.3.1 In vitro vascular responses 
In order to validate the technique, concentration response curves to PE and ACh 
were analysed. Second order and third order rat mesenteric arteries with intact 
endothelium constrict comparably to PE and relax similarly to ACh (Table 4.2; Fig 
4.1 and 4.2). 
 
 





Second order      
PE 5.63 ± 0.06 2.35 ± 0.11 3.11 ± 0.37 - 11 
ACh 7.51 ± 0.05 -1.42 ± 0.15 - 93.72 ± 2.10 11 
      
Third order      
PE 5.78 ± 0.09 2.02 ± 0.09 3.70 ± 0.52 - 6 
ACh 7.48 ± 0.04 -1.64 ± 0.29 - 89.18 ± 2.43 6 
      
 
Table 4.2: Response of second and third order rat mesenteric arteries with 

















































Figure 4.1: Constriction with PE (i) and relaxation of PE preconstricted vessels 
with ACh (ii) in rat second order mesenteric arteries. 















































Figure 4.2: Constriction with PE (i) and relaxation of PE preconstricted vessels 
with ACh (ii) in rat third order mesenteric arteries  
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Apelin-13 and apelin-36 had no effect on rat second order mesenteric arteries; both 
with (apelin-13, n = 5; apelin-36, n = 3; Fig 4.3) and without endothelium (apelin-13, 
n = 4; apelin-36, n = 3; Fig 4.3). Both forms of apelin also had no effect on second 
order mesenteric vessels with intact endothelium that were firstly preconstricted with 
PE (apelin-13, n = 6; apelin-36, n = 4; Fig 4.3). Likewise, preconstricted vessels 
denuded of endothelium failed to respond to apelin-13 (n = 4) and apelin-36 (n = 3) 
(Fig 4.3). 
 
In the presence of captopril (100 µM), apelin-13 had no effect on third order 
mesenteric arteries with intact endothelium (n = 6) or denuded of endothelium (n = 
6). In third order vessels incubated in captopril and preconstricted with PE, apelin-13 
had no effect (intact endothelium n = 5, denuded of endothelium n = 4) (Fig 4.3). 
Prism
® 
was unable to perform successful nonlinear regression on these data sets as 



























































Figure 4.3: Effect of apelin on isolated rat mesenteric arteries. 
Effect of apelin-13 (A) and apelin-36 (B) on vessel tone in rat second order 
mesenteric vessels at resting tension (i) and after constriction with PE (ii) and the 
effect of apelin-13 (C) in rat third order mesenteric vessels in the presence of 
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4.3.2 In vivo effect on blood pressure and heart rate 
In vivo effects of apelin on MAP and HR were examined. Pyr-apelin-13 (n = 5) and 
apelin-16 (n = 5) (bolus 10 nM/kg) had no effect on MAP (pyr-apelin-13 vs saline P 
= 0.10, apelin-16 vs saline P = 0.50 two-way ANOVA) when compared to the effect 
of administering the same volume of saline in the same animals over 10 minutes (n = 
5 per group). Apelin-13 (bolus 10 nmol/kg) produced a maximum decrease in MAP 
of 22 ± 8 mmHg (apelin-13 vs saline P = 0.002 two-way ANOVA; n = 6). This 
effect was rapid and was observed within 30 s of administering apelin; the maximum 
decrease was observed after 2 min and recovered towards baseline after 10 minutes, 
although complete recovery was not observed after 20 minutes (Fig 4.4(i)). 
 
HR was decreased by administration of apelin-13 by 22 ± 17.5 bpm 30 s after 
addition of apelin (P = 0.003 two-way ANOVA). Pyr-apelin-13 had no effect on HR 
(P = 0.08 two-way ANOVA), while apelin-16 decreased HR significantly within 30 s 


























































Figure 4.4: The effect of pyr-apelin-13, apelin-16 and apelin-13 on MAP (i) and 
HR (ii). 
(i) P = 0.10 pyr-apelin-13, P = 0.50 apelin-16, P = 0.002 apelin-13 two-way 




   87 
4.4 Discussion 
4.4.1 In vitro vessel responses 
In isolated rat mesenteric resistance arteries, apelin-13 and apelin-36 did not produce 
a vasodilatory response in the current study. In vitro in the rat, there are only two 
reports in the literature of the vasoactive effects of apelin and of these reports only in 
the arterioles of the kidney has apelin been shown to have a consistent vasodilatory 
effect (Hus-Citharel et al., 2008). This result suggests a species difference in the 
effect of apelin in the mesenteric vascular bed as human mesenteric arteries with 
intact endothelium vasodilate in response to apelin (Salcedo et al., 2007). Our 
results, together with the existing limited published data in these preparations, 
suggest that there may be several vessel beds in the rat that do not respond to apelin. 
Although rat aortic smooth muscle cells have been shown to produce nitric oxide 
following stimulation with apelin, a functional effect has not been demonstrated. 
Indeed previous work in our own laboratory using fixed mount myography found no 
effect on treatment with apelin in rat aortas (Emery, Japp and Gray, unpublished 
data). 
 
In the present study, apelin-13 and apelin-36 had no vasoconstrictor effect in rat 
mesenteric arteries denuded of endothelium. In contrast to the species difference 
observed when studying the potential vasodilatory effects of apelin, this was in 
agreement with the human mesenteric artery study by Salcedo et al. (2007). 
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4.4.2 In vivo blood pressure measurements 
Apelin-13, apelin-16 and pyr-apelin-13 were administered to anaesthetised rats via 
the jugular vein and blood pressure measured via the carotid artery. Apelin-13 
produced a decrease in MAP as demonstrated by Tatemoto et al. (2001). However, 
the decrease in MAP measured in the current study was larger and more variable (28 
± 11 mmHg) than that of Tatemoto et al. (2001) (11 ± 4 mmHg). Apelin-13 also 
lowered HR. Apelin-16 did not alter MAP compared to a bolus of saline in the same 
animals, but did produce a significant transient decrease in HR which recovered 2 
minutes after the bolus was administered. No effect of apelin-16 on MAP or HR has 
been previously reported. Neither a decrease in MAP nor HR was observed 
following intravenous administration of pyr-apelin-13 in these experiments which is 
in contrast to the work of Ishida et al. (2004) who observed a decrease in MAP in 
response to pyr-apelin-13.  
 
Surprisingly, administration of apelin-13 in vivo decreased heart rate and MAP, 
while apelin-16 depressed only heart rate. A decrease in MAP is usually associated 
with reflex tachycardia mediated via baroreceptors (Noll et al., 1997). Therefore, the 
observation that apelin-13 decreases both heart rate and MAP, suggests that these 
two effects are mediated via different mechanisms. A decrease in MAP in response 
to apelin-13 has been previously reported in vivo (Tatemoto et al., 2001). 
Interestingly, I noted that the majority of publications describing a vasoactive effect 
of apelin used apelin-13. Furthermore, the majority of publications describing an 
inotropic effect of apelin used apelin-16. No publication has compared apelin-13 and 
apelin-16 in a model assessing vasoactivity, yet the in vivo experiments presented in 
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this thesis demonstrate that different apelin isoforms may have different 
physiological effects. Since the twelve C-terminal amino acids have been shown to 
be responsible for the activity of the apelin peptide (De Mota et al., 2000; Reaux et 
al., 2001), it is unlikely that the activity of two different apelin isoforms on the same 
receptor in the same tissue produces a different effect. However, different effects 
may be elicited in different tissues by the same ligand and receptor if the receptor is 
coupled to different signal transduction pathways eg. Gi in one tissue and Gq in 
another. The APJ receptor may also be expressed more highly in one tissue than in 
another which could be studied by qPCR or histology with an APJ antibody. It is also 
possible that the apelin receptor may have different receptor subtypes (as in 
zebrafish), although to date there is no data to suggest this (Pitkin et al., 2010). 
 
The decrease in MAP has been previously reported to be nitric oxide dependent 
(Tatemoto et al., 2000). Therefore, if the decrease in MAP and decrease in heart rate 
are two unrelated effects, I hypothesise that in the presence of L-NAME, the 
decrease in blood pressure would be abolished, but the decrease in heart rate would 
be observed. It is also possible that the heart rate effect may be centrally mediated, 
while the decrease in MAP may be a local effect. To test this hypothesis, vagal tone 
could be inhibited with atropine. In the presence of atropine, if mean arterial pressure 
decreases in response to apelin, but heart rate does not, we conclude that the change 
in heart rate is a central effect of the apelin peptide. Secondly, the femoral artery 
could be isolated in vivo to eliminate central effects and apelin applied to the artery, 
an experimental model previously reported by Zhang et al. (2010) in a mouse model. 
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This experiment would confirm that the decrease in mean arterial pressure is a local 
effect and is not mediated centrally.  
 
The vasoactive effect of apelin in vivo in rats remains a subject of debate in the 
literature. In conscious rats, an increase in MAP was observed following both IV 
injection and intracerebroventricular (ICV) injection of apelin (Kagiyama et al., 
2004), inferring a direct action on central cardiovascular autonomic centres. Indeed, 
apelin has been reported to cross the blood-brain barrier (Higuchi et al., 2007). 
Although these publications are small in number, equal numbers report an increase in 
HR as report no change in HR. These studies are summarised in Table 4.3. 
 
Table 4.3: Summary of apelin vasoactive studies in vivo in the rat. 
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4.4.3 Conclusion 
In the published literature, there is variation of in vivo rat vasoactive effects 
described in response to apelin and only one paper demonstrating a vasoactive effect 
in vitro in isolated vessels from the rat. The use of several different models and 
different apelin isoforms in these vasoactive studies makes comparison of the 
published work difficult. In addition, the surprisingly small body of published 
literature in comparison to that of other reportedly vasoactive peptides, such as 
endothelin-1, point to a well described publication bias (Callaham et al., 1998; 
Timmer et al., 2002; Young et al., 2008) (discussed further in chapter 7). We 
conclude that the small number of publications in this area is indicative of the 
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Chapter 5  The apelin system in the zebrafish embryo 
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5.1 Introduction 
5.1.3 The Apelin/APJ system in the zebrafish 
The apelin/APJ system is present in the zebrafish. However, unlike in mammals, 
there are two forms of the apelin receptor in zebrafish: angiotensin receptor-like 1a 
(agtrl1a) and angiotensin receptor-like 1b (agtrl1b). There is significant sequence 
homology both in the apelin peptide and the apelin receptor, respectively, when 
comparing the zebrafish amino acid sequence with that of mammalian organisms 
(Figs 5.3 and 5.4). It is important to note that pyr-apelin-13 was used in all zebrafish 
experiments which is the thirteen amino acids at the C-terminal end of the apelin 
sequence. As shown in Fig 5.3, the last twelve amino acids are identical to that of 
mammalian species and it is these twelve amino acids that are important for the 
biological activity of the peptide (De Mota et al., 2000; Reaux et al., 2001). 
 
Although it is known to be present, little is known about the functional role of the 
apelin system in the zebrafish. In fact there are only 4 original research publications 






Figure 5.1: Apelin peptide sequence for human, rat, mouse, bovine, zebrafish 
and xenopus apelin-36. 
* identical amino acids, residues that differ from the human sequence are highlighted 
in red. Figure from Pitkin et al. (2010). 
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The amino acids of the human APJ receptor thought to be responsible for ligand 
binding are aspartate residues at positions 184 and 282, phenylalanine residues at 
positions 125, 210 and 257, and tryptamine residues at positions 154 and 261 
(Iturrioz et al., 2009). All are conserved in the zebrafish agtrl1a receptor with the 
exception of the aspartate residue at position 282 and all are conserved in the 
zebrafish agtrl1b receptor with the exception of the phenylalanine residue at position 
125 and the aspartate residue at position 282. Therefore, it is likely that the 
mammalian apelin used in this study will bind to the zebrafish apelin receptors. 
 
 
Figure 5.2: Amino acid sequence of the apelin receptor orthologues, agtrl1a (Dr 
Agtrl1a) and agtrl1b (Dr Agtrl1b), in the zebrafish, and the human (Hs 
AGTRL1) and xenopus (Xl X-msr) sequences. 
Conserved residues in all four species are highlighted in black; those conserved in 
three of these four species are highlighted in dark grey (white lettering); those 
conserved in two of four species are highlighted in light grey (black lettering). Figure 
from Tucker et al. (2007). 
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5.1.4 Genetic manipulation of apelin and its receptors in zebrafish embryos 
5.1.4.1 Apelin 
Overexpression of apelin by injection of apelin RNA into embryos results in a delay 
in epiboly, lack of extension of the anteroposterior axis and no visible beating heart 
at 2 dpf (Zeng et al., 2007). Overexpression of apelin also resulted in a reduction in 
cardiac myosin light chain 2 expression and no cardiac differentiation in work by 
another group (Scott et al., 2007). Knockdown of apelin using both translation 
blocking and splice site blocking morpholinos resulted in a reduction in the size of 
the region expressing cardiac myosin light chain 2 and ventricular myosin heavy 
chain cardiac markers at 17 hpf (Zeng et al., 2007), suggesting that a balance of 
apelin levels is necessary during development for normal expression of cardiac 
markers. Despite the reduction in cardiac markers, the structure of the heart was 
grossly normal at 24 hpf and, surprisingly, the paper does not report any observations 
beyond this time point. 
 
5.1.4.2 Agtrl1a receptor 
Knockdown of agtrl1a using three non-overlapping translation blocking morpholinos 
results in delayed development in zebrafish embryos (Nornes et al., 2009). Nornes et 
al. (2009) demonstrate that agtrl1a knockdown delays epiboly, as reported in apelin 
knockdown experiments by Zeng et al. (2007). The agtrl1a knockdown phenotype 
can be rescued by injection of agtrl1a RNA at the 32-cell stage, although not when 
injected with the morpholino at the single cell stage (Nornes et al., 2009). 
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5.1.4.3 Agtrl1b receptor 
Overexpression of agtrl1b by injection of agtrl1b RNA into one-cell stage zebrafish 
embryos results in an uneven surface between the blastoderm and yolk cell in 
contrast to the smooth surface observed in control embryos. However, the agtrl1b 
RNA injected embryos do develop normally despite this, although in some cases 
exhibited a shorter body length than controls at 24 hpf (Zeng et al., 2007). 
Knockdown of agtrl1b using a translation blocking morpholino results in absence of 
a beating heart at 2 dpf in 93% of injected embryos. Co-injection with agtrl1b RNA, 
lacking the morpholino binding site, partially rescued this phenotype as 54% of 
embryos in this group did have a beating heart at 2 dpf. However, in those with a 
beating heart, the heart appeared to be of reduced size (Zeng et al., 2007). The 
authors reason that their experiments demonstrate only partial rescue of the agtrl1b 
knockdown phenotype as both overexpression and knockdown of agtrl1b influence 
normal development. 
 
Scott et al. (2007) identified a single mutation in zebrafish agtrl1b which results in 
hearts of reduced size, and in the most severe cases of the mutation few or no cardiac 
myosin light chain-positive cardiomyocytes. This mutation, known as grinch, 
appears to be specific to the heart, as development of the grinch mutants is otherwise 
no different to that of wild-type embryos. However, severe grinch mutants survive 
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Manipulation of apelin and its receptors have severe developmental consequences in 
zebrafish embryos which are summarised in Table 5.1. In particular, overexpression 
of apelin or knockdown of agtrl1b results in the loss of a beating heart (Zeng et al., 
2007). However, in knockout mouse models, apelin knockout and APJ knockout do 
not appear to have severe developmental consequences. There are some 
physiological consequences in adult mice, including the development of heart failure 





 Overexpression Knockdown 
Apelin reduction in cardiac markers 
no beating heart 
delay in epiboly 
 
reduction in cardiac markers 
grossly normal heart at 24 hpf 
Agtrl1a not reported delay in epiboly 
 
 
Agtrl1b uneven blastoderm/yolk cell 
surface 
 
no beating heart 
 
Table 5.1: Summary of reported effects of overexpression and knockdown of 
apelin, agtrl1a and agtrl1b in zebrafish embryos. 
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5.1.5 Aims of this chapter 
This chapter investigates the apelin system in the zebrafish and the specific aims 
were: 
 i. to determine the abundance of apelin, agtrl1a and agtrl1b mRNA transcripts 
 during the first 5 days of development 
 ii. to demonstrate whether or not apelin, agtrl1a and agtrl1b mRNA are 
 present in the adult zebrafish heart 
 ii. to study the effect of exogenous apelin on heart function of zebrafish 
 embryos in vivo and on isolated zebrafish embryonic hearts 
 iii. to investigate mRNA knockdown of the apelin system using a morpholino 
























qPCR was carried out as described in section 2.7.2.4. RNA was extracted from whole 
zebrafish embryos (12 – 15 embryos per stage) at each of the following 
developmental stages (8, 18, 24, 36, 48, 72, 96 and 120 hpf) and transcribed to 
cDNA. Apelin, agtrl1a and agtrl1b assays were performed in addition to assays for 
the reference genes, elongation factor 1 alpha (EF1a) and ribosomal subunit L13A 
(RPL13a) (see Table 5.2). EF1a and RPL13a mRNA expression did not change 
across the developmental stages (EF1a P = 0.06 one-way ANOVA; RPL13a P = 0.43 
one-way ANOVA; n = 2 (12 – 15 embryos per stage per experiment)). Apelin, 
agtrl1a and agtrl1b mRNA were corrected for the mean of reference genes, EF1a and 
RPL13a, and expressed as a percentage of abundance at 8 hpf.  
 




Primer sequences (5’ – 3’) Product 
size 
(bp) 








Agtrl1b NM_001030197.1 24 F:AAAAAGCTCTTCACGCCAGT 
R:ACTGGGCCTCGGTCTTCT 
60 
     




RPL13a NM_212784.1 3 F: TCCCGTGGATCATATCACTTC 
R: GGTTTTGTGTGGAAGCATACC 
78 
     
     
 
Table 5.2: UPL probes and primer sequences for RT qPCR in the zebrafish.  
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5.2.2 PCR to detect the presence or absence of mRNA of interest 
PCR to detect apelin, agtrl1a and agtrl1b was performed on zebrafish adult hearts (n 
= 3, 3 hearts per group) as described in section 2.7.2.3, using primer sequences from 
Table 5.3.  
 
Target gene NCBI accession 
number 












Agtrl1b NM_001030197.1 F:GCCCAGATTACTTCGACGAT 
R:AGCAGGAGGTTCAGGAAGGT 
850 






    
 
Table 5.3: Primer sequences for RT-PCR in the zebrafish. 
 
5.2.3 Video edge detection 
5.2.3.1 Embedded zebrafish embryos 3 dpf 
Zebrafish embryos 3 dpf were embedded in agar as described (section 2.6.1). An 
Axioskop II MOT compound microscope with a x 40 water dipper objective lens was 
used to visualise the hearts of the embryos and video edge detection was carried out 
as described in section 2.6.1. Zebrafish were incubated in pyr-apelin-13 (150 nM) for 
1h. In apelin incubated embryos, measurements of ventricle wall motion were made 
at baseline and at 15 minute intervals thereafter. In vehicle incubated embryos, 
measurements were made at baseline and after 1h incubation. Contraction velocity, 
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relaxation velocity, wall motion amplitude and heart rate were expressed as a 
percentage of the measurement at baseline in each group. 
 
5.2.3.2 Zebrafish isolated embryonic hearts 3 dpf and 4 dpf 
Zebrafish hearts were isolated as described in section 2.6.1.2. Briefly, zebrafish were 
anaesthetised before being placed into HEPES buffer containing BSA. Their hearts 
were isolated mechanically using one pair of forceps to hold the tail of the embryo 
and the other to detach the heart by quickly and carefully freeing it from the 
surrounding tissue. Hearts were then placed in a well in a prepared agar mould and 
HEPES buffer (without BSA). Video edge detection, as described above, was used to 
measure the following parameters of isolated embryonic heart function: contraction 
velocity, relaxation velocity, wall motion amplitude and heart rate. 
 
Protocol 
The baseline bathing calcium concentration in these experiments was 2.5 mM. In 
isolated embryonic hearts from zebrafish 3 dpf, calcium 3.5 mM, 4.5 mM, 5.5 mM 
and 6.5 mM was added cumulatively at 2 minute intervals. In isolated embryonic 
hearts from zebrafish 3 dpf and 4 dpf, apelin 50 nM, 100 nM and 150 nM was added 
cumulatively at 3 minute intervals. At the end of each apelin experiment, calcium 5.5 
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5.2.4 Morpholino (MO) 
5.2.4.1 Design of a morpholino targeting apelin 
A morpholino targeted to apelin preRNA was designed and synthesised by 
GeneTools (5’ – ATTGTGCTGGAATGTCAAACTGACC-carboxyfluorescein - 3’). 
In order to determine that the sequence of the morpholino was specifically targeting 
apelin, the sequence was checked against the zebrafish genome using BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and UCSC genome browser 
(http://genome.ucsc.edu/). Figure 5.5 shows schematically that the morpholino binds 
at the exon 2/intron 2 junction. A five mispair control was also designed and 
synthesised by GeneTools for our experiment (5’ – 
ATTGTCCTGCAATCTGAAACTCACC-carboxyfluorescein - 3’; mispairs 
underlined). The carboxyfluorescein added to the 3’ end of both morpholinos 
allowed us to determine whether or not successful uptake of the morpholino had 
occurred.  
Figure 5.3: Morpholino targeting apelin. 
Morpholino targeting apelin is shown schematically binding to the exon/intron 
boundary of exon 2/intron 2 in the apelin gene sequence. Reverse complementary 
sequence of the morpholino is shown in diagram (5’ – 
GGTCAGTTTGACATTCCAGCACAAT – 3’); Morpholino sequence is 5’ – 
ATTGTGCTGGAATGTCAAACTGACC – 3’. 
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5.2.4.2 Determining the optimal injection quantity of the apelin morpholino 
The first step in our experimental design was to determine a suitable dose at which to 
inject our morpholinos. In preliminary experiments, the morpholino targeting apelin 
(MO-apelin) and its mispair control (MO-mispair) were injected using a 0.1 mm 
diameter bolus of 1 mM, 0.5 mM, 0.25 mM and 0.125 mM. 
 
To determine the size of the bolus administered, each morpholino was injected into a 
pool of mineral oil on a graticule (Fig 5.6). The radius of the bolus was determined 
and, making the assumption that the bolus in the oil is spherical, the volume (V) 














Figure 5.4: Calculation of bolus size in morpholino experiments. 
Diagram shows that morpholino bolus is injected into mineral oil on a graticule 
before each experiment to determine bolus size. 
needle containing 
morpholino 
0.1 mm bolus 
   104 
The molecular weights of MO-apelin and MO-mispair are 8972 and 8852 
respectively. This means that injecting 1 nl of 1 mM stock morpholino would result 
in 8.9 ng of morpholino being injected into the cytoplasmic streaming area of each 
embryo.  
 
5.2.4.3 Morpholino microinjection in 1 - 4 cell zebrafish embryos 
Morpholino injections were performed as described in section 2.6.4.2. MO-apelin 
was injected undiluted (1 mM) and diluted 0.5 mM, 0.25 mM and 0.125 mM in 
preliminary experiments. As calculated above, 0.5 nl was injected in these 
experiments, resulting in each embryo receiving 4.5 ng, 2.3 ng, 1.1 ng and 0.6 ng 
depending on the dilution injected. 
 
As a result of these preliminary experiments, we went on to perform the experiment 
injecting 1.1 ng/embryo in three independent experiments. In all experiments the 
injected embryos were treated in the same way. Non-injected controls, embryos 
injected with the morpholino targeted to apelin (MO-apelin) and the mispair 
morpholino control (MO-mispair) were kept in three separate petri dishes. Three 
hours post injection, embryos damaged by injection were removed from each 
experimental group as well as any abnormally developing embryos in the non-
injected control group. Non-fluorescing embryos (indicating unsuccessful uptake of 
the morpholino) were removed from both MO-apelin and MO-mispair groups. This 
accounted for a small proportion of all injected embryos and these embryos are not 
included in any subsequent analysis.  
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Embryos were then observed under light microscopy (x 40) for gross anatomical and 
specific cardiac phenotypes. A gross structural phenotype score was used (see Table 
5.3). The six features were included in this score were head size, body axis, heart rate 
(HR), presence/absence of blood in heart, presence/absence of blood pooling and tail 
circulation. Normal embryos were described as having a head size similar to that 
described by Kimmel et al. (1995), a straight body axis, a HR of around 150 bpm, 
blood clearly present in the heart, no blood pooling and normal tail circulation 
(determined subjectively using non-injected zebrafish embryos as a control). The 
number of assessed normal characteristics for each embryo was counted and the 
embryos were classified as detailed in Table 5.4. This classification was performed 




Number of normal 
characteristics 
 
6 4-5 2-3 1 0 
Phenotypic score 6 4.5 2.5 1 - 
 




Table 5.4: Characterisation of morpholino phenotype. 
Zebrafish were classified according to the number of normal characteristics 
following morpholino injection. Normal characteristics used for the classification 
were normal head size, straight body axis, normal HR, blood present in the heart, no 
blood pooling and normal tail circulation (further details in text). 
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5.2.4.4 Calculation of ejection fraction of MO-apelin embryos 
In a single experiment, 10 embryos were selected 3h post injection from the MO-
apelin, MO-mispair and non-injected control embryos. The selection criteria was 
simply that the embryos were of grossly normal appearance for this developmental 
timepoint according to Kimmel et al. (1995) and that fluorescence indicating 
successful uptake of the morpholino was observed. The groups of embryos were 
placed (1 fish per well) in a twelve well plate. Ejection fraction was measured in 6 
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5.3 Results 
5.3.1 The abundance of apelin, agtrl1a and agtrl1b mRNA transcripts during 
development 
Quantitative PCR revealed differences in the abundance of mRNA transcripts of 
apelin and its receptors, agtrl1a and agtrl1b, during development in the zebrafish 
embryo. Apelin mRNA abundance was lowest at 8 hpf and increased steadily from 
18 hpf, reaching a peak at 48 hpf. Apelin mRNA expression then decreased until 96 
hpf, but reached its largest expression level at 120 hpf (5 dpf) (Fig 5.7).  
 
 
Figure 5.5: The abundance of apelin mRNA in zebrafish embryos during 
development from 8 hpf to 120 hpf. 
Abundance of mRNA measured by qPCR (corrected for EF1a and RPL13a as 
reference genes and expressed as a percentage of abundance at 8 hpf; n = 2 (12-15 
embryos per timepoint per experiment). 
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The expression of both apelin receptors was highest at 8 hpf and reduced by 16 hpf. 
Agtrl1a and agtrl1b expression was maintained at a comparably low level until 120 
hpf (Figs 5.8 and 5.9). 
 
Figure 5.6: The abundance of agtrl1a mRNA in zebrafish embryos during 
development from 8 hpf to 120 hpf. 
Abundance of mRNA measured by qPCR (corrected for EF1a and RPL13a as 
reference genes and expressed as a percentage of abundance at 8 hpf; n = 2 (12-15 
embryos per timepoint per experiment). 
Figure 5.7: The abundance of agtrl1b mRNA in zebrafish embryos during 
development from 8 hpf to 120 hpf. 
Abundance of mRNA measured by qPCR (corrected for EF1a and RPL13a as 
reference genes and expressed as a percentage of abundance at 8 hpf; n = 2 (12-15 
embryos per timepoint per experiment). 
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5.3.2 Apelin, agtrl1a and agtrl1b are present in the zebrafish adult heart 
Apelin, agtrl1a and agtrl1b mRNA transcripts are present in the zebrafish adult heart 
(n = 3, 3 hearts per experiment; Fig 5.10). 
Apelin, agtrl1a and agtrl1b mRNA transcripts are present in the zebrafish adult heart 

















Figure 5.8: Apelin, agtrl1a and agtrl1b mRNA was detected in the zebrafish 
adult heart.  
GAPDH is used as a positive control (i). Apelin (ii), agtrl1a and agtrl1b (iii) mRNA 
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5.3.4 The effect of apelin on cardiac function in zebrafish embryos 
Incubation of zebrafish embryos for 1h in pyr-apelin-13 (150 nM) had no effect on 
contraction velocity (P = 0.38 one-way ANOVA; P = 0.09 apelin vs vehicle two-way 
ANOVA; Fig 5.11(i)), relaxation velocity (P = 0.37 one-way ANOVA; P = 0.37 
apelin vs vehicle two-way ANOVA; Fig 5.11(ii)) or wall motion amplitude (P = 0.48 
one-way ANOVA; P = 0.04 apelin vs vehicle two-way ANOVA; Fig 5.11(iii)) of the 
ventricle. Apelin incubation also had no effect on HR in zebrafish embryos (P = 0.97 
apelin vs vehicle two-way ANOVA; Fig 5.11(iv), although HR increased throughout 
the experiment in both apelin and vehicle treated groups (apelin P < 0.0001 one-way 



















Figure 5.9: The effect of pyr-apelin-13 (150 nM) on wall motion parameters in 
zebrafish 3 dpf. 
(i) contraction velocity P = 0.09 apelin vs vehicle two-way ANOVA, (ii) relaxation 
velocity P = 0.37 apelin vs vehicle two-way ANOVA, (iii) wall motion amplitude P 
= 0.48 apelin vs vehicle two-way ANOVA, (iv) heart rate P = 0.97 apelin vs vehicle 
two-way ANOVA (apelin n = 6, 3 – 5 embryos per experiment; vehicle n = 3, 3 
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5.3.5 The effect of calcium on isolated zebrafish embryonic hearts 
The peak response to calcium was observed at a calcium concentration of 5.5 mM in 
isolated hearts from zebrafish 3 dpf. Calcium (5.5 mM) significantly increased wall 
motion amplitude (P = 0.03 one-tailed paired t-test 2.5 mM vs 5.5 mM calcium) in 
isolated embryonic hearts from zebrafish 3 dpf (n = 3). There was also an increase in 
contraction velocity (P = 0.08 one-tailed paired t-test 2.5 mM vs 5.5 mM calcium) 
and relaxation velocity (P = 0.053 one-tailed paired t-test 2.5 mM vs 5.5 mM 
calcium) which approached significance. However, increasing calcium 
concentrations had no effect on intrinsic HR (P = 0.15 paired t-test) (Fig 5.12). 
 
5.3.6 The effect of pyr-apelin-13 on isolated zebrafish embryonic hearts 
Pyr-apelin-13 (50 - 150 nM) had no effect on contraction velocity (P = 0.21 one-way 
ANOVA) or HR (P = 0.77 one-way ANOVA) in isolated hearts 3 dpf. There was a 
small increase in wall motion amplitude which approached significance (P = 0.07 
one-way ANOVA) and a significant increase in relaxation velocity (P = 0.049 one-
way ANOVA, P = 0.01 post test for linear trend) (Fig 5.13). 
 
In isolated hearts from zebrafish 4 dpf, pyr-apelin-13 (50 – 150 nM) had no effect on 
contraction velocity (P = 0.81 one-way ANOVA), relaxation velocity (P = 0.57 one-
way ANOVA), wall motion amplitude (P = 0.91 one-way ANOVA) or HR (P = 0.92 
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Figure 5.10: The effect of calcium (5.5 mM) on wall motion parameters in 
isolated hearts of zebrafish 3 dpf. 
* P < 0.05, (i) contraction velocity P = 0.08 one-tailed t-test, (ii) relaxation velocity 
P = 0.053 one-tailed t-test, (iii) wall motion amplitude P = 0.03 one-tailed t-test, (iv) 














Figure 5.11: The effect of pyr-apelin-13 (50 - 150 nM) on wall motion 
parameters in isolated hearts of zebrafish 3 dpf and 4 dpf. 
(i) contraction velocity P = 0.21 (3 dpf) P = 0.81 (4 dpf) one-way ANOVA, (ii) 
relaxation velocity P = 0.049 (3 dpf) P = 0.57 (4 dpf) one-way ANOVA, (iii) wall 
motion amplitude P = 0.07 (3 dpf) P = 0.91 (4 dpf) one-way ANOVA, (iv) heart rate 
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5.5.6 The effect of knockdown of apelin gene expression using a targeted morpholino 
Preliminary experiments using different morpholino concentrations were carried out, 
from which we decided to inject 1.1 ng per embryo for further experiments (Fig 
5.14). 
 
Apelin mRNA knockdown of approximately 90% compared to embryos injected 
with the mispair control was shown by qPCR in embryos 3 dpf (n = 2; 7 embryos per 
experiment). Data was corrected for the reference gene EF1a which did not change 
between groups (n = 2; 7 embryos per experiment) (Fig 5.15). 
 
The probe used in qPCR binds at the exon 2/intron 2 boundary. The forward primer 
binds in exon 2 and the reverse primer binds in exon 3. As the morpholino binds at 
the same exon/intron boundary, this qPCR assay is ideal to detect apelin knockdown 
as a result of morpholino injection. 
 
5.5.6.1 Survival in embryos with apelin knockdown 
MO-apelin injected embryos had greater mortality than non-injected controls and 
MO-mispair injected embryos (P < 0.0001 log rank (Mantel-Cox) test; n = 3, 100 
embryos per group per experiment (Fig 5.16). 
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5.5.6.2 Phenotypic analysis of embryos with apelin knockdown 
Cardiovascular phenotypes and gross anatomy of the zebrafish embryos were 
assessed. We observed that a large proportion of MO-apelin injected embryos had 
reduced HR, a lack of blood in hearts and reduced or absent circulation, in addition 
to gross anatomical changes such as twisted tails or the absence of a tail, compared to 
MO-mispair controls. The phenotypic score (Table 5.4) was significantly reduced in 
MO-apelin embryos compared to MO-mispair embryos (P < 0.0001 two-way 











Figure 5.12: Percentage survival at 24h in morpholino injected embryos 
(n = 1 experiment per dose; n = 30 embryos per morpholino per dose) 
 
 
0.6 1.1 2.3 4.5 
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Figure 5.13: Apelin mRNA in MO-apelin injected embryos versus MO-mispair 
injected embryos 
Knockdown of apelin mRNA is shown by qPCR in zebrafish embryos 3 dpf (n = 2; 7 
embryos per experiment). Data corrected for EF1a as a reference gene. Both the 
morpholino and qPCR probe bind at the exon2/intron 2 boundary. The forward 
primer binds in exon 2 and the reverse primer binds in exon 3. 
 
Figure 5.14: Kaplan-Meier survival curve of MO-apelin embryos compared to 
non-injected and MO-mispair controls. 





















Figure 5.15: Mean phenotypic score in non-injected control, MO-apelin and 
MO-mispair embryos. 
A phenotypic score of 6 denotes a normal phenotype and a score of 1 denotes an 
embryo with a severe phenotype according to the characteristics listed in Table 5.4. 
** P < 0.01 *** P < 0.001 two-way ANOVA MO-apelin vs MO-mispair embryos; n 
= 3, 100 embryos per group per experiment. 
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Figure 5.16: MO-apelin and MO-mispair injected zebrafish embryos at 1 dpf. 
Fluorescent images show successful uptake of the morpholino and a severe 
anatomical phenotype can be seen in a typical MO-apelin injected embryo. Scale bar 
0.1 mm. 
 







































Figure 5.17: MO-apelin and MO-mispair injected embryos at 3 dpf. 
The majority (71 ± 6%, n = 3) of MO-mispair injected embryos display a normal or 
mild phenotype at 3 dpf, while the majority (87 ± 9%, n = 3) of MO-apelin injected 
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5.5.6.3 Ejection fraction in MO-apelin embryos 
Despite observing greater mortality and a more severe total body and cardiovascular 
phenotype in MO-apelin injected embryos, we were unable to detect an effect of 
MO-apelin on ejection fraction in surviving zebrafish embryos at 2 dpf, 3 dpf and 4 
dpf (P = 0.94 two-way ANOVA; Fig 5.20). 
 
Figure 5.18: Ejection fractions in non-injected controls, MO-apelin and MO-
mispair morpholino injected embryos. 
Ejection fractions do not differ between groups at 2 – 4 dpf (P = 0.94 two-way 





   122 
5.4 Discussion 
5.4.1 mRNA studies of apelin and its receptors in zebrafish embryos and the adult 
zebrafish heart 
The pattern of mRNA of apelin and its receptors in whole embryos during the first 
five days of development is striking. Apelin mRNA increases steadily from 8 hpf and 
reaches a peak at 48 hpf. This confirms the work of Zeng et al. (2007) who showed 
using RT-PCR that apelin mRNA is not detected at 7 hpf, but is present from 8.5 hpf 
and increases until 48 hpf. These authors stop their time course at this point. We 
were able to show that apelin mRNA declines at 72 hpf and again at 96 hpf where it 
reaches a level comparable with that of 18 hpf. However, there is a sharp increase at 
120 hpf (5 dpf) when apelin mRNA reaches its highest level in all of the 
developmental time points studied, a five fold increase in apelin mRNA abundance 
from 96 hpf.  
 
In contrast to the pattern of the abundance of the ligand, apelin, both receptors, 
agtrl1a and agtrl1b, have similar mRNA patterns. The assays used have been 
checked with BLAST for specificity for other genes and we can be confident that 
although the homology between the receptor isoforms is significant (approximately 
80% (Tucker et al., 2007)), each of our assays is detecting only one form of the 
receptor. The receptor mRNA patterns show the highest levels of both forms of the 
receptor in our time course are expressed at 8 hpf. Midblastula transition (MBT), a 
time when zygotic transcription begins and maternal regulated transcription 
decreases, occurs at 5.5 hpf (Kimmel et al., 1995). The high levels of agtrl1a and 
agtrl1b mRNA detected at 8 hpf may be in part due to maternally controlled 
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transcription. From 18 hpf until 120 hpf, the levels of both receptors are around 20 – 
30% of that observed at 8 hpf. Protein extracted from zebrafish embryos (5 dpf) was 
probed in a western blot with rat anti-APJ receptor antibody, but the antibody was 
unable to detect the zebrafish protein. In situ hybridisation studies would allow us to 
further investigate the expression of the apelin receptor in zebrafish in the absence of 
a suitable antibody.  
 
Apelin, agrtrl1a and agtrl1b mRNA were also detected in zebrafish adult heart. Our 
embryo mRNA studies represent the mRNA of the whole embryo so we are unable 
to determine the degree to which specific tissues contribute to the pattern of mRNA 
in the embryo. As I now have the technical skill to isolate embryonic hearts from 
zebrafish 3 – 5 dpf, it would be possible, in a future study, to investigate cardiac 
specific changes in apelin, agtrl1a and agtrl1b mRNA during this window of 
development. Using qPCR, it would then be possible to relate cardiac apelin mRNA 
abundance in the embryonic heart to that in the adult zebrafish heart. 
 
5.4.2 The effect of exogenous apelin on cardiac function in zebrafish embryos 
Although we detected the presence of endogenous apelin, agtrl1a and agtrl1b mRNA 
in whole zebrafish embryos, exogenous apelin had no effect on cardiac function in 
vivo of zebrafish embryos 3 dpf. Pyr-apelin-13 was administered to zebrafish via the 
bathing water. This particular apelin isoform was chosen for these studies as the 
terminal pyroglutamate is thought to afford it protection from degradation by 
endopeptidases (Russo et al., 2002). The zebrafish embryos were incubated in pyr-
apelin-13 for 1h. Previous work demonstrated that 10 minutes was sufficient time for 
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small molecule drugs, such as noradrenaline, to have an effect on cardiac function in 
zebrafish embryos embedded in agar (Denvir et al., 2008). Although the incubation 
time should have been long enough, we could not be sure that the peptide was 
entering the zebrafish embryos. Drugs have been successfully administered to 
embryonic zebrafish via the bathing water in a number of studies (Berghmans et al., 
2008; Denvir et al., 2008; Loynes et al., 2010; Milan et al., 2003; Parng et al., 2006); 
however, it is unclear whether or not small peptides enter the zebrafish embryo when 
administered via the bathing medium. 
 
One way to investigate whether or not the human apelin was entering the zebrafish 
embryo would have been to use a fluorescently tagged apelin and subsequently 
perform immunohistochemistry. However, the available fluorescent tags were much 
larger than apelin itself meaning that if apelin did not get in we could not determine 
if this was due to the fluorescent tag. Another possibility was to use a radiolabelled 
apelin and perform autoradiography after bathing the embryos in system water 
containing the radiolabelled peptide. We also attempted to inject apelin into the 
circulation of zebrafish embryos at 3 dpf.  
 
The injection of apelin into the circulation of zebrafish embryos at 3 dpf was 
attempted. Microinjection of drugs (sotalol, pentamidine and procainamide) that 
induce bradycardia have been shown to be effective when injecting directly into the 
yolk sac at 2 dpf (Milan et al., 2003); injecting directly overcomes the hydrophilicity 
and possible poor absorption of the compound. However, in embryos 3 dpf, the yolk 
sac is further separated from the circulation than at 2 dpf (Isogai et al., 2001), 
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therefore, microinjection into the caudal vein and dorsal aorta whilst attempted did 
prove to be technically too difficult. Injection into the caudal vein and dorsal aorta is 
not only compounded by the dimensions of the vessels available but also the need to 
inject, under pressure, the apelin compound into the vasculature. 
 
The only way to be certain of whether apelin had a direct action on the heart in 
zebrafish embryos was to isolate embryonic hearts and expose hearts directly to pyr-
apelin-13 in the bathing medium. Two developmental stages of embryo were chosen 
for these experiments: 3 dpf when endogenous apelin mRNA was relatively high and 
4 dpf when endogenous apelin mRNA was relatively low. Exogenous pyr-apelin-13 
administered to hearts isolated from embryos at 3 dpf and 4 dpf had no inotropic 
effect i.e. there was no increase in wall motion amplitude or contraction velocity. 
There was also no change in heart rate. However there was a small, but significant, 
increase in relaxation velocity in isolated hearts (3 dpf) in response to apelin.  
 
Nevertheless, embryonic isolated heart preparations were not without their own 
limitations. The hearts were unpaced and HR was around 60 bpm compared to 150 
bpm in vivo in zebrafish embryos. This did, however, allow us to determine that 
apelin had no effect on HR in these preparations. The experiments were also 
performed on unloaded hearts. The Frank-Starling law where increasing stretch 
results in increased cardiac contractility, has been shown to apply to all vertebrates 
(see Shiels and White, 2008). Therefore, applying stretch to the isolated embryonic 
hearts may improve this experimental approach. Other considerations are 
temperature, oxygenation and physical trauma to the tissue. The experiments were 
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carried out at room temperature (22 °C), whereas a physiological temperature for 
these preparations would be 28.5 °C. As zebrafish are poikilothermic organisms 
(they do not regulate body temperature so body temperature varies with the 
environment), this may have influenced heart rate and function. The bathing medium 
was buffered by HEPES, but was not oxygenated. Therefore, it is likely that the 
tissue was experiencing a small level of hypoxia. The physical trauma that may have 
been caused to the cardiac tissue during isolation of the heart is another limitation of 
the preparation. For these reasons, the experimental protocol was kept short in 
length. Despite these limitations, the hearts were removed from the embryos quickly 
and all were beating well for the duration of the experimental protocol. A similar 
technique has been utilised and reported using isolated embryonic zebrafish hearts to 
assess voltage mapping of the zebrafish ventricle (Panakova et al., 2010). 
 
5.4.3 Knockdown of apelin mRNA using a targeted morpholino 
Knockdown of apelin expression generated severe, abnormal total body and 
cardiovascular phenotypes. The pattern of abundance of mRNA of the ligand, apelin, 
appears to mirror the survival curve of the MO-apelin embryos i.e. the greater the 
level of endogenous apelin mRNA in our developmental time course; the greater the 
mortality rate in embryos with knockdown of apelin expression. Since no MO-apelin 
embryo has survived to 5 dpf in our morpholino experiments, we can conclude that at 
5 dpf apelin is essential for survival or that the severe abnormalities generated by 
apelin knockdown prior to this cause death by 5 dpf. A combination of both of these 
reasons may be responsible. 
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We established that (a) apelin was successfully knocked down using our morpholino 
and (b) a five mispair control morpholino demonstrated significantly greater survival 
and a less severe phenotype as determined by our phenotypic score. However, the 
specificity of the action of the morpholino requires further experiments. One way 
would be to perform a second morpholino experiment using a non-overlapping 
morpholino which also targets apelin mRNA. If the resulting phenotype was the 
same, we would conclude that the total body and cardiovascular phenotype observed 
is specific to knockdown of apelin in these experiments. Another experiment that 
would illustrate the specificity of the apelin morpholino would be to perform a 
“rescue experiment”, in which apelin mRNA lacking the morpholino binding site 
would be co-injected with the morpholino. If this attenuated the observed phenotype, 
then we would conclude that the phenotype is specifically due to apelin knockdown. 
These future experiments are further discussed in section 7.2.3. 
 
The effect of apelin knockdown in zebrafish embryos was in contrast to the effect of 
apelin knockout in mice reported in the literature. Apelin knockout mice develop 
normally with no notable phenotype (Kuba et al., 2007). This questions whether (i) 
apelin does have a developmental role in zebrafish, but not in mice or (ii) the effect 
observed in these experiments is not specific to knockdown of the apelin gene. The 
experiments described above would help in answering this question. In addition p53-
mediated cell death has been shown to be responsible for several morpholino-
induced phenotypes (Robu et al., 2007). Co-injection of a p53 morpholino and apelin 
morpholino would determine whether or not the developmental abnormalities 
observed on knockdown of the apelin gene are due to p53-mediated cell death. 
   128 
Other approaches which were considered to generate embryos in which apelin gene 
expression is knocked down were Targeted Induced Local Lesions in Genomes 
(TILLING) and zinc finger nucleases. These methods have advantages over the use 
of morpholinos as they both produce a mutation in the gene of interest. 
 
TILLING involves exposure of adult male zebrafish to a mutagen, for example, N-
ethyl-N-nitrosourea (ENU) which are crossed with untreated females in order to 
generate mutations which are passed to the offspring via the germline (see Moens et 
al., 2008). It is used in huge screens as a way of generating multiple mutant lines 
which may have phenotypes of interest to a particular field. Interesting phenotypes in 
the resulting embryos can then be followed up by sequencing the genome to find the 
mutation responsible for the phenotype (see Sood et al., 2006). However, TILLING 
cannot be used to target a particular gene of interest and therefore, although it would 
ultimately provide a more specific apelin mutant than could be generated by 
morpholino, it was not a viable option for this study. 
 
Zinc finger nucleases bind to the targeted DNA and produce double stranded breaks 
in the DNA. These breaks are repaired by non-homologous end joining which join 
the ends of the break back together. However, errors are often made in this process 
and it can result in insertions or deletions in the gene sequence leading to a frame-
shift which results can result in a non-functional protein. Zinc finger nucleases 
produce a specific mutant which may be more reliable than knockdown of gene 
expression by morpholino (see Urnov et al., 2010). The mutation generated by a zinc 
finger nuclease can also be passed to offspring and therefore a mutant line can be 
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created. This is in contrast to the use of a morpholino where the gene knockdown 
will last only for the first 5-7 days of development. In some cases, zinc finger 
nucleases produce non-specific effects (Gupta et al., 2011). Furthermore, the 
generation of a zinc finger nuclease can take months in the lab, whereas GeneTools 
are able to design a morpholino to target a specific gene in days. For these reasons, 
morpholinos were used in this study. 
 
5.4.4 Summary 
In summary, the endogenous apelin system appears to be established early in 
development and is essential at these early timepoints. Although we observed a total 
body and cardiovascular phenotype following apelin knockdown with a targeted 
morpholino, exogenous apelin had no inotropic effect on the heart function of 
embedded embryos 3 dpf or isolated embryonic hearts (3 dpf and 4 dpf). The 
functional role of the apelin system in the zebrafish remains unclear, although these 



























Chapter 6  The development of an acute hypoxia-






   131 
6.1 Introduction 
6.1.1 Cardioprotection: a definition 
Cardioprotection can be defined as a mechanism which reduces injury to the 
cardiovascular system following an ischaemic or hypoxic insult, for example by a 
pharmacological agent. Cardioprotection is measured by a decrease in myocardial 
infarct size (Simpkin et al., 2007) or, as in this study, by a lesser degree of 
depression in cardiac function in response to an ischaemic insult. 
 
6.1.2 Cardioprotective effects of apelin 
The cardioprotective effects of apelin have been previously reported in a limited 
number of publications. A thorough search of the literature for studies involving 
apelin and hypoxia or ischaemia revealed a limited number of publications. The 
published data demonstrates reduced cardiac injury in the presence of apelin 
compared to saline alone in rat and mouse models of ischaemia-reperfusion (Simpkin 
et al., 2007). The cellular mechanisms responsible for cardioprotection by apelin 
remain unclear. Apelin-mediated cardioprotection was shown to be independent of 
P13K/Akt and P70S6 kinases in a study carried out by Kleinz and Baxter (2008). 
However, Smith et al. (2007) demonstrate in isolated, perfused mouse hearts that 
phosphorylation and activity of the kinases, Akt and P44/42, are increased following 
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6.1.1.2 The relationship between the apelin and HIF-1 pathways 
Cardioprotection associated with activation of the hypoxia-inducible factor 1α (HIF-
1α) pathway has been well documented and this has been reviewed recently by Tekin 
et al. (2010). The relationship between HIF-1α and apelin pathways has been 
explored in a small number of studies (Eyries et al., 2008; Glassford et al., 2007; 
Han et al., 2008; Ronkainen et al., 2007). However, the role of apelin in HIF-1α 
mediated cardioprotection has not yet been studied. 
 
The link between HIF-1α and apelin was first established by the discovery of a 
hypoxia-response element on the human apelin gene (Eyries et al., 2008). Under 
hypoxic conditions, HIF-1α translocates to the nucleus, pairs with HIF-1β, and binds 
to hypoxia-response elements on a variety of genes to induce transcription (Qutub et 
al., 2006). In adipocytes, an increase in apelin mRNA expression in response to 
hypoxia was shown to be mediated via HIF-1α (Glassford et al., 2007). Another 
study suggested that HIF-1α-mediated apelin expression promotes enteric cell 
proliferation in response to hypoxia (Han et al., 2008). In rat myocardium and 
cultured rat cardiomyocytes exposed to hypoxia, an increase in apelin mRNA was 
mediated via HIF-1α, as inhibition of HIF-1α abolished the increase in apelin mRNA 
expression (Ronkainen et al., 2007). Although the link between the HIF pathway and 
apelin pathway has been documented in these systems, these models do not directly 
demonstrate a cardioprotective effect of apelin when activated via HIF-1α. Using the 
zebrafish as a model organism allowed us to expose the whole organism to hypoxia, 
monitor heart function non-invasively and influence the apelin system, in order to 
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further understand the potential cardioprotective role of apelin and its relationship 
with the HIF-1α pathway. 
 
6.1.2 Hypoxia studies in the zebrafish 
Zebrafish are adaptive organisms which respond to a changing environment and may 
experience hypoxia in their natural environment of shallow, slow moving waters 
(Spence et al., 2008). However, zebrafish embryos (3 dpf and older) are unable to 
survive exposure to severe hypoxia (5% oxygen) for more than 12h (Ton et al., 
2003), while embryos can survive less severe hypoxia for days (Schwerte et al., 
2003). In our experience, zebrafish embryos (3 dpf and older) are unable to survive 
very severe hypoxia (1% oxygen) for longer than 4 - 8h. Therefore, hypoxia studies 
in the zebrafish fall into two groups: (i) longer term less severe hypoxia assessing the 
developmental and adaptive capabilities of zebrafish embryos (Schwerte et al., 2003) 
and (ii) shorter more severe hypoxia studies assessing hypoxia-induced injury. 
 
Longer term hypoxia studies, in which zebrafish are exposed to hypoxia throughout 
development, demonstrate the adaptive responses of zebrafish embryos. In response 
to long-term hypoxia there is an apparent change in red blood cell distribution with 
more red blood cells in the tail and less in the gut after hypoxia (Schwerte et al., 
2003). Bagatto (2005) describes slower growth, slower HR and more variation in 
development in chronic hypoxia studies. One study showed that complete anoxia 
(24h) caused development to halt, but when oxygen was returned to normal levels, 
development restarted normally (Padilla et al., 2001). 
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Short term very severe hypoxia (< 5% oxygen) studies are fewer in number. Most 
have focussed on changes in HR or the developmental impact of acute hypoxic 
exposure. Indeed, the majority of short term hypoxic insults are exposure to 5% 
oxygen for between 4h and 24h. HIF-1α expression is up-regulated in response to 5% 
oxygen for 24h from 24 hpf to 48 hpf, in zebrafish embryos and these changes can be 
reversed by normoxic exposure (Gray et al., 2007; Ton et al., 2003). HIF-1α mRNA 
was also increased in zebrafish 4 dpf exposed to 5% oxygen for 4h (Gray et al., 
2007). The mechanisms which underpin the cardiovascular response to acute hypoxia 
have not been studied in depth to date. 
 
The aims of this chapter were to develop a hypoxia-recovery model in zebrafish 
embryos. Establishing the model involved defining a reproducible effect of hypoxia 
on the heart and circulation by incubation in a hypoxic environment for a defined 
time period. This also involved defining the time scale of normoxic recovery using 
global cardiovascular function (heart rate, heart contraction and tail circulation) as 
surrogate measure. Once these parameters were explored and defined, we used the 
model to: 
i. assess the response to hypoxia at different developmental stages 
ii. study the possible effects of apelin on the hypoxia-recovery response 
iii. study the effect of other drugs (including HIF modulators) on the hypoxia-
recovery response 
iv. assess changes in the abundance of mRNA transcripts of apelin and HIF-1α 
on exposure to hypoxia and subsequent recovery 
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6.2 Methods 
6.2.1 Hypoxia-recovery model measured using a semi-quantitative scoring system  
To determine semi-quantitative differences in the cardiac response of zebrafish 3 dpf 
and 5 dpf to hypoxia, zebrafish (15 – 20 embryos per dish) in dechlorinated system 
water were placed in the hypoxic chamber (1% oxygen, 94% nitrogen, 5% carbon 
dioxide; 26 °C) for 2h or 4h. After the assigned time in the hypoxic chamber, heart 
and circulatory function were assessed under a light microscope (at 22 °C) and each 
fish was described as having normal, reduced or absent heart rate (HR) and 
circulation compared to normoxic controls (Table 6.1, Fig 6.1). 
 
Category Normal Reduced Absent 
 
Criteria 
HR > 100 bpm, 
normal global 
circulation compared 
to normoxic controls 
HR < 100 bpm, 
reduced global 
circulation compared 
to normoxic controls 
no HR or 
circulation 
Table 6.1: Criteria for categorising HR and global circulation in the hypoxia-
recovery model. 
 
Figure 6.1: Hypoxia-recovery model. 
Zebrafish were exposed to hypoxia or normoxia for 2h or 4h as shown followed by 
4h recovery in normoxia. Measurements were made at the end of each block. 
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6.2.1.1 The effect of pharmacological agents on the hypoxia-recovery model 
Zebrafish 5 dpf exposed to 2h hypoxia with recovery in normoxia was chosen as a 
suitable model for the assessment of a possible influence of pharmacological agents 
on the hypoxia-recovery response. A series of experiments tested the effect of the 
following drugs in this model: pyr-apelin-13 (150 nM), desferrioxamine (0.1 mM), 
α-ketoglutarate (2.5 mM), glibenclamide (0.1 mM) and nicorandil (0.1 mM).  
 
Desferrioxamine is an iron chelator which can potentiate the HIF pathway by 
inhibiting the formation of the degradation complex formed by PHD enzymes. The 
drug also has antioxidant activity (Parng et al., 2006). Desferrioxamine has 
previously been administered to zebrafish embryos via the bathing water in an assay 
used to identify neuroprotectant compounds (Parng et al., 2006). The maximal effect 
was seen at 0.1 mM and therefore the same concentration was used in the 
experiments described in this thesis. Alpha-ketoglutarate can inhibit the HIF pathway 
as α-ketoglutarate is required for the PHD complex that is responsible for the 
degradation of HIF. Preliminary experiments at 0.1 mM, 2.5 mM and 25 mM 
demonstrated that the maximal effect in our model was observed at 2.5 mM and 
therefore this concentration was used in subsequent experiments. 
 
Glibenclamide acts by inhibiting ATP-dependent potassium channels. Glibenclamide 
was used in a previous study in zebrafish 2 dpf in which it produced a small decrease 
in heart rate at 100 µg/ml which equates to 0.02 mM (Milan et al., 2003). The 
concentration used in this study was five times greater which I used bearing in mind 
that the zebrafish used in the experiments presented here were older at 5 dpf. The 
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action of glibenclamide has been shown to abolish the cardioprotective effects of 
other drugs in rat models of cardioprotection (Taliyan et al.). Nicorandil is an ATP-
dependent potassium channel activator and has been shown to be beneficial in 
patients undergoing reperfusion after myocardial infarction (Iwakura et al., 2009). 
Although no published study exists in which nicorandil was administered to 
zebrafish embryos, the concentration used was the same as that of glibenclamide as 





Figure 6.2: The effect of drugs on the hypoxia-recovery model. 
Zebrafish (5 dpf) are incubated in drug, followed by a 2h exposure to normoxia (a) or 
hypoxia (b). Alternatively, zebrafish are incubated in vehicle followed by a 2h 
exposure to normoxia (c) or hypoxia (d). All fish are allowed to recover in normoxia 
for 4h and are observed at arrowed timepoints. 
 
 
These experiments were performed blinded which meant that the investigator was 
unaware of which dish of embryos had drug or vehicle added in all experiments. In 
all cases, zebrafish were incubated (10 embryos per dish) in drug or its vehicle 
throughout the experimental protocol. In the cases where DMSO was used as a 
vehicle, the final concentration of DMSO in the bathing solution was 0.1%. 
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Incubation began 1h prior to hypoxic exposure. Assessments of HR and global 
circulation (Table 6.1) were made in the same way as for the experiments comparing 
the response in 3 dpf and 5 dpf embryos and at the same timepoints, i.e. immediately 
after hypoxia, after 2h recovery in normoxia and after 4h recovery in normoxia (Fig 
6.2). 
 
6.2.1.2 The effect of hypoxia on MO-apelin embryos 
In a single experiment (n = 7 per group), MO-apelin embryos (described in chapter 
5) were exposed to hypoxia with MO-mispair embryos and non-injected controls at 3 
dpf. Normoxic embryos of all three groups were also observed as a control. To 
ensure that the MO-apelin embryos were not highly susceptible to severe hypoxic 
conditions, the hypoxia-recovery protocol was adapted. Assessment of HR and 
global circulation (see Table 6.1) of embryos was performed at 30 minute intervals 
for the first 1h 30 and at 1h intervals thereafter for a total exposure time of 5h 30. 
 
6.2.2 Hypoxia-recovery model measured using video edge detection 
6.2.2.1 Apelin 
Agar-embedded zebrafish (3 dpf) were incubated in pyr-apelin-13 (150 nM) for 1h 
prior to hypoxia and throughout the experimental protocol. Zebrafish were exposed 
to hypoxia (1% oxygen) for 2h and then placed in a normoxic environment for 2h. 
Vehicle controls were exposed to hypoxia and normoxia in the same way and 
embryos exposed to normoxia throughout the experiment were used as an additional 
control. Video edge detection (as described in section 2.6.1) was performed on apelin 
and vehicle treated embryos immediately after hypoxia and after 1h and 2h recovery 
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in normoxia. Similarly, video edge detection measurements of normoxic controls 
were performed at each of the above timepoints and at baseline. Contraction velocity, 
relaxation velocity, wall motion amplitude and heart rate were expressed as a 
percentage of baseline normoxic control measurements. 
 
6.2.2.2 Desferrioxamine 
At 5 dpf the ventricle wall was difficult to track in wild-type embryos due to 
overlying skin pigmentation reducing optical clarity of the heart region. Therefore, 
the effect of desferrioxamine on the hypoxia-recovery model was assessed using 
transgenic cardiac myosin light chain 2: green fluorescent protein (cmlc2:GFP) 
zebrafish (5 dpf). Agar-embedded cmlc2:GFP zebrafish were incubated in 
desferrioxamine (0.1 mM)  for 1h prior to hypoxia and throughout the experimental 
protocol. Embryos were exposed to hypoxia for 2h followed by recovery in normoxia 
for 4h. Video edge detection (as performed in section 6.2.2.1) was performed on 
desferrioxamine and vehicle treated embryos immediately after 2h hypoxia and after 
2h and 4h of recovery. Similarly, video edge detection measurements of normoxic 
controls were performed at each of the above timepoints and at baseline. Contraction 
velocity, relaxation velocity, wall motion amplitude and heart rate were expressed as 
a percentage of baseline normoxic control measurements. 
 
6.2.3 Quantitative PCR  
6.6.1.2 Measuring mRNA of genes of interest in the hypoxia-recovery model 
At each timepoint in the model described above (Fig 6.1) qPCR was carried out in 
groups of whole zebrafish embryos 3 dpf and 5 dpf (see section 2.7.2.4). Apelin, 
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agtrl1a, agtrl1b, HIF-1α, EF1a and ribosomal subunit 18S assays (Table 6.3) were 
run on each of the samples (10 embryos pooled per sample) against standard curves 
for each primer-probe set made by serial dilutions of pooled cDNA from all samples. 
EF1a and 18S reference (housekeeping) gene mRNA did not change across the 
groups in zebrafish 3 dpf (EF1a P = 0.75 one-way ANOVA; 18S P = 0.24 one-way 
ANOVA) or 5 dpf (EF1a P = 0.89 one-way ANOVA; 18S P = 0.76 one-way 
ANOVA). There was also no change in EF1a or 18S mRNA between zebrafish 3 dpf 
and 5 dpf at any of the timepoints measured (EF1a P = 0.32 two-way ANOVA; 18S 
P = 0.46 two-way ANOVA) (n = 6 - 8, 10 embryos per timepoint per experiment). 
Abundance of mRNA of our genes of interest was corrected for the mean of 
reference genes EF1a and 18S and expressed as a percentage of the normoxic 
control. 
 
6.2.1.1 Measuring the abundance of HIF-1α mRNA during development 
qPCR of HIF-1α mRNA transcript was carried out as described in section 2.7.2.4. 
RNA was extracted from zebrafish embryos at each of the following developmental 
time points (8, 18, 24, 36, 48, 72, 96 and 120 hpf) as was previously carried out for 
apelin, agtrl1a and agtrl1b (see chapter 5). EF1a, RPL13a and HIF-1α assays were 
run on each of the samples against standard curves for each primer-probe set made 
by serial dilutions of pooled cDNA from all samples. EF1a and RPL13a mRNA did 
not change across the groups (EF1a P = 0.06 one-way ANOVA; RPL13a P = 0.43 
one-way ANOVA; n = 2 (12 – 15 embryos per time point per experiment)). HIF-1α 
mRNA abundance was corrected for the reference genes EF1a and RPL13a and 
expressed as a percentage of abundance at 8 hpf.  
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18S BX296557 77 F: CTCAACACGGGAAACCTCAC 
R: CGCTCCACCAACTAAGAACG 
110 
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6.3 Results 
6.3.1 The effect of hypoxia-recovery on the cardiovascular response in zebrafish 
embryos 
6.3.1.1 Hypoxia-recovery response of embryos 3 dpf compared to embryos 5 dpf 
Clear differences were observed in the cardiovascular response of zebrafish 3 dpf 
and 5 dpf to severe hypoxia (Figs 6.3, 6.4). Zebrafish 3 dpf are less susceptible to a 
depression in HR and circulation in response to 2h or 4h hypoxia than zebrafish 5 
dpf. After exposure to 2h hypoxia, 90% (95% CI 80, 96) more zebrafish 3 dpf had 
normal HR and circulation than zebrafish 5 dpf (P < 0.0001 comparison of 
proportions); while a larger proportion of zebrafish 5 dpf had reduced HR and 
circulation than zebrafish 3 dpf. After 4h hypoxic exposure, there were very few 
embryos with normal heart rate and circulation among zebrafish 3 dpf and zebrafish 
5 dpf. There was no difference in the proportions of zebrafish 3 dpf and zebrafish 5 
dpf with normal HR and circulation (difference 4% (95% CI 3, 12), P = 0.32 
comparison of proportions). However, it was noted that a smaller proportion of 
zebrafish 3 dpf had absent HR and circulation than zebrafish 5 dpf after 4h hypoxia. 
 
After hypoxic exposure, zebrafish were transferred to a normoxic environment. 
Following 2h hypoxic exposure, the cardiovascular effect of acute hypoxia was 
observed to recover in the majority of embryos 3 dpf and 5 dpf. As well as being less 
susceptible to the depression in HR and circulation after the initial hypoxic insult, 
zebrafish 3 dpf also recovered more rapidly than zebrafish 5 dpf. At 2h recovery, 
59% (95% CI 46, 70) more zebrafish 3 dpf had normal HR and circulation than 
zebrafish 5 dpf (P < 0.0001 comparison of proportions). At 4h recovery, 28% (95% 
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CI 18, 40) more zebrafish 3 dpf had normal HR and circulation than zebrafish 5 dpf 
(P < 0.0001 comparison of proportions) (Fig 6.3). 
 
Following 4h hypoxic exposure, the cardiovascular effect of hypoxia on zebrafish 3 
dpf recovered, but zebrafish 5 dpf did not recover. Only 10% of zebrafish 5 dpf had 
normal HR and circulation after 4h recovery in normoxia. At 2h recovery, 88% (95% 
CI 77, 95) more zebrafish 3 dpf had normal HR and circulation than zebrafish 5 dpf 
(P < 0.0001 comparison of proportions). At 4h recovery, 83% (95% CI 69, 91) more 
zebrafish 3 dpf had normal HR and circulation than zebrafish 5 dpf (P < 0.0001 














































Figure 6.3: The percentage of assessed zebrafish embryos with normal HR and 
circulation after exposure to 2h hypoxia and 4h normoxia.  
*** P < 0.0001 comparison of proportions, 3 dpf n = 4, 15 – 20 per experiment; 5 




















Figure 6.4: The percentage of assessed zebrafish embryos with normal HR and 
circulation after exposure to 4h hypoxia and 4h normoxia. 
*** P < 0.0001 comparison of proportions, 3 dpf n = 3, 15 – 20 per experiment; 5 
dpf n = 3, 15 – 20 embryos per group per experiment; data plotted as mean ± SEM. 
4h hypoxia 
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6.3.1.2 Susceptibility to severe hypoxia by developmental stage: ventricle wall 
motion studies by video edge detection  
The observed differences in cardiovascular response to hypoxia were further 
quantified in terms of cardiovascular function. As developmental stage increased, the 
depressive effect of hypoxia on wall motion parameters increased. The effect of 2h 
hypoxia was so profound that no wall motion could be detected. Contraction velocity 
(P = 0.84 one-way ANOVA, 2 – 4 dpf) and wall motion amplitude (P = 0.28 one-
way ANOVA, 2 - 4 dpf) were unchanged across developmental stages. The decrease 
in relaxation velocity across developmental stages approached significance (P = 0.08 
one-way ANOVA, 2 - 4 dpf), while the severity of the depression in HR increased 
with developmental stage (P = 0.02 one-way ANOVA, 2 - 4 dpf) (Fig 6.5). 
Figure 6.5: Wall motion parameters in zebrafish 2 – 5 dpf exposed to 2h 
hypoxia. 
(i) contraction velocity P = 0.84 one-way ANOVA (2 – 4 dpf), (ii) relaxation 
velocity P = 0.08 one-way ANOVA (2 – 4 dpf), (iii) wall motion amplitude P = 0.28 
one-way ANOVA (2 – 4 dpf), (iv) heart rate P = 0.02 one-way ANOVA (2 – 4 dpf), 
n = 2 (4 - 6 embryos per experiment), * embryos at 5 dpf had no wall motion 
following hypoxia in these experiments. 
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6.3.1.3 mRNA abundance in the apelin and HIF systems in the hypoxia-recovery 
model 
Apelin mRNA was assessed in zebrafish embryos 3 dpf and 5 dpf following 2h and 
4h hypoxia. In zebrafish 3 dpf exposure to hypoxia for 2h, resulted in no change in 
apelin mRNA abundance immediately following hypoxic exposure or during the 
recovery period (P = 0.10 one-way ANOVA; n = 5 – 8, 10 embryos per group per 
experiment).  In zebrafish 3 dpf exposed to hypoxia for 4h, there was no change in 
apelin mRNA abundance after hypoxia or recovery in normoxia (P = 0.16 one-way 
ANOVA) (Fig 6.6 (i)). 
 
In zebrafish 5 dpf exposed to hypoxia for 2h, there were no changes in apelin mRNA 
immediately after hypoxia or during the recovery phase (P = 0.10 one-way 
ANOVA). However, in zebrafish 5 dpf exposed to hypoxia for 4h, there was a 
marked decrease in apelin mRNA immediately after hypoxia. This decrease in apelin 
mRNA was maintained throughout the 4h normoxic recovery period (P = 0.02 one-





















































Figure 6.6: The abundance of apelin mRNA transcript as determined by qPCR 
in zebrafish 3 dpf (i) and 5 dpf (ii) following 2h and 4h hypoxia and subsequent 
recovery in normoxia.   





Apelin: 2h hypoxia Apelin: 4h hypoxia 
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  baseline    0          2          4 
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  baseline    0          2          4 
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  baseline    0          2          4 
Time after removal from 
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P = 0.10 
P = 0.02 P = 0.10 
P = 0.16 
(ii) 5 dpf 
(i) 3 dpf 
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The abundance of mRNA transcript of apelin receptors, agtrl1a and agtrl1b, were 
also determined following hypoxia. In a similar pattern to that of apelin mRNA, 
agtrl1a mRNA abundance was decreased following 2h hypoxia in zebrafish 3 dpf, 
but recovered following 4h in normoxia (P = 0.048 one-way ANOVA, n = 5 – 8, 10 
embryos per group per experiment). In zebrafish 3 dpf, exposed to 4h hypoxia, no 
change in agtrl1a mRNA abundance was observed immediately after hypoxia. No 
difference in agtrl1a mRNA abundance was observed following 2h in normoxia or 
recovery in  normoxia (P = 0.50 one-way ANOVA) (Fig 6.7 (i)). 
 
In zebrafish 5 dpf exposed to 2h hypoxia, no change in agtrl1a mRNA was detected 
immediately following hypoxia. At 2h and 4h post-hypoxia, the abundance of agtrl1a 
mRNA was decreased by around 50%, although this did not reach significance (P = 
0.28 one-way ANOVA). This was in contrast to apelin mRNA in this group which 
did not change following hypoxia or recovery. However, in a similar pattern to that 
of apelin mRNA abundance, in zebrafish 5 dpf exposed to 4h hypoxia, a decrease of 
around 40% in agtrl1a mRNA abundance was observed. This decrease in agtrl1a 
mRNA expression did not recover 4h post-hypoxia although this pattern did not 


































Figure 6.7: The abundance of agtrl1a mRNA transcript in zebrafish 3 dpf (i) 
and 5 dpf (ii) exposed to 2h and 4h hypoxia and subsequent recovery in 
normoxia. 





Agtrl1a: 2h hypoxia Agtrl1a: 4h hypoxia 
Agtrl1a: 2h hypoxia Agtrl1a: 4h hypoxia 
  baseline    0           2          4 
Time after removal from 
hypoxia (h) 
  baseline   0           2          4 
Time after removal from 
hypoxia (h) 
  baseline     0          2           4 
Time after removal from 
hypoxia (h) 
  baseline   0           2          4 
Time after removal from 
hypoxia (h) 
(ii) 5 dpf 
(i) 3 dpf 
P = 0.048 
P = 0.21 P = 0.28 
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Agtrl1b mRNA abundance was unchanged in zebrafish 3 dpf exposed to 2h hypoxia. 
No change in agtrl1b mRNA abundance was observed in this group 2h post-hypoxia 
which recovered 4h post-hypoxia (P = 0.46 one-way ANOVA, n = 5 – 8, 10 embryos 
per group per experiment). In zebrafish 3 dpf exposed to 4h hypoxia, agtrl1b mRNA 
abundance was more variable than in the other groups and no changes in abundance 
of the transcript were observed after hypoxic exposure or during the recovery phase 
(P = 0.71 one-way ANOVA) (Fig 6.8 (i)). 
 
There was also no change in agtrl1b mRNA abundance in zebrafish 5 dpf exposed to 
2h hypoxia and subsequent recovery (P = 0.14 one-way ANOVA). Agtrl1b mRNA 
abundance was unchanged in zebrafish 5 dpf exposed to 4h hypoxia, immediately 
after hypoxic exposure and during recovery in normoxia (P = 0.94 one-way 





































Figure 6.8: The abundance of agtrl1b mRNA transcript in zebrafish 3 dpf (i) 
and 5 dpf (ii) exposed to 2h and 4h hypoxia and subsequent recovery in 
normoxia. 
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   152 
The abundance of HIF-1α mRNA transcript was assessed during development (8 – 
120 hpf) and subsequently in response to hypoxia at 72 hpf (3 dpf) and 120 hpf (5 
dpf). HIF-1α mRNA abundance was highest at 8 - 18 hpf and lowest at 96 hpf of the 









Figure 6.9: HIF-1α mRNA abundance in zebrafish embryos during 
development from 8 hpf to 120 hpf. 
Abundance of mRNA measured by qPCR (corrected for EF1a and RPL13a as 
reference genes and expressed as a percentage of the abundance at 8 hpf). n = 2 (12-
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In zebrafish 3 dpf exposed to 2h hypoxia and 4h hypoxia, HIF-1α mRNA abundance 
was increased (2h hypoxia: P = 0.39 one-way ANOVA, 4h hypoxia: P = 0.68 one-
way ANOVA; n = 5 – 8, 10 embryos per group per experiment) although this did not 
reach statistical significance. At 2h and 4h recovery in normoxia following both 
lengths of hypoxic exposure there appeared to be a reduction of HIF-1α mRNA back 
to control levels (Fig 6.10 (i)). 
 
In zebrafish 5 dpf, exposed to 2h hypoxia, there were no changes in HIF-1α mRNA 
as a result of hypoxic treatment or recovery in normoxia (P = 0.95 one-way 
ANOVA). In zebrafish 5 dpf, exposed to 4h hypoxia, HIF-1α mRNA was unchanged 
following hypoxia, but there was a small increase in HIF-1α mRNA 4h post-hypoxia. 





























































Figure 6.10: The abundance of HIF-1α mRNA transcript in zebrafish 3 dpf (i) 
and 5 dpf (ii) exposed to 2h and 4h hypoxia and subsequent recovery in 
normoxia. 




HIF-1α: 2h hypoxia HIF-1α: 4h hypoxia 
HIF-1α: 2h hypoxia HIF-1α: 4h hypoxia 
  baseline    0          2          4 
Time after removal from 
hypoxia (h) 
  baseline    0          2          4 
Time after removal from 
hypoxia (h) 
  baseline    0          2          4 
Time after removal from 
hypoxia (h) 
  baseline    0          2          4 
Time after removal from 
hypoxia (h) 
(ii) 5 dpf 
(i) 3 dpf 
P = 0.39 P = 0.68 
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6.3.2 The effect of pharmacological agents on the hypoxia-recovery response in 
zebrafish embryos 
6.3.2.1 Global circulatory hypoxia-recovery model 
Using the global circulatory hypoxia-recovery model, we assessed a number of 
pharmacological agents (apelin, nicorandil, glibenclamide, desferrioxamine and α-
ketoglutarate) for their potential cardioprotective effect when added to the bathing 
water. In zebrafish embryos 5 dpf (n = 3, 10 embryos per group per experiment), pyr-
apelin-13 (150 nM) did not affect the proportion of embryos with normal HR and 
circulation following hypoxia (difference 27% (95% CI 0, 50), P = 0.06 comparison 
of proportions). There was also no effect of apelin on the recovery phase at 2h 
(difference 10% (95% CI 15, 34), P = 0.57 comparison of proportions) or 4h 
(difference 0% (95% CI -26, 26), P = 0.79 comparison of proportions) in this model 
(Fig 6.11(i)). 
 
The potassium channel activator, nicorandil (0.1 mM), did not affect the proportion 
of observed embryos with normal HR and circulation immediately after hypoxia 
(difference 6.3% (95% CI 5.9, 20.8), P = 0.47 comparison of proportions, n = 3, 10 
embryos per group per experiment). There was also no difference in the proportion 
of embryos with normal HR and circulation following 2h recovery in normoxia 
(difference 9.4% (95% CI 15.4, 33.1) P = 0.59 comparison of proportions). 
Similarly, after 4h recovery in normoxia there was no difference in the proportion of 
embryos with normal HR and circulation (difference 0% (95% CI -25.0, 25.0), P = 
0.80 comparison of proportions) (Fig 6.11(ii)). 
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Glibenclamide (0.1 mM), a potassium channel inhibitor, did not affect the global 
circulatory response to acute hypoxia in this model when compared to vehicle treated 
controls immediately after hypoxic exposure (difference 10% (95% CI -4.4, 26.5) P 
= 0.24 comparison of proportions, n = 3, 10 embryos per group per experiment). 
There was also no difference in the proportion of embryos with normal HR and 
circulation in glibenclamide and vehicle treated groups following 2h recovery in 
normoxia (difference 13.5% (95% CI -4.4, 31.7) P = 0.19 comparison of proportions) 
or 4h recovery in normoxia (difference 0% (95% CI -26.0, 26.0), P = 0.79 
comparison of proportions) (Fig 6.11(iii)). 
 
 
The HIF-1α activator, desferrioxamine (DFO) (0.1 mM), did not affect the 
proportion of embryos with normal HR and circulation following 2h hypoxia 
(difference 11.7% (95% CI 0.4, 23.8), P = 0.07 comparison of proportions, n = 4, 15 
– 20 embryos per group per experiment). However, following 2h recovery in 
normoxia 31.1% (95% CI 14.6, 45.9) more desferrioxamine treated embryos had 
normal HR and circulation than vehicle treated embryos (P = 0.0002 comparison of 
proportions). Following 4h recovery in normoxia, 27.1% (95% CI 9.9, 42.7) more 
desferrioxamine treated embryos had normal HR and circulation than vehicle treated 
embryos (P = 0.002 comparison of proportions) (Fig 6.11(iv)).  
 
The HIF-1α inhibitor, α-ketoglutarate (2.5 mM), did not affect the proportion of 
embryos with normal HR and circulation following 2h hypoxia (difference 10% 
(95% CI -4.0, 26.5), P = 0.24 comparison of proportions, n = 3, 10 embryos per 
group per experiment), but reduced the effect of severe hypoxia on the gross 
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circulatory response during the recovery phase. Following 2h recovery in normoxia 
40% (95% CI 12.8, 61.4) more α-ketoglutarate incubated embryos had normal HR 
and circulation than those incubated in vehicle (P = 0.004 comparison of 
proportions). The protective effect of α-ketoglutarate was maintained after 4h 
recovery in normoxia when 36.7% (95% CI 9.6, 58.6) more α-ketoglutarate 
incubated embryos had normal HR and circulation than those incubated in vehicle (P 










































































Figure 6.11: The effect of pharmacological agents on the global hypoxia-
recovery response. 
(i) Pyr-apelin-13 P > 0.01 comparison of proportions, (ii) nicorandil P > 0.01 
comparison of proportions, (iii) glibenclamide P > 0.01 comparison of proportions, 
(iv) desferrioxamine P = 0.07 (0h) ** P = 0.0002 (2h) * P = 0.002 (4h) comparison 
of proportions, (v) α-ketoglutarate P = 0.24 (0h) * P = 0.004 (2h) * P = 0.009 (4h) 
comparison of proportions. n = 3 – 4, 10 – 20 embryos per group per experiment. 
 
Glibenclamide 
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6.3.2.2 Video edge detection of cardiac function during hypoxia-recovery 
Further experiments assessing the effect of apelin and desferrioxamine on ventricle 
wall motion during the hypoxia-recovery response were performed. Video edge 
detection experiments assessing the cardioprotective effect of apelin were performed 
in zebrafish 3 dpf. We observed that the depression in HR following acute hypoxic 
exposure and subsequent recovery in normoxia in zebrafish 3 dpf was similar in both 
apelin and vehicle treated embryos (P = 0.34 two-way ANOVA apelin vs vehicle; n 
= 8, 3 - 5 embryos per group per experiment; Fig 6.12(iv)). Contraction velocity was 
decreased in vehicle treated embryos, but not in apelin treated embryos after removal 
from hypoxia (P = 0.03 two-way ANOVA apelin vs vehicle). The depression in 
contraction velocity in vehicle treated embryos was reversed by 2h in normoxia (Fig 
6.12(i)). 
 
Relaxation velocity and wall motion amplitude displayed a trend towards apelin 
incubated zebrafish being less susceptible to the effects of acute hypoxia, but this did 
not reach statistical significance. Relaxation velocity was decreased by 27 ± 6% in 
vehicle treated embryos and by 5 ± 9% in apelin treated embryos (P = 0.09 two-way 
ANOVA apelin vs vehicle). Apelin treated embryos recovered to normoxic control 
levels following 1h in normoxia, while vehicle treated embryos recovered by 2h in 
normoxia (Fig 6.12(ii)). Wall motion amplitude was decreased by 13 ± 7% in vehicle 
treated embryos, but not in apelin treated embryos. At 1h recovery in normoxia, both 
groups had a wall motion amplitude comparable with normoxic control embryos (P = 
0.09 two-way ANOVA apelin vs vehicle; Fig 6.12(iii)). 
 







Figure 6.12: The effect of pyr-apelin-13 (150 nM) incubation on wall motion 
parameters of the zebrafish (3 dpf) ventricle in the hypoxia-recovery model. 
(i) Contraction velocity P = 0.03 two-way ANOVA apelin vs vehicle, (ii) relaxation 
velocity P = 0.09 two-way ANOVA apelin vs vehicle, (iii) wall motion amplitude P 
= 0.09 two-way ANOVA apelin vs vehicle, (iv) heart rate P = 0.34 two-way 
ANOVA apelin vs vehicle; n = 8, 3 - 5 embryos per group. 
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Desferrioxamine protected against the depression in contraction velocity following 
hypoxia in zebrafish 5 dpf (P = 0.015 two-way ANOVA DFO vs vehicle; Fig 6.13 
(i)). Relaxation velocity was decreased in vehicle treated embryos, but not in 
desferrioxamine treated embryos (P < 0.0001 two-way ANOVA DFO vs vehicle; Fig 
6.13 (ii)). Contraction velocity and relaxation velocity recovered in both 
desferrioxamine and vehicle treated groups. 
 
The depression in wall motion amplitude following hypoxia was also protected by 
incubation in desferrioxamine (P = 0.0008 two-way ANOVA DFO vs vehicle; Fig 
6.13 (iii)). Wall motion amplitude remained reduced in vehicle treated embryos 
following 2h recovery in normoxia. The depression in HR was similar in both 
desferrioxamine and vehicle treated embryos, although there was a trend towards HR 
recovering more quickly in normoxia in desferrioxamine treated embryos than in 
















Figure 6.13: The effect of desferrioxamine (0.1 mM) incubation on wall motion 
parameters of the zebrafish (5 dpf) ventricle wall in the hypoxia-recovery 
model. 
(i) Contraction velocity P = 0.015 two-way ANOVA DFO vs vehicle, (ii) relaxation 
velocity P < 0.0001 two-way ANOVA DFO vs vehicle, (iii) wall motion amplitude P 
= 0.0008 two-way ANOVA DFO vs vehicle, (iv) heart rate P = 0.064 two-way 
ANOVA DFO vs vehicle; n = 1, 5 embryos per group. 
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6.3.2.3 The effect of hypoxia-recovery in MO-apelin embryos 
MO-apelin embryos 3dpf did not have an altered response to hypoxic exposure 
compared to that of MO-mispair (P = 0.99 comparison of proportions) or non-
injected control zebrafish embryos (P = 0.99 comparison of proportions) (n = 1, 7 - 







Figure 6.14: The response to hypoxia of MO-apelin, MO-mispair and non-
injected controls (3 dpf).  
Embryos were exposed to hypoxia and viewed briefly in normoxia at 30 minute 
intervals for the first 1.5 h and one hour intervals thereafter for a total time of 5.5 h. 
MO-apelin vs MO-mispair P = 0.99, MO-apelin vs non-injected control P = 0.99 
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6.4 Discussion 
As apelin had been reported to be cardioprotective in rodent studies (Jia et al., 2006; 
Kleinz et al., 2008; Simpkin et al., 2007), I developed a hypoxia-recovery model in 
zebrafish embryos to test the hypothesis that exogenous apelin would protect against 
hypoxic injury in wild-type embryos. We hypothesised that hypoxia would increase 
apelin mRNA and that an increase in apelin mRNA would arise following induction 
of HIF-1α. 
 
In order to test our hypothesis that apelin had a cardioprotective role, we developed a 
hypoxia-recovery model, firstly using a semi-quantitative scoring method and 
subsequently using video edge detection. In the development of our hypoxia-
recovery model, we identified that with increasing age in the developmental period 
of the embryo (2 - 5 dpf) comes an increasing susceptibility to the cardiovascular 
effects of a severe hypoxic insult. We demonstrated that a semi-quantitative scoring 
method of HR and circulation was sensitive enough to detect differences between 
embryos 3 dpf and 5 dpf and allowed us to perform experiments with greater 
numbers of embryos. Increasing susceptibility to hypoxia with increasing 
developmental stage has been previously reported in the literature (Ton et al., 2003), 
but this is the first study which has quantified the differences in term of contraction 
velocity, relaxation velocity and wall motion amplitude of the zebrafish embryo 
ventricle wall. 
 
Despite the reproducibility of the model and its potential to screen compounds, it did 
have some limitations. In particular, to ensure that hypoxia was in fact induced in the 
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model, future experiments should involve degassing the solution overnight in the 
hypoxia chamber before adding the embryos and compounds. Induction of HIF-1α in 
zebrafish embryos exposed to hypoxia following overnight equilibration of the 
hypoxic water in a hypoxia chamber has been previously reported (Gray et al., 
2007). It would also have added to the model presented here if the oxygen 
concentration of the water throughout these experiments. Despite this, we have 
strong evidence that hypoxia was indeed induced in the model as we consistently 
observed a depression of cardiovascular which was reversible following removal 
from hypoxia. 
 
Exogenous pyr-apelin-13 added to the bathing water did not protect against the 
depression in HR and circulation in response to severe hypoxia in zebrafish 5 dpf. 
Zebrafish embryos incubated in apelin did not recover more quickly than vehicle 
treated controls. However, using video edge detection in zebrafish 3 dpf we 
demonstrated that contraction velocity was less severely affected by hypoxia in 
apelin incubated embryos compared to vehicle incubated embryos. We also observed 
a trend towards relaxation velocity and wall motion amplitude being less severely 
affected by hypoxia in apelin treated embryos. Interestingly, HR was affected to the 
same degree following hypoxic exposure in both apelin and vehicle treated embryos. 
In preliminary experiments, in MO-apelin embryos in which apelin mRNA had been 
knocked down, we were unable to detect a difference in their cardiovascular response 
to severe hypoxia compared to MO-mispair embryos and non-injected controls. 
 
   166 
The developed model could also be used to screen other pharmacological agents that 
may affect the hypoxia-recovery response. Activating and inhibiting potassium 
channels with nicorandil and glibenclamide respectively did not affect the number of 
embryos with normal HR and circulation in response to acute hypoxia or affect the 
rate at which the embryos recovered normal circulation during recovery in normoxia. 
 
In particular we attempted to modulate endogenous apelin mRNA by influencing the 
HIF pathway. Apelin gene expression has been previously shown to be upregulated 
via HIF (Glassford et al., 2007). Exposure of cultured adipocytes to hypoxia (1% 
oxygen) for 6h increased apelin mRNA expression as shown by qPCR. Apelin 
protein levels were also increased as shown by enzyme-linked immunosorbent assay. 
Mouse embryonic fibroblasts from HIF-1α knockout mice did not exhibit an increase 
in apelin mRNA in response to hypoxia, thus demonstrating that the increase in 
apelin expression in response to hypoxia is mediated via HIF-1α in these cells 
(Glassford et al., 2007).  
 
In a rat in vivo model of coronary artery ligation, apelin mRNA expression and APJ 
mRNA expression was increased in quadriceps muscle at 4 weeks post ligation and 
in the heart 8 weeks post ligation. Coronary artery ligation did not affect apelin 
mRNA or APJ mRNA in lung tissue at 4 weeks or 8 weeks post ligation. HIF-1α 
mRNA was increased in quadriceps muscle at 4 weeks post ligation, but HIF-1α 
mRNA expression was not reported for the heart or lungs. Continual systemic 
hypoxia (10% oxygen) for 1 week resulted in a 7-fold increase in apelin mRNA 
expression (Sheikh et al., 2008). Eyries et al. (2008) also demonstrate in mice that 
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systemic hypoxia (10% oxygen) for 5h increases apelin mRNA expression almost 2-
fold in the lung. 
 
However, analysis of the abundance of mRNA transcripts in zebrafish embryos 
exposed to hypoxia did not support the hypothesis that an increase in HIF-1α 
following severe hypoxia results in increased apelin mRNA. In zebrafish 5 dpf, 2h 
hypoxia had no effect on HIF-1α or apelin mRNA levels. Yet a marked reduction in 
apelin mRNA was observed in embryos exposed to 4h hypoxia and after subsequent 
exposure to normoxia. This decrease in abundance of apelin mRNA was not 
associated with changes in HIF-1α mRNA. As this marked reduction was 
demonstrated in embryos 5 dpf exposed to 4h hypoxia which do not recover well 
from hypoxia, it is important to note that mRNA may be less stable in these hypoxic 
tissues and that although the reference genes used did not change across these 
groups, it is possible that apelin mRNA is less stable under hypoxic conditions. This 
has been previously demonstrated in the case of tumour necrosis factor α in human 
macrophages (Werno et al., 2010). 
 
Our mRNA expression studies represent the mRNA of 10 - 15 whole embryos 
pooled for each sample. This may account for the observation that there is no marked 
increase in the abundance of HIF-1α mRNA transcript following hypoxia. Increases 
in HIF-1α mRNA expression may be tissue specific, occurring in the embryonic 
heart or muscle, but not in other tissues. Tissue specific increases in HIF-1α, apelin 
and APJ mRNA have been demonstrated previously in the mouse (Sheikh et al., 
2008). Cardiac specific transcription of monocarboxylate transporters, involved in 
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the cellular transportation of important metabolites such as pyruvate, has been 
observed in adult zebrafish in response to chronic hypoxia for 48h and 96h (Ngan et 
al., 2009). It is also a possibility that our acute hypoxic exposure was not sufficient 
for transcription to take place.  In chronic hypoxia studies (5% oxygen, 24h) in 
zebrafish embryos 2 dpf, HIF-1α mRNA expression has been reported to increase 3-
fold as detected by microarray (Ton et al., 2003). In a cell culture system a 6h 
exposure to hypoxia (1% oxygen) was sufficient to observe induction of HIF-1α and 
apelin mRNA expression (Glassford et al., 2007). In a mouse model of coronary 
artery ligation, increases in HIF-1α and apelin mRNA expression in the quadriceps 
muscle were observed only after a period of 4 weeks (Sheikh et al., 2008). 
 
Interestingly, both inhibition and activation of the HIF pathway had the same effect 
in the hypoxia-recovery model. Inhibition of the HIF pathway with α-ketoglutarate 
did not change the number of observed embryos with normal HR and circulation 
following hypoxic exposure, but did increase the ability of the embryos to recover. 
Activation of the HIF pathway with desferrioxamine produced similar findings. 
Embryos incubated in desferrioxamine were not protected from the cardiovascular 
effects of hypoxia immediately after hypoxic exposure. Yet, at 2h and 4h recovery in 
normoxia the proportion of embryos with normal HR and circulation was 
significantly greater in desferrioxamine treated embryos when compared to vehicle 
treated embryos. Using video edge detection, we further quantified the 
cardioprotective effect of desferrioxamine. The recovery in contraction velocity, 
relaxation velocity and wall motion amplitude following hypoxia was significantly 
enhanced in desferrioxamine treated embryos compared to vehicle treated controls.  
   169 
We conclude that the protective effect of desferrioxamine is not likely to be due to 
the protective effect of endogenous apelin since we observed a reduction of apelin 
mRNA with increasing HIF-1α mRNA in our model. The observation that both 
inhibition and activation of the HIF-1α pathway had similar effects suggests that one 
or both of these compounds are having a protective effect via a mechanism unrelated 
to HIF. 
 
The protective action of desferrioxamine may be due to its action as an iron chelator. 
Iron chelation has been shown to be important in free radical termination in a variety 
of studies (Morel et al., 1992; Prus et al., 2009; see Bendova et al., 2010). 
Desferrioxamine has been used previously in an assay to identify neuroprotectant 
compounds in embryonic zebrafish (Parng et al., 2006). Incubation in L-
hydroxyglutaric acid caused apoptosis in the embryonic brain. Subsequent incubation 
in desferrioxamine reversed the apoptosis in a concentration-dependent manner. The 
concentration with maximal effect (0.1 mM) was the same as the concentration used 
in our study. Parng et al. (2006) reason that the neuroprotective effect of 
desferrioxamine observed in their model is due to its antioxidant activity. The same 
may be true in our hypoxia-recovery model. This would explain why no difference 
was observed immediately after hypoxia, but the protective effect of desferrioxamine 
was more apparent in the recovery phase where free radical generation would be 
expected to occur. In ischaemia-reperfusion models in rodents, free radicals are 
generated during the reperfusion phase (Khan et al., 2010; Thu et al., 2010) which 
we would liken to the recovery phase in our zebrafish model. 
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Alternatively, the accumulation of HIF-1α as a result of desferrioxamine incubation 
may result in cardioprotection via induction of another HIF inducible gene such as 
erythropoetin, tranferrin or vascular endothelial growth factor among others (see 
Semenza, 2009). In human endothelial cell culture, it has been demonstrated that 
more than 2% of human genes are regulated by HIF-1 (Manalo et al., 2005). 
Therefore, in zebrafish embryos, it is also possible that the protective action of 
desferrioxamine is acting via another protective pathway induced by HIF. However, 
our mRNA data show no induction of HIF-1α mRNA in untreated zebrafish 5 dpf 
exposed to 2h hypoxia which was the age of embryo and length of exposure to 
hypoxia in which we observed a cardioprotective effect of desferrioxamine. This 
leads us to conclude that desferrioxamine is most likely to have its protective effect 
in this model by an antioxidant effect, probably as a result of iron chelation. 
 
The HIF-1α pathway inhibitor, α-ketoglutarate, had no effect on the proportion of 
embryos with normal HR and circulation, but increased the rate of recovery in 
normoxia. Although inhibiting HIF may be expected to detrimental to the potential of 
the embryos to maintain normal HR and circulation following acute hypoxic 
exposure (see Tekin et al., 2010), α-ketoglutarate may be acting as a metabolic 
substrate in this model. Alpha-Ketoglutarate is an intermediate in the tricarboxylic 
acid cycle which is responsible for generation of adenosine trisphosphate (ATP), or 
cellular energy, during aerobic respiration. Therefore, in the presence of oxygen 
during recovery in normoxia, the incubation of embryos in α-ketoglutarate, may 
potentiate the tricarboxylic acid cycle thus generating more cellular energy and 
allowing the embryos to recover more quickly. Metabolic substrates such as α-
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ketoglutarate have been shown to have antioxidant properties in some settings. In 
cyanide-induced oxidative stress in rat pheochromocytoma cells, α-ketoglutarate 
incubation diminished the effect of oxidative stress (Satpute et al., 2010), while in rat 
brain homogenates α-ketoglutarate had a pro-oxidant effect (Puntel et al., 2007). 
Therefore, the protective effect of α-ketoglutarate is likely to be due to its activity as 
an essential metabolite or by an antioxidant action. 
 
In conclusion, we have developed a novel model of severe hypoxia-recovery in 
zebrafish embryos. We demonstrated, and quantified in terms of wall motion of the 
embryonic ventricle, an increase in susceptibility to hypoxia with increasing 
embryonic age. We demonstrated a small, convincing cardioprotective effect of 
exogenous pyr-apelin-13 in zebrafish 3dpf, but not in zebrafish 5 dpf. In zebrafish 5 
dpf exposed to 4h hypoxia, apelin mRNA was markedly decreased with no 
associated increase in HIF-1α mRNA. Following apelin knockdown, the 
susceptibility of MO-apelin embryos to hypoxia at 3 dpf was not altered. The 
potassium channel modulators, nicorandil and glibenclamide, did not affect the 
cardiovascular response to hypoxia or the ability of the zebrafish embryos to recover. 
However, HIF modulators, desferrioxamine and α-ketoglutarate accelerated recovery 
from hypoxia. These data indicate, however, that the protective action of 
desferrioxamine is likely to be due to an antioxidant effect, while the protective 
action of α-ketoglutarate is likely to be metabolic or antioxidant in nature. The 
hypoxia-recovery model can be used for further drug screens for potentially 
cardioprotective drugs. 
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7.1 The effect of apelin on the heart 
7.1.1 Rat 
The experimental work leading to this thesis aimed to investigate the cardiovascular 
effects of apelin. The primary aim was to confirm its inotropic effects and its 
vasoactive role. We then planned to further examine the cardioprotective role of 
apelin. It was therefore important to establish the effect of apelin on the heart in the 
normal rat before embarking on studies involving ischaemia. However, in the normal 
rat, apelin had no effect in isolated right ventricular papillary muscles or isolated 
right atrial strips. Apelin did not affect developed tension, time to peak or time to 
relaxation in our experiments. Furthermore, in the isolated, paced, perfused, rat heart 
(Langendorff) apelin had no inotropic or lusitropic effect.  
 
Conversely, Szokodi et al. (2002) demonstrated a potent, sustained inotropic 
response to infusion of apelin-16 in the rat Langendorff heart. The authors reported a 
40 - 50% increase in developed tension after 10 mins of infusion when measured by 
a transducer attached to the apex of the heart. This was the first report in the 
literature of apelin’s inotropic action. Indeed, the literature since then suggests that 
apelin has a limited inotropic effect in the normal rat and that its inotropic effect is 
greater and faster in onset in animals with heart failure, whether induced by coronary 
artery ligation (Berry et al., 2004) or by chronic isoproterenol treatment (Jia et al., 
2006). In isolated right ventricular rat trabeculae, Dai et al. (2006) identified a 36% 
increase in developed tension in trabeculae from animals with heart failure induced 
by chronic hypoxia, but found no significant change in developed tension in 
trabeculae from control animals. On contacting several other investigators in the 
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apelin field, we learned that others had also found little or no inotropic effect in the 
normal rat heart in these standard physiological preparations (Dr C Terracciano, 
Imperial College London, Personal Communication), although these negative 
findings have not been published. Studies assessing the effect of apelin in humans 
remain unclear. Japp et al. (2010) described a small increase in the rate of rise of left 
ventricular pressure in response to intracoronary bolus injection of apelin-36. 
However, these authors could not be certain if this increase in contractility was 
independent of loading conditions. 
 
7.1.2 Zebrafish embryos 
In the zebrafish embryo 3 dpf, we demonstrated that apelin had no effect on HR or 
more sensitive parameters of cardiac function: contraction velocity, relaxation 
velocity and wall motion amplitude of the ventricle wall.  In isolated zebrafish hearts, 
from embryos with relatively high endogenous apelin mRNA (3 dpf), apelin 
increased relaxation velocity, but had no effect on HR, contraction velocity and wall 
motion amplitude of the ventricle wall. In isolated hearts from embryos with 
relatively low endogenous apelin mRNA (4 dpf), apelin had no effect on any of the 
measured contractility parameters. Apelin receptors were similarly expressed at both 
developmental time points (3 dpf and 4 dpf). 
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7.2 The vasoactive effect of apelin 
We also investigated the potential vasoactive effect of apelin. In vivo in the normal 
rat, this study demonstrated a reduction in both MAP and HR in response to apelin-
13. The reduction in MAP recovered spontaneously and rapidly, while the reduction 
in HR had not recovered 20 minutes post apelin administration. This suggests that 
the reduction in MAP and reduction in HR are mediated via different mechanisms. 
The reduction in MAP is likely to be a result of a vasodilatory response mediated via 
NO and is well described in the literature in an in vivo rat model (Tatemoto et al., 
2001) and in mouse, rat and human in vitro preparations (Jia et al., 2007; Salcedo et 
al., 2007; Zhong et al., 2007a; Zhong et al., 2007b). The decrease in HR has not been 
previously reported and we postulate that this may be due to a direct action of apelin 
on the sinoatrial node as vasodilation would have been expected to result in a reflex 
tachycardia as reported previously with nitrate infusions (Noll et al., 1997) and 
dihydropyridine calcium antagonists (Erickson et al., 2010). Apelin-16 also produced 
a decrease in HR, but had no effect on MAP. Yet, pyr-apelin-13 affected neither HR, 
nor MAP, when administered in an identical way via the jugular vein. 
 
In isolated mesenteric artery, a vasodilator or vasoconstrictor effect with apelin-13 or 
apelin-36 could not be demonstrated. This was in contrast to human isolated 
mesenteric arteries which are reported to vasodilate in response to apelin (Salcedo et 
al., 2007). However, we note that there has been only one published report of a 
vasoactive effect of apelin in a rat in vitro model to date, in the rat renal arterioles 
(Hus-Citharel et al., 2008). In this preparation, apelin produced a vasodilator and 
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vasoconstrictor response in the presence and absence of a functional endothelium, 
respectively. 
 
7.2.1 Activity of apelin isoforms 
The twelve terminal amino acids at the C-terminus of the apelin peptide are thought 
to be responsible for ligand binding to the receptor as apelin fragments shorter than 
twelve amino acids have no biological activity (De Mota et al., 2000; Reaux et al., 
2001). This suggests that all apelin isoforms bind with equal potency and efficacy. 
Maguire et al. (2009) demonstrated that pyr-apelin-13, apelin-13 and apelin-36 have 
comparable potency and efficacy both in terms of an inotropic action in isolated 
human trabeculae and a vasodilatory effect in isolated human internal mammary 
artery.  However, the effect of apelin-16 has not been reported in these preparations. 
 
The in vivo data presented in this thesis suggest that apelin isoforms may have 
different properties. Interestingly, the majority of publications describing an 
inotropic effect of apelin in the rat have studied apelin-16 (Berry et al., 2004; Dai et 
al., 2006; Farkasfalvi et al., 2007; Szokodi et al., 2002). In vivo in the rat, pyr-apelin-
13 had no effect on HR or MAP. Apelin-16 consistently decreased HR, but had no 
effect on MAP. Apelin-13 reduced MAP and HR. The effect on MAP recovered 
rapidly, while the effect on HR had not recovered 20 minutes after apelin 
administration. 
 
It is possible that although the apelin fragments bind equally to the receptor, that 
activation of the downstream signal transduction pathways is dependent upon the 
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bound apelin isoform, specific tissue type, distribution and accessibility of the 
receptor and temporal differences in activation of downstream pathways. There is 
some evidence to suggest that receptor internalisation is related to apelin isoform. 
Apelin-17 is a more potent inducer of APJ receptor internalisation than pyr-apelin-13 
in Chinese hamster ovary cells (El Messari et al., 2004). The authors also 
demonstrate that the rate of receptor internalisation appears to be related to the 
magnitude of decrease in MAP, with apelin-17 lowering MAP by 13 mmHg 
compared to a decrease of 6 mmHg with pyr-apelin-13 when administered 
intravenously. This provides an interesting avenue for further studies. 
 
7.3 The cardioprotective effects of apelin 
Despite the intention to focus on the cardioprotective effects of apelin using the 
isolated, perfused, rat heart (Langendorff) model which is a widely-used standard 
preparation for ischaemia-reperfusion studies (see Skrzypiec-Spring et al., 2007), the 
lack of effect in rat tissues led us instead to pursue the cardioprotective effects of 
apelin in the zebrafish embryo. The zebrafish embryo was an attractive model as the 
apelin system had been described previously and developmental studies had 
suggested a specific cardiovascular role for the peptide in zebrafish. Zeng et al. 
(2007) demonstrate that knockdown of apelin results in reduction of the myocardial 
marker cardiac myosin light chain 2 and that knockdown of the apelin receptor, 
agtrl1b, prevents the formation of a beating heart, while the embryos appeared 
otherwise grossly normal. 
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However, the possible functional role of apelin in the zebrafish at baseline or under 
conditions of hypoxia had not been determined. Although apelin had no dramatic 
effects at baseline on heart function in vivo or in isolated embryonic hearts, we 
demonstrated a modest cardioprotective effect of pyr-apelin-13 in zebrafish embryos 
3 dpf. However, in zebrafish 5 dpf, using a more efficient semi-quantitative scoring 
assessment, pyr-apelin-13 did not produce a cardioprotective effect. The semi-
quantitative approach proved to be more efficient as 10-20 embryos could be 
analysed per experimental group using this method compared with only 3-5 embryos 
per group in video edge detection experiments. 
 
7.4 Relevance of findings 
Since its discovery as the endogenous peptide ligand of the orphan APJ receptor; the 
physiological role of apelin has been investigated in a variety of settings. Unlike the 
discovery of other endogenous peptides such as endothelin-1 where the effect was 
known prior to the discovery of the ligand and the receptor (Itoh et al., 1988); the 
discovery of apelin as a ligand of an orphan receptor meant that investigators had no 
clear starting point in elucidating its biological role. As apelin and its receptor are 
well conserved across vertebrate species, there is adequate reason to suspect that it 
has a key, essential physiological and possibly developmental role. 
 
In the last twelve years, apelin has been reported to have effects in a large number of 
organ systems in rodent models and in vitro studies which are represented in Fig 7.1. 
The effects reported range from an inotropic action in isolated rat heart (Szokodi et 
al., 2002) and vasodilation of human arteries (Maguire et al., 2009) to effects on the 
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central control of fluid homeostasis (Roberts et al., 2009) and protective effects on 
bone (Xie et al., 2007). However, for each of these reported effects, there exist a 
limited number of publications (Fig 7.2). 
 
The data presented in this thesis demonstrate the challenges of working with the 
apelin peptide. Our studies of the peptide in several standard and well-described 
preparations of normal rat tissue indicate that apelin has consistently no effect, 
particularly in vitro. There may be a variety of reasons for this. Apelin may be 
enzymatically degraded when added to isolated preparations or high levels of 











































Figure 7.1: Expression and physiological functions of the apelin–APJ system. 
Most physiological effects not yet documented in humans. ACTH, 
adrenocorticotrophic hormone; AVP, arginine vasopressin; CCK, cholecystokinin. 
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Figure 7.2: Comparison of apelin publication number to that of other named 
peptides. 
Graphs display number of publications retrieved in PubMed for the search “named 
peptide” for the total publications and for the searches “named peptide and keyword 
eg. inotropic”. Results are limited to publications within twelve years of the peptide’s 
first report in the scientific literature and do not include review articles. ET-1 
endothelin-1; ANP atrial natriuretic peptide; PACAP pituitary adenylate cyclase 
activating peptide. 
 
From our knowledge of the literature, the apelin field and several personal 
communications with others investigating apelin, we speculate that others have either 
not published negative findings or failed to have work accepted for publication in 
spite of carrying out similar experiments in isolated cardiac tissue, isolated perfused 
rat heart and isolated rat vessel preparations. This idea of positive-outcome 
publication bias is widely discussed in the literature (Callaham et al., 1998, Timmer 
et al., 2002, Young et al., 2008). We also note that when compared to three other 
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peptides (endothelin-1, pituitary adenylate cyclase activating peptide (PACAP) and 
atrial natriuretic peptide (ANP)) in a twelve year period after their discovery apelin 
lags behind total publications and in the number of publications describing 
vasoactive effects (Figure 7.2). When compared to endothelin-1, apelin has limited 
numbers of papers describing an inotropic and cardioprotective effect; despite the 
claim of Szokodi et al. (2002) that apelin is an equally potent inotrope to endothelin-
1 in the isolated, perfused, rat heart. Interestingly, this work was published eight 
years ago and has not been replicated in the literature since then. 
 
7.5 Limitations and Future Directions 
The data presented in this thesis illustrate that apelin has no inotropic, or lusitropic, 
effect in isolated cardiac tissue or the isolated, perfused heart (Langendorff) of the 
normal rat. In vivo in the normal rat, apelin has some influence on systemic blood 
pressure and HR. Yet, in isolated mesenteric arteries, we found no vasodilator or 
vasoconstrictor role of apelin. We had initially intended to pursue a cardioprotective 
effect of apelin using the Langendorff technique.  
 
However, having been unable to demonstrate an effect of apelin in cardiac tissue of 
the rat, we felt that we should further develop our zebrafish model to investigate the 
potential cardioprotective effects of apelin. This decision was based upon the high 
cost of carrying on the model in the rat compared to the significantly lower cost of 
using the zebrafish. The rat Langendorff approach was a more high risk approach to 
pursue since we were uncertain of the baseline effect of the peptide in the rat heart. 
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In zebrafish 3 dpf, we demonstrated an apparent cardioprotective effect of apelin 
using video edge detection; however, in zebrafish 5 dpf we saw no cardioprotective 
effect of apelin using a semi-quantitative scoring assessment of global heart function 
and circulation. Interestingly, knockdown of apelin using a targeted morpholino 
resulted in severe developmental abnormalities. All MO-apelin embryos had died by 
5 dpf suggesting a key role for apelin in development. 
 
7.5.1 Is the cardioprotective effect of apelin dependent on developmental stage in 
zebrafish embryos? 
We demonstrate a cardioprotective effect of apelin in zebrafish 3 dpf using video 
edge detection, but not in zebrafish 5 dpf using a semi-quantitative scoring 
assessment of HR and global circulation. The question remains as to whether: (a) 
apelin is cardioprotective in embryos 3 dpf and not in embryos 5 dpf or (b) apelin is 
equally cardioprotective in both settings yet the cardioprotective effect is too subtle 
to be detected by the semi-quantitative scoring assessment technique used in 
zebrafish 5 dpf. This study has also demonstrated that zebrafish 5 dpf are more 
susceptible to the cardiovascular effects of hypoxia than zebrafish 3 dpf. It is 
therefore possible that although apelin produced a modest cardioprotective effect in 
zebrafish 3 dpf, the peptide was unable to protect in zebrafish 5 dpf where the effect 
of hypoxia is more severe.  
 
The question of whether apelin’s cardioprotective effect is dependent on 
developmental stage would be answered by performing video edge detection on 
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zebrafish 5 dpf and using the semi-quantitative scoring assessment to measure global 
cardiovascular function in zebrafish 3 dpf following apelin incubation and hypoxia. 
However, the cardioprotective effect of desferrioxamine was demonstrated in 
zebrafish 5 dpf using both the global circulatory method and video edge detection. 
Therefore, we can infer that, as both methods are able to detect the same 
cardioprotective effect, it is likely that the findings are accurate and apelin is 
cardioprotective in zebrafish 3 dpf, but not zebrafish 5 dpf. Furthermore, plasma 
apelin has been shown to be increased in patients with mild heart failure compared to 
controls. However, in patients with end-stage heart failure, plasma apelin was 
reduced compared to controls (Sarzani et al., 2007). The authors reason that it is 
therefore possible that apelin is protective in mild disease, but cannot protect in the 
face of more severe heart failure. This is in agreement with our data which suggest 
that apelin can protect zebrafish embryos from the mild cardiovascular effects of 
hypoxia at 3 dpf, but cannot protect against the severe cardiovascular effects of 
hypoxia at 5 dpf. 
 
7.5.2 Mechanism of cardioprotection  
Apelin has previously been reported to have cardioprotective properties in rodent 
models. In zebrafish, we demonstrate a small cardioprotective effect in zebrafish 
embryos exposed to acute hypoxia at 3 dpf. However, the mechanism of the 
cardioprotective effect remains unclear. 
 
Cardioprotection is measured by a decrease in myocardial infarct size and/or by a 
measured improvement in heart function, for example, contraction velocity in the 
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zebrafish studies presented in this thesis. Necrosis, inflammation, hypertrophy and 
apoptosis of cardiac tissue contribute to injury in the face of an ischaemic or hypoxic 
insult. A reduction in one or more of these processes and an increase in beneficial 
processes such as angiogenesis will result in a cardioprotective effect (see Burger et 
al., 2009) (Fig 7.3). The molecular and cellular mechanisms involved are complex 
and differ among cardioprotective agents.  
 
Figure 7.3: Summary of processes which may produce a cardioprotective 
outcome. 
Figure summarises information gathered from Burger et al., 2009; Matsui et al., 
2005; Schorlemmer et al., 2008. 
 
Several cellular pathways have been implicated in the cardioprotective response 
(Matsui et al., 2005; see Schorlemmer et al., 2008) (Fig 7.4). There is a wealth of 
evidence supporting the role of the protein kinase B (Akt) and nitric oxide (NO) 
pathway in the cardioprotective effect of other endogenous cardioprotective agents 
including erythropoietin (see Burger et al., 2009), ET-1 (Araki et al., 2000) and 
bradykinin (Yang et al., 2004). As the vasodilator action of apelin is mediated via the 
NO pathway, the cardioprotective action of apelin may also be mediated via NO. 
Further cardioprotective studies using the NO synthase inhibitor, L-NAME, would 
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allow us to test this hypothesis. However, the PI3K inhibitor, wortmannin, did not 
prevent the cardioprotective effect of apelin demonstrated in a model of ischaemia-
reperfusion in the isolated rat heart, indicating that the cardioprotective effect of 
apelin is not via the Akt pathway (Kleinz et al., 2008). Smith et al. (2007) did 
however show increased activity of Akt on reperfusion with apelin in a rat model of 
ischaemia-reperfusion. The role of the Akt pathway and the other cardioprotective 
mediators shown in Fig 7.4 in relation to apelin’s cardioprotective effect clearly 
require further investigation.  
 
Figure 7.4: Cardioprotective mechanisms documented in the literature. 
Many cardioprotective agents signal through more than one of these known 
cardioprotective pathways. The cardioprotective pathway(s) through which apelin 
signals is currently unclear. Figure summarises information gathered from the 
following publications: Burger et al., 2009; Matsui et al., 2005; Schorlemmer et al., 
2008  
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7.5.3 Further investigation of the role of apelin in development 
The apelin morpholino experiments presented in this thesis and genetic manipulation 
of the apelin system conducted by others (Nornes et al., 2009; Scott et al., 2007; 
Zeng et al., 2007) identify a role for apelin in development. When apelin mRNA was 
knocked down by 92% in zebrafish embryos, severe total body developmental 
abnormalities were observed. Abnormal heart rate and circulation were also observed 
in MO-apelin embryos. However, no detrimental effect on baseline cardiac function 
or cardiac function in response to hypoxia was observed in MO-apelin embryos. 
More experiments are required to confirm or refute the findings of these experiments. 
 
A splice blocking morpholino was used in these experiments as knockdown could be 
readily measured with a qPCR assay. A zebrafish apelin antibody could have been 
used to measure successful knockdown using a translation blocking morpholino (Bill 
et al., 2009). However, a zebrafish apelin antibody was not commercially available 
and it would have been time-consuming and expensive to have the antibody custom 
made.  
 
Further experiments are required to determine whether the severe developmental 
abnormalities observed following apelin knockdown are specific to the absence of 
functional apelin mRNA. The use of a translation blocking morpholino, or a non-
overlapping splice blocking morpholino, would complement the data presented here. 
If the same phenotype was generated using a non-overlapping morpholino targeted to 
the apelin mRNA, then this would help define whether the phenotype is indeed 
specific to the knockdown of apelin mRNA (see Eisen and Smith et al., 2008).  
   188 
The final control for specificity of the phenotype is a “rescue” experiment (Corey et 
al., 2001). The rescue experiment involves co-injection of apelin mRNA which does 
not contain the morpholino binding sequence. This is most commonly performed 
with a morpholino targeted to the 5’-untranslated region of the mRNA of interest, 
which sterically blocks translation of the mRNA without binding to the start codon, 
ATG (Fig 7.5). This means that, in this case, apelin mRNA could be co-injected to 
rescue apelin mRNA levels and phenotype, without the morpholino binding to the 
rescue sequence (see Ekker, 2000). The rescue experiment can also be performed 
with a splice blocking morpholino as the rescue mRNA does not contain the intron 
sequence to which the morpholino binds. 
 
Figure 7.5: Morpholino rescue experiment involving coinjection of a rescue 
mRNA that does not contain the morpholino binding site. 
 
However, rescue experiments are not always successful. In cases where the wild-type 
endogenous mRNA is low at the time of injection, overexpressing the mRNA of 
interest may also produce severe developmental abnormalities (see Eisen and Smith 
et al., 2008). Our apelin mRNA expression profile suggests that this may be true in 
the case of apelin. Overexpression of apelin in the early zebrafish embryo has been 
previously reported to result in severe developmental abnormalities, including the 
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absence of a beating heart at 48 hpf (Zeng et al., 2007). A rescue of the morpholino 
phenotype of around 60% is deeemed successful (Zeng et al., 2007). 
 
Further evidence for the difficulty in performing a successful rescue experiment is 
presented by Nornes et al. (2009). The authors report that the delay in epiboly they 
witness on agtrl1a knockdown can be rescued by injection of agtrl1a RNA at the 32-
cell stage, but not at the single cell stage. The authors reason that this may be due to 
the RNA being specifically targeted to the phenotypically abnormal area of the 
embryo. Rescue RNA is injected specifically into the yolk cell at the 32-cell stage 
rather than into the total embryo at the single-cell stage, where in fact the RNA may 
not be as easily distributed throughout the embryo as a MO (Scholpp et al., 2004).  
 
7.5.4 Development of an apelin activity assay 
As apelin had no effect in in vitro preparations, it was difficult to be convinced of the 
activity of the apelin peptide in all cases. Where possible, this resulted in the use of 
the same batch of apelin in in vivo experiments, where I did observe a response, as in 
in vitro experiments. The development of a cell-based system expressing the APJ 
receptor would be a more efficient and less costly way of assessing apelin activity 
routinely before performing other experiments. Application of apelin to the cells, for 
example CHO cells expressing the APJ receptor as used in the initial discovery of the 
peptide (Tatemoto et al., 1998), and the subsequent measurement of a downstream 
second messenger would allow the activity of the apelin peptide to be confirmed. For 
example, measurement of cAMP (which would decrease following activation of the 
G-protein, Gi) or IL-1, a metabolite of IP3 (which would increase following 
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activation of the G-protein, Gq) would be ideal candidates to measure in this 
approach. 
 
7.6 Therapeutic potential of the apelin system in 
cardiovascular disease 
The apelin system has effects on several organ systems (see Fig 7.1). Within the 
cardiovascular system, our data and the available published data suggest that apelin 
has limited inotropic (Berry et al., 2004) and vasoactive effects (Tatemoto et al., 
2001) in the normal rat. The cardioprotective effect of apelin has been demonstrated 
in rodent models (Simpkin et al., 2007) and we observe a modest cardioprotective 
effect in zebrafish 3 dpf. Importantly, in patients attending for diagnostic coronary 
angiography, apelin-36 increased rate of rise of left ventricular pressure towards the 
peak, but decreased maximum left ventricular pressure and left ventricular end 
diastolic pressure (Japp et al., 2010). Furthermore, apelin-13, pyr-apelin-13 and 
apelin-36 elicited a positive inotropic effect in isolated atrial strips from atrial 
appendage of patients undergoing coronary artery bypass (Maguire et al., 2009). 
 
It is unclear whether apelin functions in an endocrine manner or has a paracrine 
action that is controlled locally. Apelin has been detected in human and rodent 
plasma (Foldes et al., 2003; Kawamata et al., 2001). However, Kleinz et al. (2005) 
postulate that apelin release is controlled locally and that low levels of apelin in 
plasma is due to overspill from tissues such as endothelial cells where apelin may be 
synthesised for local release. As the apelin receptor is widely expressed, a key 
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challenge of using an apelin agonist or antagonist therapeutically will be to influence 
the system in a target tissue, for example the heart, without influencing other organs.  
 
Although we demonstrated that the inotropic and vasoactive effects are limited in the 
normal rat, apelin’s reported inotropic and vasoactive effects appear to be enhanced 
in heart failure (Berry et al., 2004; Dai et al., 2006; Jia et al., 2006). This would 
make the apelin system an attractive potential target for the treatment of heart failure. 
Endothelin-1 also has comparable positive inotropic actions, in addition to a potent 
vasoconstrictor action. Yet, modulation of the endothelin system is currently only 
approved for use in the treatment of pulmonary arterial hypertension by endothelin 
antagonists (Aubert et al., 2009). An apelin agonist may therefore be suitable for use 
in some, but not other, cardiovascular conditions. The development of selective tools 
such as a non-peptidic apelin agonist, recently reported in the literature (Iturrioz et 
al., 2009), or an apelin antagonist will allow for further characterisation of the effects 
of apelin in different tissues and species. Although the apelin system has clear 
therapeutic potential, only time will tell whether or not drugs targeting the apelin 
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